BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction. N Engl J Med 2001;345:725-30. [DOI: 10.1056/nejmoa010187] [Cited by in Crossref: 2301] [Cited by in F6Publishing: 910] [Article Influence: 115.1] [Reference Citation Analysis]
Number Citing Articles
1 Jabo B, Selleck MJ, Morgan JW, Lum SS, Bahjri KA, Aljehani M, Garberoglio CA, Reeves ME, Namm JP, Solomon NL, Luca F, Dyke C, Senthil M. Comparison of perioperative chemotherapy with adjuvant chemoradiotherapy for resectable gastric cancer: findings from a population-based study. J Gastrointest Oncol 2018;9:35-45. [PMID: 29564169 DOI: 10.21037/jgo.2017.10.13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
2 Lin SH. The utility of proton beam therapy with concurrent chemotherapy for the treatment of esophageal cancers. Cancers (Basel) 2011;3:4090-101. [PMID: 24213126 DOI: 10.3390/cancers3044090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Leo S, Accettura C, Gnoni A, Licchetta A, Giampaglia M, Mauro A, Saracino V, Carr BI. Systemic treatment of gastrointestinal cancer in elderly patients. J Gastrointest Cancer. 2013;44:22-32. [PMID: 23150086 DOI: 10.1007/s12029-012-9447-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
4 Zhao Q, Li Y, Wang J, Zhang J, Qiao X, Tan B, Tian Y, Shi G, Xu Q, Li R, Liu Y, Yang P. Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction. Am J Med Sci 2015;349:472-6. [PMID: 25996101 DOI: 10.1097/MAJ.0000000000000476] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
5 Welsh J, Amini A, Likhacheva A, Erasmus J J, Gomez D, Davila M, Mehran RJ, Komaki R, Liao Z, Hofstetter WL, Lee H J, Bhutani MS, Ajani JA. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep 2011;13:157-67. [PMID: 21365188 DOI: 10.1007/s11912-011-0158-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
6 Yamashita K, Hosoda K, Niihara M, Hiki N. History and emerging trends in chemotherapy for gastric cancer. Ann Gastroenterol Surg 2021;5:446-56. [PMID: 34337293 DOI: 10.1002/ags3.12439] [Reference Citation Analysis]
7 Ema A, Yamashita K, Sakuramoto S, Wang G, Mieno H, Nemoto M, Shibata T, Katada N, Kikuchi S, Watanabe M. Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy. Gastric Cancer. 2014;17:67-75. [PMID: 23801337 DOI: 10.1007/s10120-013-0253-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
8 Xiao L, Liu YP, Xiao CX, Ren JL, Guleng B. Serum TFF3 may be a pharamcodynamic marker of responses to chemotherapy in gastrointestinal cancers. BMC Clin Pathol 2014;14:26. [PMID: 25031551 DOI: 10.1186/1472-6890-14-26] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wang F, Kumar P. The role of radiotherapy in management of pancreatic cancer. J Gastrointest Oncol. 2011;2:157-167. [PMID: 22811846 DOI: 10.3978/j.issn.2078-6891.2011.032] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
10 Li H, Jin X, Liu P, Hong W. Time to local recurrence as a predictor of survival in unrecetable gastric cancer patients after radical gastrectomy. Oncotarget 2017;8:89203-13. [PMID: 29179512 DOI: 10.18632/oncotarget.19038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
11 Zhu H, Huang M, Ren D, He J, Zhao F, Yi C, Huang Y. The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells. Biomed Res Int 2013;2013:293874. [PMID: 24324958 DOI: 10.1155/2013/293874] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
12 Chen H, Wu S, Kundra A, Aja Onu I, Gotlieb V, Wang JC. Gastric Perforation in a Patient Receiving Neoadjuvant Chemoradiotherapy. World J Oncol 2015;6:383-6. [PMID: 28983335 DOI: 10.14740/wjon924w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Dao TV, Nguyen CV, Nguyen QT, Vu HTN, Phung HT, Bui OT, Nguyen DK, Luong BV, Tran TV. Evaluation of Tumor Budding in Predicting Survival for Gastric Carcinoma Patients in Vietnam. Cancer Control 2020;27:1073274820968883. [PMID: 33136444 DOI: 10.1177/1073274820968883] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Lee JH, Kim JG, Jung HK, Kim JH, Jeong WK, Jeon TJ, Kim JM, Kim YI, Ryu KW, Kong SH, Kim HI, Jung HY, Kim YS, Zang DY, Cho JY, Park JO, Lim DH, Jung ES, Ahn HS, Kim HJ. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer. 2014;14:87-104. [PMID: 25061536 DOI: 10.5230/jgc.2014.14.2.87] [Cited by in Crossref: 119] [Cited by in F6Publishing: 118] [Article Influence: 17.0] [Reference Citation Analysis]
15 Papadimitriou K, Antoniou G, Rolfo C, Russo A, Bronte G, Vassiliou V, Papamichael D, Peeters M, Kountourakis P. Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward. Gastroenterol Res Pract 2015;2015:650846. [PMID: 26101524 DOI: 10.1155/2015/650846] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Grau JJ, Palmero R, Marmol M, Domingo-Domenech J, Monzo M, Fuster J, Vidal O, Fondevila C, Garcia-Valdecasas JC. Time-related improvement of survival in resectable gastric cancer: the role of Japanese-style gastrectomy with D2 lymphadenectomy and adjuvant chemotherapy. World J Surg Oncol. 2006;4:53. [PMID: 16904003 DOI: 10.1186/1477-7819-4-53] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
17 Menges M. Gastric cancer: Where is the place for the surgeon, the oncologist and the endoscopist today? World J Gastrointest Oncol 2011; 3(1): 10-13 [PMID: 21267398 DOI: 10.4251/wjgo.v3.i1.10] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
18 Chang AY, Foo KF, Koo WH, Ong S, So J, Tan D, Lim KH. Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer. BMJ Open Gastroenterol 2016;3:e000095. [PMID: 27648294 DOI: 10.1136/bmjgast-2016-000095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
19 Meng J, Zhang J, Xiu Y, Jin Y, Xiang J, Nie Y, Fu S, Zhao K. Prognostic value of an immunohistochemical signature in patients with esophageal squamous cell carcinoma undergoing radical esophagectomy. Mol Oncol 2018;12:196-207. [PMID: 29160958 DOI: 10.1002/1878-0261.12158] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
20 Jabo B, Selleck MJ, Morgan JW, Lum SS, Bahjri K, Aljehani M, Garberoglio CA, Reeves ME, Namm JP, Solomon NL, Luca F, Yang G, Senthil M. Role of lymph node ratio in selection of adjuvant treatment (chemotherapy vs. chemoradiation) in patients with resected gastric cancer. J Gastrointest Oncol 2018;9:708-17. [PMID: 30151267 DOI: 10.21037/jgo.2018.05.12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
21 Rhodin KE, Raman V, Jawitz OK, Tong BC, Harpole DH, D'Amico TA. The Effect of Timing of Adjuvant Therapy on Survival After Esophagectomy. Ann Thorac Surg 2020;110:1023-9. [PMID: 32330471 DOI: 10.1016/j.athoracsur.2020.03.040] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wang J, Tian Y, Tang Y, Wang X, Li N, Ren H, Fang H, Feng Y, Wang S, Song Y, Liu Y, Wang W, Li Y, Jin J. A Phase II prospective nonrandomized trial of magnetic resonance imaging-guided hematopoietic bone marrow-sparing radiotherapy for gastric cancer patients with concurrent chemotherapy. Onco Targets Ther 2016;9:2701-7. [PMID: 27217780 DOI: 10.2147/OTT.S91586] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
23 Herbreteau E, Jooste V, Hamza S, Lepage C, Faivre J, Bouvier AM. Trends in the management of gastric cancer over a 32-year period: a French population-based study. Gastric Cancer 2015;18:129-37. [PMID: 24488016 DOI: 10.1007/s10120-014-0342-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
24 Huang CY, Zhao JJ, Lv L, Chen YB, Li YF, Jiang SS, Wang W, Pan K, Zheng Y, Zhao BW, Wang DD, Chen YM, Yang L, Zhou ZW, Xia JC. Decreased expression of AZGP1 is associated with poor prognosis in primary gastric cancer. PLoS One 2013;8:e69155. [PMID: 23935945 DOI: 10.1371/journal.pone.0069155] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
25 Huang H, Wang Z, Li Y, Zhao Q, Niu Z. Amplification of the human epidermal growth factor receptor 2 (HER2) gene is associated with a microsatellite stable status in Chinese gastric cancer patients. J Gastrointest Oncol 2021;12:377-87. [PMID: 34012633 DOI: 10.21037/jgo-21-47] [Reference Citation Analysis]
26 Badgwell B, Das P, Ajani J. Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. J Hematol Oncol 2017;10:149. [PMID: 28810883 DOI: 10.1186/s13045-017-0517-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
27 Hoffman KE, Neville BA, Mamon HJ, Kachnic LA, Katz MS, Earle CC, Punglia RS. Adjuvant therapy for elderly patients with resected gastric adenocarcinoma: population-based practices and treatment effectiveness. Cancer 2012;118:248-57. [PMID: 21692071 DOI: 10.1002/cncr.26248] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
28 Chen X, Zhi Y, Lin Z, Ma J, Mou W, Yu J. Prognosis prediction model for a special entity of gastric cancer, linitis plastica. J Gastrointest Oncol 2021;12:307-27. [PMID: 34012628 DOI: 10.21037/jgo-20-264] [Reference Citation Analysis]
29 Nassour I, Fullington H, Hynan LS, Yopp AC, Augustine MM, Polanco PM, Choti MA, Mansour JC, Wang SC, Porembka MR. The Yield of Staging Laparoscopy in Gastric Cancer is Affected by Racial and Ethnic Differences in Disease Presentation. Ann Surg Oncol 2017;24:1787-94. [PMID: 28194592 DOI: 10.1245/s10434-017-5805-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
30 Krasniqi E, Pellicori S, Formica V. Emerging role of S-1 in gastric cancer. Indian J Med Paediatr Oncol 2015;36:219-28. [PMID: 26811591 DOI: 10.4103/0971-5851.171542] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
31 Ikoma N, Das P, Hofstetter W, Ajani JA, Estrella JS, Chen HC, Wang X, Callender RA, Zhu C, Roland CL, Fournier KF, Cormier JN, Mansfield P, Badgwell BD. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric Cancer 2018;21:1004-13. [PMID: 29730720 DOI: 10.1007/s10120-018-0832-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
32 Uemura N, Kurashige J, Kosumi K, Iwatsuki M, Yamashita K, Iwagami S, Baba Y, Sakamoto Y, Miyamoto Y, Yoshida N, Honda Y, Mikami Y, Baba H. Early gastric cancer metastasizing to the rectum, possibly via a hematogenous route: a case report and review of literature. Surg Case Rep 2016;2:58. [PMID: 27271470 DOI: 10.1186/s40792-016-0180-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
33 Choi YY, Noh SH, Cheong JH. Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. Yonsei Med J 2015;56:1177-85. [PMID: 26256958 DOI: 10.3349/ymj.2015.56.5.1177] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 7.2] [Reference Citation Analysis]
34 Vošmik M, Laco J, Sirák I, Dvořák J, Lochman P, Hodek M, Malá P, Rejchrt S, Repák R, Leško M, Ferko A, Ryška A, Melichar B, Petera J. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery. Pathol Oncol Res 2018;24:373-83. [PMID: 28550507 DOI: 10.1007/s12253-017-0253-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Liu Y, Wang D, Zhao KL, Zhu JW, Yin HB, Wei YZ, Wu ZJ, Cheng GJ, Wang F, Ni F, Wang XL, Cao GX, Huang J, Cai J. NEDD9 overexpression correlates with poor prognosis in gastric cancer. Tumour Biol 2014;35:6351-6. [PMID: 24664584 DOI: 10.1007/s13277-014-1839-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
36 Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol 2012; 18(40): 5679-5687 [PMID: 23155307 DOI: 10.3748/wjg.v18.i40.5679] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
37 Katz MH, Fleming JB, Lee JE, Pisters PW. Current status of adjuvant therapy for pancreatic cancer. Oncologist. 2010;15:1205-1213. [PMID: 21045189 DOI: 10.1634/theoncologist.2010-0121] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
38 Shigaki H, Baba Y, Watanabe M, Murata A, Iwagami S, Miyake K, Ishimoto T, Iwatsuki M, Baba H. LINE-1 hypomethylation in gastric cancer, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastric Cancer 2013;16:480-7. [PMID: 23179365 DOI: 10.1007/s10120-012-0209-7] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 6.7] [Reference Citation Analysis]
39 Asakura H, Hashimoto T, Harada H, Mizumoto M, Furutani K, Hasuike N, Matsuoka M, Ono H, Boku N, Nishimura T. Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? J Cancer Res Clin Oncol. 2011;137:125-130. [PMID: 20336314 DOI: 10.1007/s00432-010-0866-z] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
40 Scartozzi M, Galizia E, Verdecchia L, Berardi R, Graziano F, Catalano V, Giordani P, Mari D, Silva RR, Marmorale C, Zingaretti C, Cascinu S. Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. Br J Cancer 2006;95:445-9. [PMID: 16880789 DOI: 10.1038/sj.bjc.6603286] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
41 Kim HS, Shin SJ, Beom SH, Jung M, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH, Chung H, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Rha SY. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy.Oncotarget. 2016;44608. [DOI: 10.18632/oncotarget.10115] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
42 Ashraf N, Hoffe S, Kim R. Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist 2013;18:1013-21. [PMID: 23966224 DOI: 10.1634/theoncologist.2012-0462] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
43 Dabak R, Uygur-Bayramicli O, Gemici C, Yavuzer D, Sargin M, Yildirim M. Endoscopic scoring of late gastrointestinal mucosal damage after adjuvant radiochemotherapy. World J Gastroenterol 2006; 12(27): 4411-4415 [PMID: 16865788 DOI: 10.3748/wjg.v12.i27.4411] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
44 Meng C, Yin H, Sun Z, Zhou J, Chen S, Bai C, Zhao L. Adjuvant Chemotherapy with Docetaxel, Cisplatin, and Continuous-Infusion 5-Fluorouracil for Gastric Cancer: A Phase II Study. Transl Oncol 2014;7:277-83. [PMID: 24704535 DOI: 10.1016/j.tranon.2014.02.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
45 Ott K, Lordick F, Blank S, Büchler M. Gastric cancer: surgery in 2011. Langenbecks Arch Surg 2011;396:743-58. [PMID: 21234760 DOI: 10.1007/s00423-010-0738-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
46 Arai H, Nakajima TE. Recent Developments of Systemic Chemotherapy for Gastric Cancer. Cancers (Basel) 2020;12:E1100. [PMID: 32354119 DOI: 10.3390/cancers12051100] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
47 Xu Y, Yu X, Chen Q, Mao W. Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? World J Surg Oncol 2012;10:173. [PMID: 22920951 DOI: 10.1186/1477-7819-10-173] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
48 Samalin E, Ychou M. Neoadjuvant therapy for gastroesophageal adenocarcinoma. World J Clin Oncol 2016; 7(3): 284-292 [PMID: 27298768 DOI: 10.5306/wjco.v7.i3.284] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
49 McNamara MJ, Adelstein DJ, Allende DS, Bodmann JW, Ives DI, Murthy SC, Raymond D, Raja S, Rodriguez CP, Sohal D, Stephans KL, Videtic GMM, Rybicki LA. Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes. J Gastrointest Cancer 2017;48:181-9. [PMID: 27734205 DOI: 10.1007/s12029-016-9881-x] [Reference Citation Analysis]
50 Ramos MFKP, de Castria TB, Pereira MA, Dias AR, Antonacio FF, Zilberstein B, Hoff PMG, Ribeiro U Jr, Cecconello I. Return to Intended Oncologic Treatment (RIOT) in Resected Gastric Cancer Patients. J Gastrointest Surg. 2020;24:19-27. [PMID: 31745892 DOI: 10.1007/s11605-019-04462-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
51 Deng ZJ, Nie RC, Lu J, Chen XJ, Xiang J, Huang CM, Chen YB, Peng JS, Chen S. Survival analysis of stage II gastric cancer patients after D2 gastrectomy: a Chinese people-based research. BMC Gastroenterol 2021;21:363. [PMID: 34620108 DOI: 10.1186/s12876-021-01937-9] [Reference Citation Analysis]
52 Maduekwe UN, Lauwers GY, Fernandez-Del-Castillo C, Berger DL, Ferguson CM, Rattner DW, Yoon SS. New metastatic lymph node ratio system reduces stage migration in patients undergoing D1 lymphadenectomy for gastric adenocarcinoma. Ann Surg Oncol. 2010;17:1267-1277. [PMID: 20099040 DOI: 10.1245/s10434-010-0914-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
53 Reed VK, Krishnan S, Mansfield PF, Bhosale PR, Kim M, Das P, Janjan NA, Delclos ME, Lowy AM, Feig BW. Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2008;71:741-747. [PMID: 18164837 DOI: 10.1016/j.ijrobp.2007.10.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
54 Lee JH, Kim KM, Cheong JH, Noh SH. Current management and future strategies of gastric cancer. Yonsei Med J 2012;53:248-57. [PMID: 22318810 DOI: 10.3349/ymj.2012.53.2.248] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
55 Zhu X, Li J. Gastric carcinoma in China: Current status and future perspectives (Review). Oncol Lett 2010;1:407-12. [PMID: 22966316 DOI: 10.3892/ol_00000071] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
56 Pajuelo-Lozano N, Bargiela-Iparraguirre J, Dominguez G, Quiroga AG, Perona R, Sanchez-Perez I. XPA, XPC, and XPD Modulate Sensitivity in Gastric Cisplatin Resistance Cancer Cells. Front Pharmacol 2018;9:1197. [PMID: 30386247 DOI: 10.3389/fphar.2018.01197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
57 Khorfan R, Schlick CJR, Yang AD, Odell DD, Bentrem DJ, Merkow RP. Utilization of Minimally Invasive Surgery and Its Association with Chemotherapy for Locally Advanced Gastric Cancer. J Gastrointest Surg 2020;24:243-52. [PMID: 31749097 DOI: 10.1007/s11605-019-04410-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Wals A, Contreras J, Macías J, Fortes I, Rivas D, González P, Herruzo I. Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP's from the differential HDV of the organs at risk. Clin Transl Oncol 2006;8:271-8. [PMID: 16648103 DOI: 10.1007/BF02664938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 2012;20:13-24. [PMID: 21617522 DOI: 10.1097/PAI.0b013e31821c821c] [Cited by in Crossref: 80] [Cited by in F6Publishing: 49] [Article Influence: 8.9] [Reference Citation Analysis]
60 Ni W, Yu S, Zhang W, Xiao Z, Zhou Z, Chen D, Feng Q, Liang J, Lv J, Gao S, Mao Y, Xue Q, Sun K, Liu X, Fang D, Li J, Wang D. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma. BMC Cancer 2020;20:130. [PMID: 32070309 DOI: 10.1186/s12885-020-6592-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
61 He Q, Zhao J, Yuan J, Gong Z, Yi T. Combined perioperative EOX chemotherapy and postoperative chemoradiotherapy for locally advanced gastric cancer. Mol Clin Oncol 2017;7:211-6. [PMID: 28781787 DOI: 10.3892/mco.2017.1300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Wang K, Li E, Busuttil RA, Kong JC, Pattison S, Sung JJY, Yu J, El-Omar EM, Simpson JA, Boussioutas A. A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer. Ther Adv Med Oncol 2020;12:1758835920930359. [PMID: 32754227 DOI: 10.1177/1758835920930359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Tai P, Yu E. Esophageal cancer management controversies: Radiation oncology point of view. World J Gastrointest Oncol 2014; 6(8): 263-274 [PMID: 25132924 DOI: 10.4251/wjgo.v6.i8.263] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
64 Liu GF, Bair RJ, Bair E, Liauw SL, Koshy M. Clinical outcomes for gastric cancer following adjuvant chemoradiation utilizing intensity modulated versus three-dimensional conformal radiotherapy. PLoS One 2014;9:e82642. [PMID: 24416146 DOI: 10.1371/journal.pone.0082642] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
65 Liu X, Xiao M, Zhang L, Li L, Zhu G, Shen E, Lv M, Lu X, Sun Z. The m6A methyltransferase METTL14 inhibits the proliferation, migration, and invasion of gastric cancer by regulating the PI3K/AKT/mTOR signaling pathway. J Clin Lab Anal 2021;35:e23655. [PMID: 33314339 DOI: 10.1002/jcla.23655] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
66 Stark AP, Estrella JS, Chiang YJ, Das P, Minsky BD, Blum Murphy MA, Ajani JA, Mansfield P, Badgwell BD, Ikoma N. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol 2020;122:422-32. [PMID: 32462681 DOI: 10.1002/jso.25984] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Claassen YHM, Hartgrink HH, de Steur WO, Dikken JL, van Sandick JW, van Grieken NCT, Cats A, Trip AK, Jansen EPM, Kranenbarg WMM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH. Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial. Gastric Cancer 2019;22:369-76. [PMID: 30238171 DOI: 10.1007/s10120-018-0875-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Unger JM, Barlow WE, Martin DP, Ramsey SD, Leblanc M, Etzioni R, Hershman DL. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst 2014;106:dju002. [PMID: 24627276 DOI: 10.1093/jnci/dju002] [Cited by in Crossref: 115] [Cited by in F6Publishing: 116] [Article Influence: 16.4] [Reference Citation Analysis]
69 De Franco L, Marrelli D, Voglino C, Vindigni C, Ferrara F, Di Mare G, Iudici L, Marini M, Roviello F. Prognostic Value of Perineural Invasion in Resected Gastric Cancer Patients According to Lauren Histotype. Pathol Oncol Res 2018;24:393-400. [PMID: 28555306 DOI: 10.1007/s12253-017-0257-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
70 Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113-123. [PMID: 21573742 DOI: 10.1007/s10120-011-0042-4] [Cited by in Crossref: 1577] [Cited by in F6Publishing: 1567] [Article Influence: 157.7] [Reference Citation Analysis]
71 Edwards P, Blackshaw GR, Lewis WG, Barry JD, Allison MC, Jones DR. Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma. Br J Cancer. 2004;90:1888-1892. [PMID: 15138467 DOI: 10.1038/sj.bjc.6601790] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 3.9] [Reference Citation Analysis]
72 Pang X, Wei W, Leng W, Chen Q, Xia H, Chen L, Li R. Radiotherapy for gastric cancer: a systematic review and meta-analysis. Tumour Biol. 2014;35:387-396. [PMID: 23929390 DOI: 10.1007/s13277-013-1054-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
73 Inaba K, Okamoto H, Wakita A, Nakamura S, Kobayashi K, Harada K, Kitaguchi M, Sekii S, Takahashi K, Yoshio K, Murakami N, Morota M, Ito Y, Sumi M, Uno T, Itami J. Radiotherapy for gastric lymphoma: a planning study of 3D conformal radiotherapy, the half-beam method, and intensity-modulated radiotherapy. J Radiat Res 2014;55:1141-5. [PMID: 25161174 DOI: 10.1093/jrr/rru052] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
74 Wei Q, Arami H, Santos HA, Zhang H, Li Y, He J, Zhong D, Ling D, Zhou M. Intraoperative Assessment and Photothermal Ablation of the Tumor Margins Using Gold Nanoparticles. Adv Sci (Weinh) 2021;8:2002788. [PMID: 33717843 DOI: 10.1002/advs.202002788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Meyer HJ, Wilke H. Treatment strategies in gastric cancer. Dtsch Arztebl Int. 2011;108:698-705; quiz 706. [PMID: 22114638 DOI: 10.3238/arztebl.2011.0698] [Cited by in Crossref: 3] [Cited by in F6Publishing: 34] [Article Influence: 0.3] [Reference Citation Analysis]
76 Zheng Y, Li Y, Liu X, Zhang R, Wang Z, Sun H, Liu S. A phase III, multicenter randomized controlled trial of neo-adjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA-IIIB esophageal squamous cell carcinoma. J Thorac Dis 2017;9:200-4. [PMID: 28203424 DOI: 10.21037/jtd.2017.01.44] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
77 Harada S, Yanagisawa M, Kaneko S, Yorozu K, Yamamoto K, Moriya Y, Harada N. Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model. Mol Clin Oncol 2015;3:987-94. [PMID: 26623038 DOI: 10.3892/mco.2015.609] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
78 Ott K, Lordick F. [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]. Chirurg 2009;80:1028-34. [PMID: 19756431 DOI: 10.1007/s00104-009-1736-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
79 Miceli R, Tomasello G, Bregni G, Bartolomeo MD, Pietrantonio F. Adjuvant chemotherapy for gastric cancer: Current evidence and future challenges. World J Gastroenterol 2014; 20(16): 4516-4525 [PMID: 24782604 DOI: 10.3748/wjg.v20.i16.4516] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
80 Fu J, Wang CY, Wang CG, Li HL, Yang XJ, Sun Y, Shao YH, Zhang LH, Yang XM, Zhang XL. Efficacy and Side Effects of Combined Capecitabine Plus Intensity Modulated Radiotherapy as an Effective Adjuvant Therapy for Gastric Cancers. Iran J Pharm Res 2020;19:365-71. [PMID: 33841549 DOI: 10.22037/ijpr.2019.14622.12542] [Reference Citation Analysis]
81 Lee JM, Kim SS, Cho YS. The Role of PPARγ in Helicobacter pylori Infection and Gastric Carcinogenesis. PPAR Res 2012;2012:687570. [PMID: 22936949 DOI: 10.1155/2012/687570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
82 Ryan P, Furlong H, Murphy CG, O'Sullivan F, Walsh TN, Shanahan F, O'Sullivan GC. Prognostic significance of prospectively detected bone marrow micrometastases in esophagogastric cancer: 10-year follow-up confirms prognostic significance. Cancer Med 2015;4:1281-8. [PMID: 25914238 DOI: 10.1002/cam4.470] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
83 Salem A, Hashem S, Mula-Hussain LY, Mohammed I, Nour A, Shelpai W, Daoud F, Morcos B, Yamin Y, Jaradat I, Khader J, Almousa A. Management strategies for locoregional recurrence in early-stage gastric cancer: retrospective analysis and comprehensive literature review. J Gastrointest Cancer 2012;43:77-82. [PMID: 20835925 DOI: 10.1007/s12029-010-9207-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
84 Tanizawa Y, Terashima M. Lymph node dissection in the resection of gastric cancer: review of existing evidence. Gastric Cancer. 2010;13:137-148. [PMID: 20820982 DOI: 10.1007/s10120-010-0560-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
85 Wilson KS. Postoperative chemoradiotherapy helps in gastric adenocarcinoma. BMJ. 2002;324:977. [PMID: 11964354 DOI: 10.1136/bmj.324.7343.977/a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
86 Shui L, Ren H, Yang X, Li J, Chen Z, Yi C, Zhu H, Shui P. The Era of Radiogenomics in Precision Medicine: An Emerging Approach to Support Diagnosis, Treatment Decisions, and Prognostication in Oncology. Front Oncol 2020;10:570465. [PMID: 33575207 DOI: 10.3389/fonc.2020.570465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
87 Sun Z, Shenoi MM, Nussbaum DP, Keenan JE, Gulack BC, Tyler DS, Speicher PJ, Blazer DG 3rd. Feeding jejunostomy tube placement during resection of gastric cancers. J Surg Res 2016;200:189-94. [PMID: 26248478 DOI: 10.1016/j.jss.2015.07.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
88 Fukagawa T, Sasako M, Ito S, Nakanishi H, Iinuma H, Natsugoe S, Katai H, Shimoda T. The prognostic significance of isolated tumor cells in the lymph nodes of gastric cancer patients. Gastric Cancer 2010;13:191-6. [PMID: 20820989 DOI: 10.1007/s10120-010-0556-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
89 Isa N. Evidence based radiation oncology with existing technology. Rep Pract Oncol Radiother. 2014;19:259-266. [PMID: 25061519 DOI: 10.1016/j.rpor.2013.09.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
90 Jiang DM, Suzuki C, Espin-Garcia O, Lim CH, Ma LX, Sun P, Sim HW, Natori A, Chan BA, Moignard S, Chen EX, Liu G, Swallow CJ, Darling GE, Wong R, Jang RW, Elimova E. Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma. Cancer Med 2020;9:3023-32. [PMID: 32130793 DOI: 10.1002/cam4.2948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Helyer LK, O'Brien C, Coburn NG, Swallow CJ. Surgeons' knowledge of quality indicators for gastric cancer surgery. Gastric Cancer 2007;10:205-14. [PMID: 18095075 DOI: 10.1007/s10120-007-0435-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
92 Egawa N, Tanaka T, Matsufuji S, Yamada K, Ito K, Kitagawa H, Okuyama K, Kitajima Y, Noshiro H. Antitumor effects of low-dose tipifarnib on the mTOR signaling pathway and reactive oxygen species production in HIF-1α-expressing gastric cancer cells. FEBS Open Bio 2021;11:1465-75. [PMID: 33773069 DOI: 10.1002/2211-5463.13154] [Reference Citation Analysis]
93 Oechsle K, Bokemeyer C, Hartmann JT, Budach W, Trarbach T, Stahl M, Boehlke I, Kollmannsberger C; German AIO/ARO/CAO group. Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group. J Cancer Res Clin Oncol 2009;135:163-72. [PMID: 18825411 DOI: 10.1007/s00432-008-0463-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
94 Qian J, Qian Y, Wang J, Gu B, Pei D, He S, Zhu F, Røe OD, Xu J, Liu L, Gu Y, Guo R, Yin Y, Shu Y, Chen X. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy. Drug Des Devel Ther 2016;10:241-58. [PMID: 26966350 DOI: 10.2147/DDDT.S88743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
95 Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575-1581. [PMID: 21431408 DOI: 10.1245/s10434-011-1631-5] [Cited by in Crossref: 334] [Cited by in F6Publishing: 312] [Article Influence: 33.4] [Reference Citation Analysis]
96 Li Y, Zhu Z, Ma F, Xue L, Tian Y. Improving survival of stage II-III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy. Cancer Med 2020;9:6617-28. [PMID: 32744431 DOI: 10.1002/cam4.3342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
97 Choi YY, Lee JE, Kim H, Sim MH, Kim KK, Lee G, Kim HI, An JY, Hyung WJ, Kim CB, Noh SH, Kim S, Cheong JH. Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci Rep 2016;6:22172. [PMID: 26926953 DOI: 10.1038/srep22172] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 12.2] [Reference Citation Analysis]
98 Peixoto RD, Rocha-Filho DR, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Filho RPDP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Jr UR, Jesus VHF, Jr WLC, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer. Ecancermedicalscience 2020;14:1126. [PMID: 33209117 DOI: 10.3332/ecancer.2020.1126] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
99 Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002;86:1864-1870. [PMID: 12085177 DOI: 10.1038/sj.bjc.6600310] [Cited by in Crossref: 184] [Cited by in F6Publishing: 159] [Article Influence: 9.7] [Reference Citation Analysis]
100 Liakakos T, Xeropotamos N, Ziogas D, Roukos D. EGFR as a Prognostic Marker for Gastric Cancer. World J Surg. 2008;32:1225-1226; author reply 1227-1229. [PMID: 18224475 DOI: 10.1007/s00268-007-9434-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
101 Jimenez P, Pathak A, Phan AT. The role of taxanes in the management of gastroesphageal cancer. J Gastrointest Oncol 2011;2:240-9. [PMID: 22811858 DOI: 10.3978/j.issn.2078-6891.2011.027] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
102 Merrett ND. Multimodality treatment of potentially curative gastric cancer: Geographical variations and future prospects. World J Gastroenterol 2014; 20(36): 12892-12899 [PMID: 25278686 DOI: 10.3748/wjg.v20.i36.12892] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
103 Willett CG, Moughan J, O'Meara E, Galvin JM, Crane CH, Winter K, Manfredi D, Rich TA, Rabinovitch R, Lustig R, Machtay M, Curran WJ. Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trials. Radiother Oncol 2012;105:9-13. [PMID: 23084596 DOI: 10.1016/j.radonc.2012.09.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
104 Lim JB, Kim DK, Chung HW. Clinical significance of serum thymus and activation-regulated chemokine in gastric cancer: potential as a serum biomarker. Cancer Sci 2014;105:1327-33. [PMID: 25154912 DOI: 10.1111/cas.12505] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
105 Yeh CN, Jung SM, Chen TW, Hwang TL, Jan YY, Chen MF. Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy. Langenbecks Arch Surg. 2010;395:217-225. [PMID: 20012317 DOI: 10.1007/s00423-009-0573-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
106 Turgeon MK, Gamboa AC, Rupji M, Lee RM, Switchenko JM, El-Rayes BF, Russell MC, Cardona K, Kooby DA, Staley CA, Maithel SK, Shah MM. Should Signet Ring Cell Histology Alter the Treatment Approach for Clinical Stage I Gastric Cancer? Ann Surg Oncol 2021;28:97-105. [PMID: 32524459 DOI: 10.1245/s10434-020-08714-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
107 Ohkura Y, Shinohara H, Haruta S, Ueno M, Hashimoto M, Sakai Y, Udagawa H. Hepatectomy Offers Superior Survival Compared with Non-surgical Treatment for ≤ 3 Metastatic Tumors with Diameters < 3 cm from Gastric Cancer: A Retrospective Study. World J Surg 2015;39:2757-63. [PMID: 26148522 DOI: 10.1007/s00268-015-3151-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
108 Fujitani K, Kurokawa Y, Takeno A, Endoh S, Ohmori T, Fujita J, Yamasaki M, Takiguchi S, Mori M, Doki Y; Osaka University Clinical Research Group for Gastroenterological Surgery. Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer? Gastric Cancer 2018;21:446-52. [PMID: 28965205 DOI: 10.1007/s10120-017-0767-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
109 Shin SJ, Chun SH, Kim KO, Kim MK, Lee KH, Hyun MS, Bae SH, Ryoo HM, Do YR, Kwon KY, Song HS. The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study. Korean J Intern Med 2005;20:135-40. [PMID: 16134768 DOI: 10.3904/kjim.2005.20.2.135] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
110 Lieto E, Auricchio A, Tirino G, Pompella L, Panarese I, Del Sorbo G, Ferraraccio F, De Vita F, Galizia G, Cardella F. Naples Prognostic Score Predicts Tumor Regression Grade in Resectable Gastric Cancer Treated with Preoperative Chemotherapy. Cancers (Basel) 2021;13:4676. [PMID: 34572903 DOI: 10.3390/cancers13184676] [Reference Citation Analysis]
111 Liao F, Yang Z, Lu X, Guo X, Dong W. Sinomenine sensitizes gastric cancer cells to 5-fluorouracil in vitro and in vivo.. Oncol Lett 2013;6:1604-10. [PMID: 24260052 DOI: 10.3892/ol.2013.1592] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
112 Cuneo KC, Davis MA, Feng MU, Novelli PM, Ensminger WD, Lawrence TS. Low dose rate radiosensitization of hepatocellular carcinoma in vitro and in patients. Transl Oncol 2014;7:472-8. [PMID: 24956939 DOI: 10.1016/j.tranon.2014.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
113 Zhou Y, Zhang J, Cao S, Li Y. The evaluation of metastatic lymph node ratio staging system in gastric cancer. Gastric Cancer. 2013;16:309-317. [PMID: 22945599 DOI: 10.1007./s10120-012-0190-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
114 Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575-1581. [PMID: 21431408 DOI: 10.1245/s10434- 011-1631-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Yu DH, Tang L, Dong H, Dong Z, Zhang L, Fu J, Su X, Zhang T, Fu H, Han L, Xie L, Chen H, Qian Z, Zhu G, Wang J, Ye Q, Zhang J, Yin X, Zhang X, Ji J, Ji Q. Oncogenic HER2 fusions in gastric cancer. J Transl Med 2015;13:116. [PMID: 25889497 DOI: 10.1186/s12967-015-0476-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
116 Sakuramoto S, Yamashita K, Watanabe M. Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients. World J Gastrointest Oncol 2009; 1(1): 47-54 [PMID: 21160774 DOI: 10.4251/wjgo.v1.i1.47] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
117 Özçelik M, Ercelep Ö, Keser S, Özdemir Barışık N, Başar M, Odabaş H, Oyman A, Işık S, Özçelik S, Aliustaoğlu M. PTK-7 Expression in Gastric Cancer: A Prognostic Determinant. Balkan Med J 2020;37:91-7. [PMID: 31820857 DOI: 10.4274/balkanmedj.galenos.2019.2019.8.12] [Reference Citation Analysis]
118 Zhou WH, Tang F, Xu J, Wu X, Feng ZY, Li HG, Lin DJ, Shao CK, Liu Q. Aberrant upregulation of 14-3-3ơ expression serves as an inferior prognostic biomarker for gastric cancer. BMC Cancer 2011;11:397. [PMID: 21933426 DOI: 10.1186/1471-2407-11-397] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
119 Natori A, Chan BA, Sim HW, Ma L, Yokom DW, Chen E, Liu G, Darling G, Swallow C, Brar S, Brierley J, Ringash J, Wong R, Kim J, Rogalla P, Hafezi-Bakhtiari S, Conner J, Knox J, Elimova E, Jang RW. Outcomes by treatment modality in elderly patients with localized gastric and esophageal cancer. Curr Oncol 2018;25:366-70. [PMID: 30607110 DOI: 10.3747/co.25.4208] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
120 Sakamoto J, Matsui T, Kodera Y. Paclitaxel chemotherapy for the treatment of gastric cancer. Gastric Cancer. 2009;12:69-78. [PMID: 19562460 DOI: 10.1007/s10120-009-0505-z] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 5.9] [Reference Citation Analysis]
121 Barzi A, Yang D, Kim AW, Shah MA, Sadeghi S. Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database. BMJ Open Gastroenterol 2020;7:e000483. [PMID: 33148789 DOI: 10.1136/bmjgast-2020-000483] [Reference Citation Analysis]
122 Zhu Z, Gong YB, Xu HM. Neoadjuvant therapy strategies for advanced gastric cancer: Current innovations and future challenges. Chronic Dis Transl Med 2020;6:147-57. [PMID: 32908968 DOI: 10.1016/j.cdtm.2020.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
123 Ma HY, Liu XZ, Liang CM. Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer. World J Gastroenterol 2016; 22(29): 6619-6628 [PMID: 27547005 DOI: 10.3748/wjg.v22.i29.6619] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
124 Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018;10:239-48. [PMID: 29445300 DOI: 10.2147/CMAR.S149619] [Cited by in Crossref: 339] [Cited by in F6Publishing: 223] [Article Influence: 113.0] [Reference Citation Analysis]
125 Choi YY, An JY, Hyung WJ, Noh SH. Comments to young surgeons concerning laparoscopic spleen-preserving D2 lymph node dissection for advanced gastric cancer on the upper body. Chin J Cancer Res 2014;26:231-3. [PMID: 25035646 DOI: 10.3978/j.issn.1000-9604.2014.06.15] [Reference Citation Analysis]
126 Vellayappan BA, Soon YY, Ku GY, Leong CN, Lu JJ, Tey JC. Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. Cochrane Database Syst Rev 2017;8:CD010511. [PMID: 28829911 DOI: 10.1002/14651858.CD010511.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
127 Brenner B, Hoshen MB, Purim O, David MB, Ashkenazi K, Marshak G, Kundel Y, Brenner R, Morgenstern S, Halpern M, Rosenfeld N, Chajut A, Niv Y, Kushnir M. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol 2011; 17(35): 3976-3985 [PMID: 22046085 DOI: 10.3748/wjg.v17.i35.3976] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 62] [Article Influence: 6.7] [Reference Citation Analysis]
128 Raigani S, Hardacre JM, Kim J, Ammori JB. Trends in the surgical treatment of gastric adenocarcinoma. Ann Surg Oncol. 2014;21:569-574. [PMID: 24165900 DOI: 10.1245/s10434-013-3314-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
129 Shigeoka H, Imamoto H, Nishimura Y, Shimono T, Furukawa H, Imamura H, Yasuda T, Shiozaki H. Complete response to preoperative chemoradiotherapy in highly advanced gastric adenocarcinoma. World J Gastrointest Oncol 2010; 2(6): 282-286 [PMID: 21160641 DOI: 10.4251/wjgo.v2.i6.282] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
130 Lin JX, Wang ZK, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Zheng CH, Huang CM, Li P. Clinicopathological features and impact of adjuvant chemotherapy on the long-term survival of patients with multiple gastric cancers: a propensity score matching analysis. Cancer Commun (Lond) 2019;39:4. [PMID: 30744696 DOI: 10.1186/s40880-019-0350-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Bokemeyer C, Stein A, Ridwelski K, Atanackovic D, Arnold D, Wöll E, Ulrich A, Fischer R, Krüger C, Schuhmacher C. A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. Gastric Cancer 2015;18:833-42. [PMID: 25214034 DOI: 10.1007/s10120-014-0423-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
132 Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, Ye XS, Do IG, Liu S, Gong L, Fu J, Jin JG, Choi MG, Sohn TS, Lee JH, Bae JM, Kim ST, Park SH, Sohn I, Jung SH, Tan P, Chen R, Hardwick J, Kang WK, Ayers M, Hongyue D, Reinhard C, Loboda A, Kim S, Aggarwal A. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449-456. [PMID: 25894828 DOI: 10.1038/nm.3850] [Cited by in Crossref: 806] [Cited by in F6Publishing: 781] [Article Influence: 134.3] [Reference Citation Analysis]
133 Shinde A, Novak J, Amini A, Chen YJ. The evolving role of radiation therapy for resectable and unresectable gastric cancer. Transl Gastroenterol Hepatol 2019;4:64. [PMID: 31559345 DOI: 10.21037/tgh.2019.08.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
134 Deans C, Yeo MS, Soe MY, Shabbir A, Ti TK, So JB. Cancer of the gastric cardia is rising in incidence in an Asian population and is associated with adverse outcome. World J Surg. 2011;35:617-624. [PMID: 21203759 DOI: 10.1007/s00268-010-0935-0] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 8.2] [Reference Citation Analysis]
135 Helgason HH, Engwegen JY, Zapatka M, Cats A, Boot H, Beijnen JH, Schellens JH. Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer. Oncol Lett 2010;1:327-33. [PMID: 22966303 DOI: 10.3892/ol_00000058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
136 Dong YP, Deng JY. Advances in para-aortic nodal dissection in gastric cancer surgery: A review of research progress over the last decade. World J Clin Cases 2020; 8(13): 2703-2716 [PMID: 32742981 DOI: 10.12998/wjcc.v8.i13.2703] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
137 Kodera Y. Neoadjuvant S-1 and cisplatin for gastric carcinoma: there will be more to come. Gastric Cancer 2006;9:72-3. [PMID: 16767360 DOI: 10.1007/s10120-006-0376-5] [Reference Citation Analysis]
138 Assi T, El Rassy E, Khazzaka A, Moussa T, Ibrahim T, Kattan C, El Karak F, Farhat F, Ghosn M, Kattan J. Characteristics of Gastric Cancer in Lebanon: a Descriptive Study from a Single Institutional Experience. J Gastrointest Cancer 2018;49:21-4. [PMID: 27975180 DOI: 10.1007/s12029-016-9903-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
139 D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240:808-816. [PMID: 15492562 DOI: 10.1097/01.sla.0000143245.28656.15] [Cited by in Crossref: 378] [Cited by in F6Publishing: 379] [Article Influence: 22.2] [Reference Citation Analysis]
140 Brunner TB, Scott-Brown M. The role of radiotherapy in multimodal treatment of pancreatic carcinoma. Radiat Oncol. 2010;5:64. [PMID: 20615227 DOI: 10.1186/1748-717x-5-64] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
141 James L, Dossou S, Bellfiq S, Irigo J, Ogandaga E, Mouden K, Loughmari S, Filali D, El Majjaoui S, Kebdani T, Ahid S, Benjafaar N. [Adjuvant chemoradiotherapy in gastric adenocarcinoma: about 34 cases and review of the literature]. Pan Afr Med J 2014;19:70. [PMID: 25709728 DOI: 10.11604/pamj.2014.19.70.5312] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
142 Chen QY, Lin GT, Zhong Q, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Huang CM. Laparoscopic total gastrectomy for upper-middle advanced gastric cancer: analysis based on lymph node noncompliance. Gastric Cancer 2020;23:184-94. [PMID: 31300914 DOI: 10.1007/s10120-019-00986-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
143 McNamara MJ, Rybicki LA, Sohal D, Allende DS, Videtic GM, Rodriguez CP, Stephans KL, Murthy SC, Raja S, Raymond D, Ives DI, Bodmann JW, Adelstein DJ. The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen. J Gastrointest Oncol 2016;7:196-205. [PMID: 27034786 DOI: 10.3978/j.issn.2078-6891.2015.097] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
144 Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, Cameron JL, Pawlik TM, Schulick RD, Wolfgang CL, Laheru DA, Farnell MB, Swartz MJ, Gunderson LL, Miller RC. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010;17:981-90. [PMID: 20087786 DOI: 10.1245/s10434-009-0743-7] [Cited by in Crossref: 180] [Cited by in F6Publishing: 157] [Article Influence: 16.4] [Reference Citation Analysis]
145 Song T, Chen P, Fang M, Zhang X, Du D, Wu S. The Role of Adjuvant Chemoradiotherapy Over Radiotherapy After R0 Resection for Stage II-III Esophageal Squamous Cell Carcinoma. Cancer Manag Res 2020;12:1631-9. [PMID: 32184666 DOI: 10.2147/CMAR.S232930] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
146 Yu WW, Guo YM, Zhang Q, Fu S. Benefits from adjuvant intraoperative radiotherapy treatment for gastric cancer: A meta-analysis. Mol Clin Oncol 2015;3:185-9. [PMID: 25469292 DOI: 10.3892/mco.2014.444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
147 Kundel Y, Purim O, Idelevich E, Lavrenkov K, Man S, Kovel S, Karminsky N, Pfeffer RM, Nisenbaum B, Fenig E, Sulkes A, Brenner B. Postoperative chemoradiation for resected gastric cancer--is the Macdonald Regimen Tolerable? a retrospective multi-institutional study. Radiat Oncol 2011;6:127. [PMID: 21958692 DOI: 10.1186/1748-717X-6-127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
148 Vita FD, Martino ND, Fabozzi A, Laterza MM, Ventriglia J, Savastano B, Petrillo A, Gambardella V, Sforza V, Marano L, Auricchio A, Galizia G, Ciardiello F, Orditura M. Clinical management of advanced gastric cancer: The role of new molecular drugs. World J Gastroenterol 2014; 20(40): 14537-14558 [PMID: 25356019 DOI: 10.3748/wjg.v20.i40.14537] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
149 Zhao Q, Li Y, Tan B, Fan L, Yang P, Tian Y, Cheng JQ. HIF-1α Induces Multidrug Resistance in Gastric Cancer Cells by Inducing MiR-27a. PLoS ONE 2015;10:e0132746. [DOI: 10.1371/journal.pone.0132746] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
150 Shin K, Park SJ, Lee J, Park CH, Song KY, Lee HH, Seo HS, Jung YJ, Park JM, Lee SH, Roh SY, Kim IH. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage. BMC Cancer 2019;19:1232. [PMID: 31852475 DOI: 10.1186/s12885-019-6433-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
151 Zheng Y, Li Y, Liu X, Sun H, Wang Z, Zhang R. Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 Years. Medicine (Baltimore) 2015;94:e1102. [PMID: 26166100 DOI: 10.1097/MD.0000000000001102] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
152 Allen CJ, Blumenthaler AN, Smith GL, Das P, Minsky BD, Blum M, Ajani J, Mansfield PF, Ikoma N, Badgwell BD. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience. Ann Surg Oncol 2021;28:758-65. [PMID: 32696305 DOI: 10.1245/s10434-020-08864-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Knight G, Earle CC, Cosby R, Coburn N, Youssef Y, Malthaner R, Wong RK; Gastrointestinal Cancer Disease Site Group. Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America. Gastric Cancer. 2013;16:28-40. [PMID: 22467061 DOI: 10.1007/s10120-012-0148-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
154 Rajdev L. Treatment options for surgically resectable gastric cancer. Curr Treat Options Oncol. 2010;11:14-23. [PMID: 20358316 DOI: 10.1007/s11864-010-0117-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
155 Saragoni L. Upgrading the definition of early gastric cancer: better staging means more appropriate treatment. Cancer Biol Med 2015;12:355-61. [PMID: 26779372 DOI: 10.7497/j.issn.2095-3941.2015.0054] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
156 Su Y, Lin L, Zhang J, Jiang Y, Pan C, Sun L, Duan J, Liao W. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer. Mol Med Rep 2015;12:5771-9. [PMID: 26239822 DOI: 10.3892/mmr.2015.4173] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
157 Maduekwe UN, Yoon SS. An evidence-based review of the surgical treatment of gastric adenocarcinoma. J Gastrointest Surg 2011;15:730-41. [PMID: 21399886 DOI: 10.1007/s11605-011-1477-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
158 Yan SM, Tang JJ, Huang CY, Xi SY, Huang MY, Liang JZ, Jiang YX, Li YH, Zhou ZW, Ernberg I, Wu QL, Du ZM. Reduced expression of ZDHHC2 is associated with lymph node metastasis and poor prognosis in gastric adenocarcinoma. PLoS One 2013;8:e56366. [PMID: 23457560 DOI: 10.1371/journal.pone.0056366] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
159 Onal C, Dölek Y, AkkuşYıldırım B. Dosimetric comparison of 3-dimensional conformal radiotherapy, volumetric modulated arc therapy, and helical tomotherapy for postoperative gastric cancer patients.Jpn J Radiol. 2018;36:30-39. [PMID: 29101643 DOI: 10.1007/s11604-017-0696-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
160 Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, Wang C, Qiu MZ, Cai MY, Wu Q, Liu H, Guan WL, Zhou AP, Zhang YJ, Liu TS, Bi F, Yuan XL, Rao SX, Xin Y, Sheng WQ, Xu HM, Li GX, Ji JF, Zhou ZW, Liang H, Zhang YQ, Jin J, Shen L, Li J, Xu RH. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond) 2021;41:747-95. [PMID: 34197702 DOI: 10.1002/cac2.12193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
161 Shih WT, Yang PR, Chen KJ, Yang YH, Lu ML, Chen VC, Shen YC. Antidepressants use is associated with overall survival improvement of patients with gastric cancer after surgery and adjuvant chemotherapy in Taiwan: A large population-based cohort study. Medicine (Baltimore) 2021;100:e27031. [PMID: 34449480 DOI: 10.1097/MD.0000000000027031] [Reference Citation Analysis]
162 Ishida K, Ito C, Ohmori Y, Kume K, Sato KA, Koizumi Y, Konta A, Iwaya T, Nukatsuka M, Kobunai T, Takechi T, Nishizuka SS. Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil. Sci Rep 2017;7:2262. [PMID: 28536445 DOI: 10.1038/s41598-017-02548-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
163 Liu Z, Wang Y, Shan F, Ying X, Zhang Y, Li S, Jia Y, Li Z, Ji J. 5-Fu-Based Doublet Regimen in Patients Receiving Perioperative or Postoperative Chemotherapy for Locally Advanced Gastric Cancer: When to Start and How Long Should the Regimen Last? Cancer Manag Res 2021;13:147-61. [PMID: 33469359 DOI: 10.2147/CMAR.S285361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 何若冰, 陈俊强. 胃癌新辅助化疗的研究进展. 世界华人消化杂志 2009; 17(12): 1207-1211 [DOI: 10.11569/wcjd.v17.i12.1207] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
165 Coyle C, Cafferty FH, Rowley S, MacKenzie M, Berkman L, Gupta S, Pramesh CS, Gilbert D, Kynaston H, Cameron D. ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemp Clin Trials. 2016;51:56-64. [PMID: 27777129 DOI: 10.1016/j.cct.2016.10.004] [Cited by in Crossref: 79] [Cited by in F6Publishing: 78] [Article Influence: 15.8] [Reference Citation Analysis]
166 Zhang S, Liu Y, Jiao Z, Li Z, Wang J, Li C, Qu X, Xu L. Development and Validation of a Prognostic Nomogram for Gastric Signet Ring Cell Carcinoma: A Multicenter Population-Based Study. Front Oncol 2021;11:603031. [PMID: 33763350 DOI: 10.3389/fonc.2021.603031] [Reference Citation Analysis]
167 Nelson R, Ko EB, Arrington A, Lee W, Kim J, Garcia-Aguilar J, Kim J. Race and correlations between lymph node number and survival for patients with gastric cancer. J Gastrointest Surg. 2013;17:471-481. [PMID: 23288716 DOI: 10.1007/s11605-012-2125-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
168 Li Z, Wu X, Gao X, Shan F, Ying X, Zhang Y, Ji J. Development and validation of an artificial neural network prognostic model after gastrectomy for gastric carcinoma: An international multicenter cohort study. Cancer Med. 2020;9:6205-6215. [PMID: 32666682 DOI: 10.1002/cam4.3245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
169 Yabusaki N, Yamada S, Murai T, Kanda M, Kobayashi D, Tanaka C, Fujii T, Nakayama G, Sugimoto H, Koike M. Clinical significance of zinc-finger E-box binding homeobox 1 mRNA levels in peritoneal washing for gastric cancer. Mol Clin Oncol. 2015;3:435-441. [PMID: 25798282 DOI: 10.3892/mco.2014.462] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
170 Chon SH, Berlth F, Plum PS, Herbold T, Alakus H, Kleinert R, Moenig SP, Bruns CJ, Hoelscher AH, Meyer HJ. Gastric cancer treatment in the world: Germany. Transl Gastroenterol Hepatol 2017;2:53. [PMID: 28616608 DOI: 10.21037/tgh.2017.05.07] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
171 Che K, Liu F, Wu N, Liu Q, Yuan L, Wei J. Individualized prediction of survival benefits from perioperative chemoradiotherapy for patients with resectable gastric cancer. Cancer Med 2020;9:7137-50. [PMID: 32810384 DOI: 10.1002/cam4.3350] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Song KY, Park YG, Jeon HM, Park CH. A nomogram for predicting individual survival of patients with gastric cancer who underwent radical surgery with extended lymph node dissection. Gastric Cancer 2014;17:287-93. [PMID: 23712439 DOI: 10.1007/s10120-013-0270-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
173 Wu B, Li T, Cai J, Xu Y, Zhao G. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer 2014;14:984. [PMID: 25526802 DOI: 10.1186/1471-2407-14-984] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
174 Farooq F, Zarrabi K, Sweeney K, Kim J, Bandovic J, Patel C, Choi M. Multiregion Comprehensive Genomic Profiling of a Gastric Mixed Neuroendocrine-Nonneuroendocrine Neoplasm with Trilineage Differentiation. J Gastric Cancer 2018;18:200-7. [PMID: 29984070 DOI: 10.5230/jgc.2018.18.e16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
175 Jomrich G, Schoppmann SF. Targeted therapy in gastric cancer. Eur Surg 2016;48:278-84. [PMID: 27795701 DOI: 10.1007/s10353-016-0389-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
176 Singh P, Toom S, Huang Y. Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. J Hematol Oncol 2017;10:105. [PMID: 28494772 DOI: 10.1186/s13045-017-0473-4] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 12.3] [Reference Citation Analysis]
177 钟琼, 肖震宇, 吴仁瑞, 钟豪, 邓江华, 曾爱群. 进展期胃癌术后调强放疗加同期口服替吉奥胶囊化疗的临床疗效. 世界华人消化杂志 2011; 19(36): 3700-3704 [DOI: 10.11569/wcjd.v19.i36.3700] [Reference Citation Analysis]
178 Peng J, Gong J, Wang X, Mou J, Xu H, Dai J, Zhou F, Zhou Y. 4-Dimensional computed tomography analysis of clinical target volume displacement in adjuvant radiation of patients with gastric cancer and its implication on radiotherapy. Oncol Lett 2019;17:3641-8. [PMID: 30881488 DOI: 10.3892/ol.2019.10037] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
179 Phan AT, Ajani JA. Gastric carcinoma. Curr Oncol Rep 2004;6:192-8. [PMID: 15066230 DOI: 10.1007/s11912-004-0049-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
180 Chang AT, Ng WT, Law AL, Ku KM, Lee MC, Lee AW. Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. Gastric Cancer. 2011;14:63-71. [PMID: 21327926 DOI: 10.1007/s10120-011-0011-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
181 Chen HS, Hung WH, Ko JL, Hsu PK, Liu CC, Wu SC, Lin CH, Wang BY. Impact of Treatment Modalities on Survival of Patients With Locoregional Esophageal Squamous-Cell Carcinoma in Taiwan. Medicine (Baltimore) 2016;95:e3018. [PMID: 26962818 DOI: 10.1097/MD.0000000000003018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
182 Shen J, Zhu X, Du Y, Zhu Y, Yu P, Yang L, Xu Z, Huang L, Zhang Y, Zhang Y, Liu L, Cheng X. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG). Trials 2021;22:753. [PMID: 34717717 DOI: 10.1186/s13063-021-05617-7] [Reference Citation Analysis]
183 Park S, Woo Y, Kim H, Lee YC, Choi S, Hyung WJ, Noh SH. In vitro adenosine triphosphate based chemotherapy response assay in gastric cancer. J Gastric Cancer 2010;10:155-61. [PMID: 22076180 DOI: 10.5230/jgc.2010.10.4.155] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
184 Shiraishi K, Mimura K, Izawa S, Inoue A, Shiba S, Maruyama T, Watanabe M, Kawaguchi Y, Inoue M, Fujii H. Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. Gastric Cancer. 2013;16:571-580. [PMID: 23187882 DOI: 10.1007/s10120-012-0219-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
185 Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477-490. [PMID: 19625077 DOI: 10.1016/s0140-6736(09)60617-6] [Cited by in Crossref: 635] [Cited by in F6Publishing: 410] [Article Influence: 52.9] [Reference Citation Analysis]
186 Enzinger PC, Benedetti JK, Meyerhardt JA, McCoy S, Hundahl SA, Macdonald JS, Fuchs CS. Impact of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg. 2007;245:426-434. [PMID: 17435550 DOI: 10.1097/01.sla.0000245469.35088.42] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
187 Hensel F, Timmermann W, von Rahden BH, Rosenwald A, Brändlein S, Illert B. Ten-year follow-up of a prospective trial for the targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1. Oncol Rep 2014;31:1059-66. [PMID: 24452482 DOI: 10.3892/or.2014.2987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
188 Blumenthaler AN, Newhook TE, Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Ajani JA, Mansfield PF, Badgwell BD. Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol 2021;123:911-22. [PMID: 33400838 DOI: 10.1002/jso.26367] [Reference Citation Analysis]
189 Kauppila JH, Ohtonen P, Karttunen TJ, Kokkola A, Laine S, Rantanen T, Ristimäki A, Räsänen JV, Saarnio J, Sihvo E, Toikkanen V, Tyrväinen T. Finnish National Esophago-Gastric Cancer Cohort (FINEGO) for studying outcomes after oesophageal and gastric cancer surgery: a protocol for a retrospective, population-based, nationwide cohort study in Finland. BMJ Open 2019;9:e024094. [PMID: 30782726 DOI: 10.1136/bmjopen-2018-024094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
190 Morganti AG, Di Castelnuovo A, Massaccesi M, Cellini F, Cilla S, Macchia G, Forte P, Buwenge M, Digesu C, Ferro M, Picardi V, Caravatta L, Valentini V, Deodato F. Planning comparison between standard and conformal 3D techniques in post-operative radiotherapy of gastric cancer: a systematic review. Br J Radiol 2013;86:20130274. [PMID: 23894149 DOI: 10.1259/bjr.20130274] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
191 Ikoma N, Lee JH, Bhutani MS, Ross WA, Weston B, Chiang YJ, Blum MA, Sagebiel T, Devine CE, Matamoros A Jr, Fournier K, Mansfield P, Ajani JA, Badgwell BD. Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. J Gastrointest Oncol 2017;8:1009-17. [PMID: 29299361 DOI: 10.21037/jgo.2017.04.04] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
192 Li W, Qin J, Sun YH, Liu TS. Neoadjuvant chemotherapy for advanced gastric cancer: A meta-analysis. World J Gastroenterol 2010; 16(44): 5621-5628 [PMID: 21105197 DOI: 10.3748/wjg.v16.i44.5621] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
193 Chen X, Liu H, Li G, Yu J. Implications of clinical research on adjuvant chemotherapy for gastric cancer: Where to go next? Chin J Cancer Res 2019;31:892-900. [PMID: 31949391 DOI: 10.21147/j.issn.1000-9604.2019.06.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
194 Schwartz GK, Winter K, Minsky BD, Crane C, Thomson PJ, Anne P, Gross H, Willett C, Kelsen D. Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). J Clin Oncol. 2009;27:1956-1962. [PMID: 19273696 DOI: 10.1200/jco.2008.20.3745] [Cited by in Crossref: 52] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
195 Cho JH, Lim JY, Cho JY. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. PLoS One 2017;12:e0186362. [PMID: 29040299 DOI: 10.1371/journal.pone.0186362] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
196 Leiting JL, Grotz TE. Advancements and challenges in treating advanced gastric cancer in the West. World J Gastrointest Oncol 2019; 11(9): 652-664 [PMID: 31558971 DOI: 10.4251/wjgo.v11.i9.652] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
197 Su X, Xue Y, Wei J, Huo X, Gong Y, Zhang H, Han R, Chen Y, Chen H, Chen J. Establishment and Characterization of gc-006-03, a Novel Human Signet Ring Cell Gastric Cancer Cell Line Derived from Metastatic Ascites. J Cancer 2018;9:3236-46. [PMID: 30271482 DOI: 10.7150/jca.26051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
198 Sim SH, Kim YJ, Oh DY, Lee SH, Kim DW, Kang WJ, Im SA, Kim TY, Kim WH, Heo DS. The role of PET/CT in detection of gastric cancer recurrence. BMC Cancer. 2009;9:73. [PMID: 19250554 DOI: 10.1186/1471-2407-9-73] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
199 Anderson C, Nijagal A, Kim J. Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther 2006;10:345-52. [PMID: 17154651 DOI: 10.1007/BF03256211] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
200 Chen T, Yan D, Zheng Z, Yang J, Dong XDE. Evolution in the surgical management of gastric cancer: is extended lymph node dissection back in vogue in the USA? World J Surg Oncol. 2017;15:135. [PMID: 28716043 DOI: 10.1186/s12957-017-1204-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
201 Xu D, Huang Y, Geng Q, Guan Y, Li Y, Wang W, Yuan S, Sun X, Chen Y, Li W, Zhou Z, Zhan Y. Effect of lymph node number on survival of patients with lymph node-negative gastric cancer according to the 7th edition UICC TNM system. PLoS One 2012;7:e38681. [PMID: 22723875 DOI: 10.1371/journal.pone.0038681] [Cited by in Crossref: 28] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
202 Roy MK, Sadhu S, Dubey SK. Advances in the management of gastric cancer. Indian J Surg. 2009;71:342-349. [PMID: 23133189 DOI: 10.1007/s12262-009-0092-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
203 Lordick F. [Value of postoperative radiochemotherapy after completely resected gastric cancer not definitive despite negative overall results of the ARTIST trial]. Strahlenther Onkol 2012;188:636-7. [PMID: 22638935 DOI: 10.1007/s00066-012-0133-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
204 Arienti C, Pignatta S, Tesei A. Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. Front Oncol 2019;9:1308. [PMID: 31850207 DOI: 10.3389/fonc.2019.01308] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
205 Koushyar S, Powell AG, Vincan E, Phesse TJ. Targeting Wnt Signaling for the Treatment of Gastric Cancer. Int J Mol Sci 2020;21:E3927. [PMID: 32486243 DOI: 10.3390/ijms21113927] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
206 Martínez-Lago N, Vieito-Villar M, Vidal-Insua Y, Padin-Iruegas ME, Vazquez-Rivera F, Candamio-Folgar S, Lopez-Lopez R. Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction. Clin Transl Oncol 2015;17:856-61. [PMID: 26133519 DOI: 10.1007/s12094-015-1314-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
207 Ilson DH. New developments in the treatment of esophageal cancer. Curr Oncol Rep 2002;4:213-21. [PMID: 11937011 DOI: 10.1007/s11912-002-0018-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
208 Magge D, Zenati M, Mavanur A, Winer J, Ramalingam L, Jones H, Zureikat A, Holtzman M, Lee K, Ahrendt S. Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis. Ann Surg Oncol. 2014;21:1448-1455. [PMID: 24197761 DOI: 10.1245/s10434-013-3327-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
209 Martin-Romano P, Sola JJ, Diaz-Gonzalez JA, Chopitea A, Iragorri Y, Martínez-Regueira F, Ponz-Sarvise M, Arbea L, Subtil JC, Cano D, Ceniceros L, Legaspi J, Hernandez JL, Rodríguez J. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer. Br J Cancer 2016;115:655-63. [PMID: 27537382 DOI: 10.1038/bjc.2016.252] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
210 Costa LB, Toneto MG, Moreira LF. DO PROXIMAL AND DISTAL GASTRIC TUMOURS BEHAVE DIFFERENTLY? Arq Bras Cir Dig 2016;29:232-5. [PMID: 28076476 DOI: 10.1590/0102-6720201600040005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
211 Okuyama T, Korenaga D, Edagawa A, Itoh S, Oki E, Kawanaka H, Ikeda Y, Kakeji Y, Tateishi M, Tsujitani S. Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery. Surg Today. 2012;42:734-740. [PMID: 22278622 DOI: 10.1007/s00595-012-0129-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
212 Tural D, Selçukbiricik F, Serdengeçti S, Büyükünal E. A comparison of patient characteristics, prognosis, treatment modalities, and survival according to age group in gastric cancer patients. World J Surg Oncol. 2012;10:234. [PMID: 23121731 DOI: 10.1186/1477-7819-10-234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
213 Elimova E, Slack RS, Chen HC, Planjery V, Shiozaki H, Shimodaira Y, Charalampakis N, Lin Q, Harada K, Wadhwa R, Estrella JS, Kaya DM, Sagebiel T, Lee JH, Weston B, Bhutani M, Murphy MB, Matamoros A, Minsky B, Das P, Mansfield PF, Badgwell BD, Ajani JA. Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. Oncotarget 2017;8:81430-40. [PMID: 29113402 DOI: 10.18632/oncotarget.19226] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
214 Di Bartolomeo M, Pietrantonio F, Pellegrinelli A, Martinetti A, Mariani L, Daidone MG, Bajetta E, Pelosi G, de Braud F, Floriani I. Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer. 2015;Epub ahead of print. [PMID: 25862567 DOI: 10.1007/s10120-015-0495-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
215 Chang KK, Patel MS, Yoon SS. Linear-Stapled Side-to-Side Esophagojejunostomy with Hand-Sewn Closure of the Common Enterotomy After Prophylactic and Therapeutic Total Gastrectomy. J Gastrointest Surg 2017;21:712-22. [PMID: 27882512 DOI: 10.1007/s11605-016-3326-5] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
216 Reddy D, Wainberg ZA. Targeted therapies for metastatic esophagogastric cancer. Curr Treat Options Oncol 2011;12:46-60. [PMID: 21298375 DOI: 10.1007/s11864-011-0138-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
217 Ustaalioğlu BBÖ, Tilki M, Sürmelioğlu A, Bilici A, Gönen C, Ustaalioğlu R, Balvan Ö, Aliustaoğlu M. The clinicopathologic characteristics and prognostic factors of gastroesophageal junction tumors according to Siewert classification. Turk J Surg 2017;33:18-24. [PMID: 28589183 DOI: 10.5152/UCD.2017.3379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
218 Ning ZK, Hu CG, Huang C, Liu J, Zhou TC, Zong Z. Molecular Subtypes and CD4+ Memory T Cell-Based Signature Associated With Clinical Outcomes in Gastric Cancer. Front Oncol 2020;10:626912. [PMID: 33816214 DOI: 10.3389/fonc.2020.626912] [Reference Citation Analysis]
219 Pedrazzani C, Sivins A, Ancans G, Marrelli D, Corso G, Krumins V, Roviello F, Leja M. Ratio between metastatic and examined lymph nodes (N ratio) may have low clinical utility in gastric cancer patients treated by limited lymphadenectomy: results from a single-center experience of 526 patients. World J Surg. 2010;34:85-91. [PMID: 20020295 DOI: 10.1007/s00268-009-0288-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
220 Hsieh CH, Hsieh YJ, Liu CY, Tai HC, Huang YC, Shueng PW, Wu LJ, Wang LY, Tsai TH, Chen YJ. Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics. J Transl Med 2010;8:29. [PMID: 20338060 DOI: 10.1186/1479-5876-8-29] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
221 Stahl KA, Olecki EJ, Dixon ME, Peng JS, Torres MB, Gusani NJ, Shen C. Gastric Cancer Treatments and Survival Trends in the United States. Curr Oncol 2020;28:138-51. [PMID: 33704182 DOI: 10.3390/curroncol28010017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
222 Harada K, Mizrak Kaya D, Shimodaira Y, Ajani JA. Global chemotherapy development for gastric cancer. Gastric Cancer 2017;20:92-101. [PMID: 27718136 DOI: 10.1007/s10120-016-0655-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
223 Gubanski M, Glimelius B, Lind PA. Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin). Med Oncol 2014;31:906. [PMID: 24627237 DOI: 10.1007/s12032-014-0906-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
224 Xue SL, Su HF, Hu XQ, Deng X, Hu ML, Xie CY. Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer. Oncol Lett 2012;4:1309-14. [PMID: 23205128 DOI: 10.3892/ol.2012.914] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
225 Yoong J, Michael M, Leong T. Targeted therapies for gastric cancer: current status. Drugs. 2011;71:1367-1384. [PMID: 21812503 DOI: 10.2165/11592530-000000000-00000] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
226 Cravo M, Fidalgo C, Garrido R, Rodrigues T, Luz G, Palmela C, Santos M, Lopes F, Maio R. Towards curative therapy in gastric cancer: Faraway, so close!. World J Gastroenterol 2015; 21(41): 11609-11620 [PMID: 26556990 DOI: 10.3748/wjg.v21.i41.11609] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
227 Schirren R, Reim D, Novotny AR. Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review. Ther Adv Med Oncol. 2015;7:39-48. [PMID: 25553082 DOI: 10.1177/1758834014558839] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
228 Parisi A, Cortellini A, Roberto M, Venditti O, Santini D, Dell'Aquila E, Stellato M, Marchetti P, Occhipinti MA, Zoratto F, Mazzuca F, Tinari N, De Tursi M, Iezzi L, Natoli C, Ratti M, Pizzo C, Ghidini M, Porzio G, Ficorella C, Cannita K. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. J Cancer Res Clin Oncol 2019;145:2365-73. [PMID: 31280347 DOI: 10.1007/s00432-019-02971-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
229 Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013;24:1754-1761. [PMID: 23524864 DOI: 10.1093/annonc/mdt106] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 6.8] [Reference Citation Analysis]
230 Yi H, Yan X, Luo Q, Yuan L, Li B, Pan W, Zhang L, Chen H, Wang J, Zhang Y, Zhai Y, Qiu MZ, Yang DJ. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma. J Exp Clin Cancer Res 2018;37:97. [PMID: 29716622 DOI: 10.1186/s13046-018-0765-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
231 Lee J, An JY, Choi MG, Park SH, Kim ST, Lee JH, Sohn TS, Bae JM, Kim S, Lee H, Min BH, Kim JJ, Jeong WK, Choi DI, Kim KM, Kang WK, Kim M, Seo SW. Deep Learning-Based Survival Analysis Identified Associations Between Molecular Subtype and Optimal Adjuvant Treatment of Patients With Gastric Cancer. JCO Clin Cancer Inform 2018;2:1-14. [PMID: 30652558 DOI: 10.1200/CCI.17.00065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
232 Cummings D, Wong J, Palm R, Hoffe S, Almhanna K, Vignesh S. Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors. Cancers (Basel) 2021;13:582. [PMID: 33540736 DOI: 10.3390/cancers13030582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
233 Woo Y, Goldner B, Ituarte P, Lee B, Melstrom L, Son T, Noh SH, Fong Y, Hyung WJ. Lymphadenectomy with Optimum of 29 Lymph Nodes Retrieved Associated with Improved Survival in Advanced Gastric Cancer: A 25,000-Patient International Database Study. J Am Coll Surg 2017;224:546-55. [PMID: 28017807 DOI: 10.1016/j.jamcollsurg.2016.12.015] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 6.8] [Reference Citation Analysis]
234 Stahl P, Seeschaaf C, Lebok P, Kutup A, Bockhorn M, Izbicki JR, Bokemeyer C, Simon R, Sauter G, Marx AH. Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterol 2015;15:7. [PMID: 25649416 DOI: 10.1186/s12876-015-0231-4] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 11.7] [Reference Citation Analysis]
235 Schuhmacher C, Reim D, Novotny A. Neoadjuvant treatment for gastric cancer. J. Gastric Cancer. 2013;13:73-78. [PMID: 23844320 DOI: 10.5230/jgc.2013.13.2.73] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
236 Yang W, Hu R, Li GC, Zhou ML, Wang Y, Shen LJ, Liang LP, Zhang Z. Survival outcomes and patterns of failure after D2 dissection and adjuvant chemoradiotherapy for locally advanced gastric cancer: a retrospective study. Br J Radiol 2018;91:20170594. [PMID: 29927628 DOI: 10.1259/bjr.20170594] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
237 Mokadem I, Dijksterhuis WPM, van Putten M, Heuthorst L, de Vos-Geelen JM, Haj Mohammad N, Nieuwenhuijzen GAP, van Laarhoven HWM, Verhoeven RHA. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study. Gastric Cancer. 2019;. [PMID: 30949777 DOI: 10.1007/s10120-019-00956-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
238 Yang Y, Qu A, Zhao R, Hua M, Zhang X, Dong Z, Zheng G, Pan H, Wang H, Yang X, Zhang Y. Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer. Mol Oncol. 2018;12:2072-2084. [PMID: 30242969 DOI: 10.1002/1878-0261.12385] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
239 Zhang Y, Yu Z, Xiao Q, Sun X, Zhu Z, Zhang J, Xu H, Wei M, Sun M. Expression of BAMBI and its combination with Smad7 correlates with tumor invasion and poor prognosis in gastric cancer. Tumour Biol 2014;35:7047-56. [PMID: 24752577 DOI: 10.1007/s13277-014-1962-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
240 Aizawa M, Nagatsuma AK, Kitada K, Kuwata T, Fujii S, Kinoshita T, Ochiai A. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014;17:34-42. [PMID: 23430266 DOI: 10.1007/s10120-013-0239-9] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
241 Zhao JH, Gao P, Song YX, Sun JX, Chen XW, Ma B, Yang YC, Wang ZN. Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis. BMC Cancer 2016;16:631. [PMID: 27519527 DOI: 10.1186/s12885-016-2667-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
242 Shridhar R, Imani-Shikhabadi R, Davis B, Streeter OA, Thomas CR Jr. Curative treatment of esophageal cancer; an evidenced based review. J Gastrointest Cancer 2013;44:375-84. [PMID: 23824628 DOI: 10.1007/s12029-013-9511-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
243 Blackham AU, Swords DS, Levine EA, Fino NF, Squires MH, Poultsides G, Fields RC, Bloomston M, Weber SM, Pawlik TM, Jin LX, Spolverato G, Schmidt C, Worhunsky D, Cho CS, Maithel SK, Votanopoulos KI. Is Linitis Plastica a Contraindication for Surgical Resection: A Multi-Institution Study of the U.S. Gastric Cancer Collaborative. Ann Surg Oncol 2016;23:1203-11. [PMID: 26530447 DOI: 10.1245/s10434-015-4947-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
244 Batista TP, Martins MR. Lymph node dissection for gastric cancer: a critical review. Oncol Rev 2012;6:e12. [PMID: 25992202 DOI: 10.4081/oncol.2012.e12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
245 Wagner AD, Wedding U. Advances in the pharmacological treatment of gastro-oesophageal cancer. Drugs Aging. 2009;26:627-646. [PMID: 19685930 DOI: 10.2165/11315740-000000000-00000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
246 Riquelme I, Saavedra K, Espinoza JA, Weber H, García P, Nervi B, Garrido M, Corvalán AH, Roa JC, Bizama C. Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget 2015;6:24750-79. [PMID: 26267324 DOI: 10.18632/oncotarget.4990] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 15.6] [Reference Citation Analysis]
247 Peixoto RD, Cheung WY, Lim HJ. Perioperative chemotherapy for gastroesophageal cancer in British Columbia: a multicentre experience. Curr Oncol 2014;21:77-83. [PMID: 24764696 DOI: 10.3747/co.21.1788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
248 Chen L, Zhang C, Yao Z, Cui M, Xing J, Yang H, Zhang N, Liu M, Xu K, Tan F, Li Y, Jiang B, Su X. Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study. BMC Cancer 2021;21:974. [PMID: 34461860 DOI: 10.1186/s12885-021-08717-4] [Reference Citation Analysis]
249 Elmi M, Mahar A, Kagedan D, Law CH, Karanicolas PJ, Lin Y, Callum J, Coburn NG, Hallet J. The impact of blood transfusion on perioperative outcomes following gastric cancer resection: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Can J Surg 2016;59:322-9. [PMID: 27668330 DOI: 10.1503/cjs.004016] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
250 Uyeturk U, Arslan SH, Bal O, Arslan UY, Oksuzoglu OB. Isolated ovarian metastasis of gastric cancer: Krukenberg tumor. Contemp Oncol (Pozn) 2013;17:515-9. [PMID: 24592139 DOI: 10.5114/wo.2013.37542] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
251 Li YF, Wang DD, Zhao BW, Wang W, Yuan SQ, Huang CY, Chen YM, Zheng Y, Keshari RP, Xia JC, Zhou ZW. Poor prognosis of gastric adenocarcinoma with decreased expression of AHRR. PLoS One 2012;7:e43555. [PMID: 22952704 DOI: 10.1371/journal.pone.0043555] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
252 Zhao Q, Lian C, Huo Z, Li M, Liu Y, Fan L, Tan B, Zhao X, Zhang Z, Wang D, Liu Y, Guo H, Yang P, Tian Y, Li Y. The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial. Cancer Med 2020;9:5731-45. [PMID: 32583567 DOI: 10.1002/cam4.3224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
253 Ohri N, Garg MK, Aparo S, Kaubisch A, Tome W, Kennedy TJ, Kalnicki S, Guha C. Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis. Int J Radiat Oncol Biol Phys. 2013;86:330-335. [PMID: 23523184 DOI: 10.1016/j.ijrobp.2013.02.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
254 Leong D, Rai R, Nguyen B, Lee A, Yip D. Advances in adjuvant systemic therapy for non-small-cell lung cancer. World J Clin Oncol 2014; 5(4): 633-645 [PMID: 25302167 DOI: 10.5306/wjco.v5.i4.633] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
255 Piessen G, Amielh D, Messager M, Vinatier E, Leteurtre E, Triboulet JP, Mariette C. Is pretreatment endoscopic biopsy a good predictor of signet ring cell histology in gastric carcinoma? World J Surg. 2012;36:346-354. [PMID: 22102091 DOI: 10.1007/s00268-011-1351-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
256 Nakauchi M, Vos E, Janjigian YY, Ku GY, Schattner MA, Nishimura M, Gonen M, Coit DG, Strong VE. Comparison of Long- and Short-term Outcomes in 845 Open and Minimally Invasive Gastrectomies for Gastric Cancer in the United States. Ann Surg Oncol 2021;28:3532-44. [PMID: 33709174 DOI: 10.1245/s10434-021-09798-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
257 Fuse N, Bando H, Chin K, Ito S, Yoshikawa T, Tsuburaya A, Terashima M, Kawashima Y, Fukunaga T, Gotoh M, Emi Y, Yoshida K, Oki E, Takahashi S, Kuriki H, Sato K, Sasako M. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study. Gastric Cancer. 2017;20:332-340. [PMID: 26956689 DOI: 10.1007/s10120-016-0606-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
258 Duan S, Wang P, Liu F, Huang H, An W, Pan S, Wang X. Novel immune-risk score of gastric cancer: A molecular prediction model combining the value of immune-risk status and chemosensitivity. Cancer Med 2019;8:2675-85. [PMID: 30945466 DOI: 10.1002/cam4.2077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
259 Milne AN, Carneiro F, O'Morain C, Offerhaus GJ. Nature meets nurture: molecular genetics of gastric cancer. Hum Genet. 2009;126:615-628. [PMID: 19657673 DOI: 10.1007/s00439-009-0722-x] [Cited by in Crossref: 146] [Cited by in F6Publishing: 142] [Article Influence: 12.2] [Reference Citation Analysis]
260 Quan R, Huang J, Chen H, Liao Y, Lv W, Chen N, Liu J, Zhang H, Xu D. Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer : a propensity-matched analysis. Oncotarget 2016;7:76316-26. [PMID: 27602756 DOI: 10.18632/oncotarget.11783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
261 Redman MW, Goldman BH, LeBlanc M, Schott A, Baker LH. Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Clin Cancer Res 2013;19:2646-56. [PMID: 23669424 DOI: 10.1158/1078-0432.CCR-12-2939] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
262 Nakajima T, Fujii M. What make differences in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol 2014; 20(33): 11567-11573 [PMID: 25206264 DOI: 10.3748/wjg.v20.i33.11567] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
263 Wang P, Zhou H, Han G, Ni Q, Dai S, Huang J, Dai C, Yu L. Assessment of the value of adjuvant radiotherapy for treatment of gastric adenocarcinoma based on pattern of post-surgical progression. World J Surg Oncol 2021;19:205. [PMID: 34238296 DOI: 10.1186/s12957-021-02304-4] [Reference Citation Analysis]
264 Yang Y, Ma Y, Xiang X, Xing P, Wu Y, Zhang L, Tian Y. The prognostic value of the lymph node ratio for local advanced gastric cancer patients with intensity-modulated radiation therapy and concurrent chemotherapy after radical gastrectomy in China. Radiat Oncol 2020;15:237. [PMID: 33054848 DOI: 10.1186/s13014-020-01687-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;374:477-490. [PMID: 19625077 DOI: 10.1016/s0140-6736(09)] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
266 Tai DJ, Jin WS, Wu CS, Si HW, Cao XD, Guo AJ, Chang JC. Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells. Exp Ther Med 2012;4:291-6. [PMID: 23139717 DOI: 10.3892/etm.2012.591] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
267 Benli Yavuz B, Koç M, Kozacıoğlu S, Kanyılmaz G, Aktan M. Prognostic importance of PTEN, EGFR, HER-2, and IGF-1R in gastric cancer patients treated with postoperative chemoradiation. Turk J Med Sci 2019;49:1025-32. [PMID: 31318186 DOI: 10.3906/sag-1802-34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
268 Kassam Z, Mackay H, Buckley CA, Fung S, Pintile M, Oza A, Brierley J, Swallow C, Cummings B, Knox JJ, Kim J, Wong R, Siu L, Feld R, Ringash J. Adjuvant chemoradiation for gastric cancer with infusional 5-fluorouracil and cisplatin: a phase I study. Curr Oncol 2010;17:34-41. [PMID: 20697512 DOI: 10.3747/co.v17i4.521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
269 Rim CH, Shin IS, Lee HY, Yoon WS, Park S. Oncologic Benefit of Adjuvant Chemoradiation after D2 Gastrectomy: A Stepwise Hierarchical Pooled Analysis and Systematic Review. Cancers (Basel) 2020;12:E2125. [PMID: 32751879 DOI: 10.3390/cancers12082125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
270 Agolli L, Nicosia L. Between evidence and new perspectives on the current state of the multimodal approach to gastric cancer: Is there still a role for radiation therapy? World J Gastrointest Oncol 2018; 10(9): 271-281 [PMID: 30254722 DOI: 10.4251/wjgo.v10.i9.271] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
271 Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327-33. [PMID: 22585691 DOI: 10.1200/JCO.2011.36.7136] [Cited by in Crossref: 466] [Cited by in F6Publishing: 257] [Article Influence: 51.8] [Reference Citation Analysis]
272 Wu Y, Wei ZW, He YL, Schwarz RE, Smith DD, Xia GK, Zhang CH. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World J Gastroenterol 2013; 19(21): 3309-3315 [PMID: 23745033 DOI: 10.3748/wjg.v19.i21.3309] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
273 Park JH, Ryu MH, Kim HJ, Ryoo BY, Yoo C, Park I, Park YS, Oh ST, Yook JH, Kim BS, Kang YK. Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer. Gastric Cancer 2016;19:226-33. [PMID: 25614467 DOI: 10.1007/s10120-015-0464-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
274 Luo W, Zhang H, Zhao Y, Wang L, Qi L, Ran J, Liu L, Wu A. A retrospective study on intensity-modulated radiation therapy combined with chemotherapy after D2 radical surgery for gastric carcinoma. Mol Clin Oncol 2016;4:740-8. [PMID: 27123273 DOI: 10.3892/mco.2016.804] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
275 Zhang YX, Yang K. Significance of nodal dissection and nodal positivity in gastric cancer. Transl Gastroenterol Hepatol 2020;5:17. [PMID: 32258521 DOI: 10.21037/tgh.2019.09.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
276 Yu C, Yu R, Zhu W, Song Y, Li T. Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. J Cancer Res Clin Oncol 2012;138:255-9. [DOI: 10.1007/s00432-011-1085-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
277 Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013;24:1754-1761. [PMID: 23524864 DOI: 10.1093/an-nonc/mdt106] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
278 Kung CH, Jestin Hannan C, Linder G, Johansson J, Nilsson M, Hedberg J, Lindblad M. Impact of surgical resection rate on survival in gastric cancer: nationwide study. BJS Open 2021;5:zraa017. [PMID: 33688944 DOI: 10.1093/bjsopen/zraa017] [Reference Citation Analysis]
279 Koelzer VH, Langer R, Zlobec I, Lugli A. Tumor budding in upper gastrointestinal carcinomas. Front Oncol 2014;4:216. [PMID: 25177546 DOI: 10.3389/fonc.2014.00216] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
280 Zhang A, Deek MP, Kim S, Sayan M, Grann A, Wagman RT, Malhotra U, Hathout L, Biswal N, Zhang Y, Langenfeld J, Kennedy T, August DA, Jabbour SK. Vertebral body irradiation during chemoradiation therapy for esophageal cancer contributes to acute bone marrow toxicity. J Gastrointest Oncol 2019;10:513-22. [PMID: 31183202 DOI: 10.21037/jgo.2019.01.20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
281 Ge L, Wang HJ, Yin D, Lei C, Zhu JF, Cai XH, Zhang GQ. Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: A meta-analysis. World J Gastroenterol 2012; 18(48): 7384-7393 [PMID: 23326149 DOI: 10.3748/wjg.v18.i48.7384] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
282 Gamboa AC, Winer JH. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer.Cancers (Basel). 2019;11:1662. [PMID: 31717799 DOI: 10.3390/cancers11111662] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
283 Xu S, Feng L, Chen Y, Sun Y, Lu Y, Huang S, Fu Y, Zheng R, Zhang Y, Zhang R. Consistency mapping of 16 lymph node stations in gastric cancer by CT-based vessel-guided delineation of 255 patients. Oncotarget 2017;8:41465-73. [PMID: 28611300 DOI: 10.18632/oncotarget.18407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
284 Wang X, Tian Y, Tang Y, Hu ZH, Zhang JJ, Fu GS, Ma P, Ren H, Zhang T, Li N, Liu WY, Fang H, Li YX, Jin J. Tomotherapy as an adjuvant treatment for gastroesophageal junction and stomach cancer may reduce bowel and bone marrow toxicity compared to intensity-modulated radiotherapy and volumetric-modulated arc therapy.Oncotarget. 2017;8:39727-39735. [PMID: 28061474 DOI: 10.18632/oncotarget.14459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
285 Fan M, Hu W, Zhang Z. Chemoradiation for gastric cancer: controversies, updates and novel techniques. Br J Radiol 2015;88:20150027. [PMID: 25827208 DOI: 10.1259/bjr.20150027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
286 Kim YW, Kim MJ, Ryu KW, Lim HS, Lee JH, Kong SY, Lee JS, Choi IJ, Kim CG, Lee JY, Cho SJ, Kook MC, Park YI, Kim SK, Park SR. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. Gastric Cancer 2016;19:586-96. [PMID: 25851942 DOI: 10.1007/s10120-015-0490-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
287 Amedei A, Benagiano M, della Bella C, Niccolai E, D'Elios MM. Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol 2011;2011:437348. [PMID: 22253528 DOI: 10.1155/2011/437348] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
288 Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, Nagao N, Takahashi M, Takagane A, Watanabe T, Kaji M, Okitsu H, Nomura T, Matsui T, Yoshikawa T, Matsuyama J, Yamada M, Ito S, Takeuchi M, Fujii M. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. J Clin Oncol. 2019;37:1296-1304. [PMID: 30925125 DOI: 10.1200/jco.18.01138] [Cited by in Crossref: 80] [Cited by in F6Publishing: 46] [Article Influence: 40.0] [Reference Citation Analysis]
289 Syrios J, Sougioultzis S, Xynos ID, Kavantzas N, Kosmas C, Agrogiannis G, Griniatsos J, Karavokyros I, Pikoulis E, Patsouris ES, Tsavaris N. Survival in patients with stage IV noncardia gastric cancer - the influence of DNA ploidy and Helicobacter pylori infection. BMC Cancer 2012;12:264. [PMID: 22892134 DOI: 10.1186/1471-2407-12-264] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
290 Kleinberg L. Does postoperative radiation therapy benefit patients with esophageal cancer? J Gastrointest Oncol 2010;1:70-1. [PMID: 22811808 DOI: 10.3978/j.issn.2078-6891.2010.015] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
291 Russo A, Strong VE. Minimally invasive surgery for gastric cancer in USA: current status and future perspectives. Transl Gastroenterol Hepatol.  2017; 30(2):38. E collection.. [PMID: 28529992 DOI: 10.21037/tgh.2017.03.14] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
292 Cao J, Gong J, Li X, Hu Z, Xu Y, Shi H, Li D, Liu G, Jie Y, Hu B, Chong Y. Unsupervised Hierarchical Clustering Identifies Immune Gene Subtypes in Gastric Cancer. Front Pharmacol 2021;12:692454. [PMID: 34248641 DOI: 10.3389/fphar.2021.692454] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
293 Giacopuzzi S, Bencivenga M, Weindelmayer J, Verlato G, de Manzoni G. Western strategy for EGJ carcinoma. Gastric Cancer. 2017;20:60-68. [PMID: 28039533 DOI: 10.1007/s10120-016-0685-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
294 Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: A 2014 update. World J Gastroenterol 2014; 20(38): 13637-13647 [PMID: 25320502 DOI: 10.3748/wjg.v20.i38.13637] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
295 Yeh JM, Tramontano AC, Hur C, Schrag D. Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER-Medicare study. Gastric Cancer 2017;20:811-24. [PMID: 28205057 DOI: 10.1007/s10120-017-0693-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
296 Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA, Psyrri A. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018;7:123-133. [PMID: 29239137 DOI: 10.1002/cam4.1274] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 18.0] [Reference Citation Analysis]
297 Onal C, Cengiz M, Guler OC, Dolek Y, Ozkok S. The role of delineation education programs for improving interobserver variability in target volume delineation in gastric cancer. Br J Radiol 2017;90:20160826. [PMID: 28339289 DOI: 10.1259/bjr.20160826] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
298 Dixit S, Tilston M, Peter WM. Risk stratification for recurrence in patients with esophageal and junctional carcinoma treated with neoadjuvant chemotherapy and surgery. Med Oncol. 2010;27:242-248. [PMID: 19308739 DOI: 10.1007/s12032-009-9199-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
299 Kodera Y. Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan. Surg Today. 2017;47:899-907. [PMID: 28247105 DOI: 10.1007/s00595-017-1473-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
300 Lacueva FJ, Oliver I, Costa D, Calpena R. To perform or not D2 extended lymphadenectomy in patients with gastric cancer in the West. Effectiveness and limits. Clin Transl Oncol 2006;8:139-41. [PMID: 16648110 DOI: 10.1007/s12094-006-0001-4] [Reference Citation Analysis]
301 Sun Z, Zhu RJ, Yang GF, Li Y. Neoadjuvant chemotherapy with FOLFOX4 regimen to treat advanced gastric cancer improves survival without increasing adverse events: a retrospective cohort study from a Chinese center. ScientificWorldJournal 2014;2014:418694. [PMID: 25136668 DOI: 10.1155/2014/418694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
302 Baba H, Kuwabara K, Ishiguro T, Kumamoto K, Kumagai Y, Ishibashi K, Haga N, Ishida H. Prognostic factors for stage IV gastric cancer. Int Surg 2013;98:181-7. [PMID: 23701157 DOI: 10.9738/INTSURG-D-12-00027.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
303 Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer: current status of diagnosis and treatment. Cancers (Basel). 2013;5:48-63. [PMID: 24216698 DOI: 10.3390/cancers5010048] [Cited by in Crossref: 102] [Cited by in F6Publishing: 105] [Article Influence: 12.8] [Reference Citation Analysis]
304 Lurje G, Husain H, Power DG, Yang D, Groshen S, Pohl A, Zhang W, Ning Y, Manegold PC, El-Khoueiry A. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol. 2010;21:78-86. [PMID: 19622587 DOI: 10.1093/annonc/mdp280] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
305 李向柯, 樊青霞. 食管癌药物治疗的研究进展. 世界华人消化杂志 2012; 20(35): 3482-3487 [DOI: 10.11569/wcjd.v20.i35.3482] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
306 Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer 2005;92:246-51. [PMID: 15655540 DOI: 10.1038/sj.bjc.6602336] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
307 Pattison S, Mitchell C, Lade S, Leong T, Busuttil RA, Boussioutas A. Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer. PLoS One 2017;12:e0183891. [PMID: 28922362 DOI: 10.1371/journal.pone.0183891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
308 Ren F, Li S, Zhang Y, Zhao Z, Wang H, Cui Y, Wang M. Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis. Radiat Oncol 2019;14:84. [PMID: 31118042 DOI: 10.1186/s13014-019-1294-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
309 Abuderman AA. Gastric cancer & prospects of cancer in Saudi Arabia peninsula. Saudi J Biol Sci 2019;26:1095-100. [PMID: 31516334 DOI: 10.1016/j.sjbs.2018.02.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
310 Meyer HJ, Hölscher AH, Lordick F, Messmann H, Mönig S, Schumacher C, Stahl M, Wilke H, Möhler M. [Current S3 guidelines on surgical treatment of gastric carcinoma]. Chirurg 2012;83:31-7. [PMID: 22127381 DOI: 10.1007/s00104-011-2149-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
311 Raman V, Jawitz OK, Voigt SL, Yang CJ, D'Amico TA, Harpole DH Jr. The Role of Adjuvant Therapy in Patients With Margin-Positive (R1) Esophagectomy: A National Analysis. J Surg Res 2020;249:82-90. [PMID: 31926400 DOI: 10.1016/j.jss.2019.11.035] [Reference Citation Analysis]
312 Squires MH 3rd, Fisher SB, Fisher KE, Patel SH, Kooby DA, El-Rayes BF, Staley CA 3rd, Farris AB 3rd, Maithel SK. Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma. Cancer 2013;119:3242-50. [PMID: 23719746 DOI: 10.1002/cncr.28175] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
313 Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 2011;8:492-503. [DOI: 10.1038/nrclinonc.2011.45] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 10.8] [Reference Citation Analysis]
314 Wang Q, Liu X, Zhou J, Huang Y, Zhang S, Shen J, Loera S, Yuan X, Chen W, Jin M, Shibata S, Liu Y, Chu P, Wang L, Yen Y. Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer. PLoS One 2013;8:e70191. [PMID: 23922955 DOI: 10.1371/journal.pone.0070191] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
315 Zeng WJ, Hu WQ, Wang LW, Yan SG, Li JD, Zhao HL, Peng CW, Yang GF, Li Y. Long term follow up and retrospective study on 533 gastric cancer cases. BMC Surg. 2014;14:29. [PMID: 24886548 DOI: 10.1186/1471-2482-14-29] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
316 Higuchi K, Phan A, Ajani JA. Gastric cancer: advances in adjuvant and adjunct therapy. Curr Treat Options Oncol. 2003;4:413-419. [PMID: 12941201 DOI: 10.1007/s11864-003-0042-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
317 van Werkhoven E, Tajik P, Bossuyt PM. Always randomize as late as possible. Gastric Cancer 2019;22:1308-9. [PMID: 30963320 DOI: 10.1007/s10120-019-00959-3] [Reference Citation Analysis]
318 Liu JS, Che XM, Chang S, Qiu GL, He SC, Fan L, Zhao W, Zhang ZL, Wang SF. β-elemene enhances the radiosensitivity of gastric cancer cells by inhibiting Pak1 activation. World J Gastroenterol 2015; 21(34): 9945-9956 [PMID: 26379399 DOI: 10.3748/wjg.v21.i34.9945] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
319 Kim DW, Kwon OK, Yoo MW, Ryu SW, Oh SJ, Hur H, Hwang SH, Lee J, Jin SH, Lee SE, Kim JH, Kim JJ, Jeong IH, Jee YS. Actual compliance to adjuvant chemotherapy in gastric cancer. Ann Surg Treat Res 2019;96:185-90. [PMID: 30941322 DOI: 10.4174/astr.2019.96.4.185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
320 Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun 2018;9:1777. [PMID: 29725014 DOI: 10.1038/s41467-018-04179-8] [Cited by in Crossref: 70] [Cited by in F6Publishing: 78] [Article Influence: 23.3] [Reference Citation Analysis]
321 Liao X, Fan Y, Hou J, Chen X, Xu X, Yang Y, Shen J, Mi P, Huang X, Zhang W, Cao H, Hong X, Hu T, Zhan YY. Identification of Chaetocin as a Potent non-ROS-mediated Anticancer Drug Candidate for Gastric Cancer. J Cancer 2019;10:3678-90. [PMID: 31333785 DOI: 10.7150/jca.32803] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
322 Zhao Y, Wang Y, Shan L, Peng C, Zhang W, Zhao X. A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus. Sci Rep 2021;11:6800. [PMID: 33762694 DOI: 10.1038/s41598-021-86102-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
323 Ashraf N, Hoffe S, Kim R. Locally advanced gastroesophageal junction tumor: a treatment dilemma. Oncologist 2015;20:134-42. [PMID: 25561508 DOI: 10.1634/theoncologist.2014-0377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
324 Yan Z, Xiong Y, Xu W, Gao J, Cheng Y, Wang Z, Chen F, Zheng G. Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS One. 2012;7:e40037. [PMID: 22802949 DOI: 10.1371/journal.pone.0040037] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 7.1] [Reference Citation Analysis]
325 Xu JF, Zhao ZG, Ye LL, Zhuge W, Han Z, Zhang TM, Ye SS, Chen WJ, Zhu S, Shi L, Zhang J, Guo AZ, Xue XY, Shen X. Prognostic significance of Daxx NCR (Nuclear/Cytoplasmic Ratio) in gastric cancer. Cancer Med 2017;6:2063-75. [PMID: 28812328 DOI: 10.1002/cam4.1144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
326 Lim DH, Kim DY, Kang MK, Kim YI, Kang WK, Park CK, Kim S, Noh JH, Joh JW, Choi SH, Sohn TS, Heo JS, Park CH, Park JO, Lee JE, Park YJ, Nam HR, Park W, Ahn YC, Huh SJ. Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view. Br J Cancer 2004;91:11-7. [PMID: 15162146 DOI: 10.1038/sj.bjc.6601896] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis]
327 Giuliani A, Miccini M, Basso L. Extent of lymphadenectomy and perioperative therapies: Two open issues in gastric cancer. World J Gastroenterol 2014; 20(14): 3889-3904 [PMID: 24744579 DOI: 10.3748/wjg.v20.i14.3889] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
328 Seow-En I, Seow-Choen F. Intestinal type gastric adenocarcinoma with unusual synchronous metastases to the colorectum and bladder. World J Clin Cases 2015; 3(6): 533-537 [PMID: 26090375 DOI: 10.12998/wjcc.v3.i6.533] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
329 Campbell NP, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol 2010; 16(30): 3793-3803 [PMID: 20698042 DOI: 10.3748/wjg.v16.i30.3793] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
330 Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005;241:27-39. [PMID: 15621988 DOI: 10.1097/01.sla.0000149300.28588.23] [Cited by in Crossref: 405] [Cited by in F6Publishing: 383] [Article Influence: 25.3] [Reference Citation Analysis]
331 Sakuramoto S, Yamashita K, Kikuchi S, Futawatari N, Katada N, Watanabe M, Okutomi T, Wang G, Bax L. Laparoscopy versus open distal gastrectomy by expert surgeons for early gastric cancer in Japanese patients: short-term clinical outcomes of a randomized clinical trial. Surg Endosc 2013;27:1695-705. [PMID: 23247737 DOI: 10.1007/s00464-012-2658-9] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 6.9] [Reference Citation Analysis]
332 Lee SJ, Do IG, Lee J, Kim KM, Jang J, Sohn I, Kang WK. Gastric cancer (GC) patients with hedgehog pathway activation: PTCH1 and GLI2 as independent prognostic factors. Target Oncol. 2013;8:271-280. [PMID: 23371028 DOI: 10.1007/s11523-013-0253-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
333 Nautiyal J, Kanwar SS, Majumdar AP. EGFR(s) in aging and carcinogenesis of the gastrointestinal tract. Curr Protein Pept Sci 2010;11:436-50. [PMID: 20491625 DOI: 10.2174/138920310791824110] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
334 Kim SY, Song X, Zhang L, Bartlett DL, Lee YJ. Role of Bcl-xL/Beclin-1 in interplay between apoptosis and autophagy in oxaliplatin and bortezomib-induced cell death. Biochem Pharmacol. 2014;88:178-188. [PMID: 24486574 DOI: 10.1016/j.bcp.2014.01.027] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
335 Gallo A, Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol 2006; 12(20): 3237-3242 [PMID: 16718845 DOI: 10.3748/wjg.v12.i20.3237] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 74] [Article Influence: 5.3] [Reference Citation Analysis]
336 Yuan SQ, Wu WJ, Qiu MZ, Wang ZX, Yang LP, Jin Y, Yun JP, Gao YH, Li YH, Zhou ZW, Wang F, Xu RH. Development and Validation of a Nomogram to Predict the Benefit of Adjuvant Radiotherapy for Patients with Resected Gastric Cancer. J Cancer 2017;8:3498-505. [PMID: 29151934 DOI: 10.7150/jca.19879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
337 Costa WL, Coimbra FJ, Ribeiro HS, Diniz AL, de Godoy AL, Begnami M, Silva MJ, Fanelli MF, Mello CA. Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients. World J Surg Oncol. 2012;10:195. [PMID: 22992263 DOI: 10.1186/1477-7819-10-195] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
338 Wu H, Qiao F, Zhao Y, Wu S, Hu M, Wu T, Huang F, Chen W, Sun D, Liu M, Zhao J. Downregulation of Long Non-coding RNA FALEC Inhibits Gastric Cancer Cell Migration and Invasion Through Impairing ECM1 Expression by Exerting Its Enhancer-Like Function. Front Genet 2019;10:255. [PMID: 30984243 DOI: 10.3389/fgene.2019.00255] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
339 Zhao B, Blair SL, Katz MHG, Lowy AM, Kelly KJ. Adherence with operative standards in the treatment of gastric cancer in the United States. Gastric Cancer 2020;23:550-60. [PMID: 31745679 DOI: 10.1007/s10120-019-01028-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
340 Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Ohashi N, Ito Y, Nakayama G, Koike M, Yamamura Y, Nakao A. In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues. Int J Clin Oncol 2006;11:449-53. [PMID: 17180513 DOI: 10.1007/s10147-006-0618-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
341 Zhu K, Diao D, Dang C, Shi L, Wang J, Yan R, Yuan D, Li K. Elevated KIAA0101 expression is a marker of recurrence in human gastric cancer. Cancer Sci 2013;104:353-9. [PMID: 23240630 DOI: 10.1111/cas.12083] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
342 Eun H, Hur H, Byun CS, Son SY, Han SU, Cho YK. Effects of Continuing Adjuvant S-1 for 1 Year on the Prognosis of Gastric Cancer Patients: Results from a Prospective Single Center Study. J Gastric Cancer 2015;15:113-20. [PMID: 26161284 DOI: 10.5230/jgc.2015.15.2.113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
343 Chen XZ, Yang K, Liu J, Chen XL, Hu JK. Neoadjuvant plus adjuvant chemotherapy benefits overall survival of locally advanced gastric cancer. World J Gastroenterol 2011; 17(40): 4542-4544 [PMID: 22110287 DOI: 10.3748/wjg.v17.i40.4542] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
344 Slagter AE, Vollebergh MA, Jansen EPM, van Sandick JW, Cats A, van Grieken NCT, Verheij M. Towards Personalization in the Curative Treatment of Gastric Cancer. Front Oncol. 2020;10:614907. [PMID: 33330111 DOI: 10.3389/fonc.2020.614907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
345 Choi AH, Kim J, Chao J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World J Gastroenterol 2015; 21(24): 7343-7348 [PMID: 26139980 DOI: 10.3748/wjg.v21.i24.7343] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 39] [Article Influence: 7.7] [Reference Citation Analysis]
346 Hingorani DV, Crisp JL, Doan MK, Camargo MF, Quraishi MA, Aguilera J, Gilardi M, Gross LA, Jiang T, Li WT, Ongkeko WM, Cohen EEW, Gutkind JS, Adams SR, Advani SJ. Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors. Biomaterials 2020;248:120032. [PMID: 32304937 DOI: 10.1016/j.biomaterials.2020.120032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
347 Straatman J, van der Wielen N, Cuesta MA, Gisbertz SS, Hartemink KJ, Alonso Poza A, Weitz J, Mateo Vallejo F, Ahktar K, Diez Del Val I. Surgical techniques, open versus minimally invasive gastrectomy after chemotherapy (STOMACH trial): study protocol for a randomized controlled trial. Trials. 2015;16:123. [PMID: 25873249 DOI: 10.1186/s13063-015-0638-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
348 Shi H, Ji M, Wu J, Zhou Q, Li X, Li Z, Zheng X, Xu B, Zhao W, Wu C. Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer. World J Surg Oncol. 2014;12:188. [PMID: 24947047 DOI: 10.1186/1477-7819-12-188] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
349 Song H, Zhu J, Lu D. Molecular-targeted first-line therapy for advanced gastric cancer. Cochrane Database Syst Rev 2016;7:CD011461. [PMID: 27432490 DOI: 10.1002/14651858.CD011461.pub2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
350 Andreollo NA, Drizlionoks E, Tercioti-Junior V, Coelho-Neto JS, Ferrer JAP, Carvalheira JBC, Lopes LR. ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER? Arq Bras Cir Dig 2019;32:e1464. [PMID: 31859917 DOI: 10.1590/0102-672020190001e1464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
351 Yang ZL, Zhu MH, Shi Q, Lu FM, Wang CX. Prognostic Value of the Number of Lymph Nodes Examined in Patients with Node-Negative Gastric Cancer. J Gastrointest Surg 2019;23:460-7. [PMID: 30225793 DOI: 10.1007/s11605-018-3947-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
352 Oh DY, Bang YJ. Adjuvant and neoadjuvant therapy for gastric cancer. Curr Treat Options Oncol. 2013;14:311-320. [PMID: 23686725 DOI: 10.1007/s11864-013-0238-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
353 Wang F, Dai W, Wang Y, Shen M, Chen K, Cheng P, Zhang Y, Wang C, Li J, Zheng Y, Lu J, Yang J, Zhu R, Zhang H, Zhou Y, Xu L, Guo C. The synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma. PLoS One 2014;9:e97414. [PMID: 24816638 DOI: 10.1371/journal.pone.0097414] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
354 Buffart TE, Carvalho B, van Grieken NC, van Wieringen WN, Tijssen M, Kranenbarg EM, Verheul HM, Grabsch HI, Ylstra B, van de Velde CJ, Meijer GA. Losses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancer. Oncologist 2012;17:653-62. [PMID: 22531355 DOI: 10.1634/theoncologist.2010-0379] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
355 Proserpio I, Rausei S, Barzaghi S, Frattini F, Galli F, Iovino D, Rovera F, Boni L, Dionigi G, Pinotti G. Multimodal treatment of gastric cancer. World J Gastrointest Surg 2014; 6(4): 55-58 [PMID: 24829622 DOI: 10.4240/wjgs.v6.i4.55] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
356 Wang X, Jin J, Li YX, Ren H, Fang H, Wang SL, Liu YP, Wang WH, Yu ZH, Song YW, Liu XF. Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer. World J Gastroenterol 2014; 20(4): 1067-1073 [PMID: 24574780 DOI: 10.3748/wjg.v20.i4.1067] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
357 Wang YN, Chang SY, Hwang JM, Chang YK, Kao WY, Wan HL, Tzeng IS, Wu CC. Evaluating the benefit of adjuvant radiotherapy after extensive lymph node dissection for gastric cancer: a single-institute retrospective study. Tzu Chi Med J 2021;33:288-93. [PMID: 34386368 DOI: 10.4103/tcmj.tcmj_230_20] [Reference Citation Analysis]
358 Huang Z, Li S, Yang X, Lu F, Huang M, Zhang S, Xiong Y, Zhang P, Si J, Ma Y, Yang Y. Long-term survival of patients with locally advanced esophageal squamous cell carcinoma receiving esophagectomy following neoadjuvant chemotherapy: a cohort study. Cancer Manag Res 2019;11:1299-308. [PMID: 30799956 DOI: 10.2147/CMAR.S195355] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
359 Wang X, Wang WH, Wang SL, Song YW, Liu YP, Tang Y, Li N, Liu WY, Fang H, Li YX, Zhao DB, Chi Y, Yang L, Jin J. Efficacy and toxicity of capecitabine combined with intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with gastric cancer. World J Gastrointest Oncol 2021; 13(10): 1532-1543 [PMID: 34721783 DOI: 10.4251/wjgo.v13.i10.1532] [Reference Citation Analysis]
360 Lee JY, Son T, Cheong JH, Hyung WJ, Noh SH, Kim CB, Park CG, Kim HI. Association between Chemotherapy-Response Assays and Subsets of Tumor-Infiltrating Lymphocytes in Gastric Cancer: A Pilot Study. J Gastric Cancer. 2015;15:223-230. [PMID: 26819801 DOI: 10.5230/jgc.2015.15.4.223] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
361 Bautista-Quach MA, Ake CD, Chen M, Wang J. Gastrointestinal lymphomas: Morphology, immunophenotype and molecular features. J Gastrointest Oncol 2012;3:209-25. [PMID: 22943012 DOI: 10.3978/j.issn.2078-6891.2012.024] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
362 Das P. Esophageal cancer: Is preoperative chemoradiation the new standard? J Gastrointest Oncol 2010;1:68-9. [PMID: 22811807 DOI: 10.3978/j.issn.2078-6891.2010.014] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
363 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 2011;71:541-555. [PMID: 21443280 DOI: 10.2165/11585460-000000000-000003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
364 Huang ZN, Desiderio J, Chen QY, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Lin JL, Zheng HL, Huang CM. Indications for adjuvant chemotherapy in patients with AJCC stage IIa T3N0M0 and T1N2M0 gastric cancer-an east and west multicenter study. BMC Gastroenterol 2019;19:205. [PMID: 31791240 DOI: 10.1186/s12876-019-1096-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
365 Sharma A, Radhakrishnan V. Gastric cancer in India. Indian J Med Paediatr Oncol 2021;32:12-6. [DOI: 10.4103/0971-5851.81884] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
366 Li XH, He F, Yan SM, Li Y, Cao Y, Huang CY, Zhou ZW. Increased expression of stomatin-like protein 2 (STOML2) predicts decreased survival in gastric adenocarcinoma: a retrospective study. Med Oncol 2014;31:763. [PMID: 24258357 DOI: 10.1007/s12032-013-0763-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
367 Chen S, Chen YB, Li YF, Feng XY, Zhou ZW, Yuan XH, Qian CN. Normal carcinoembryonic antigen indicates benefit from perioperative chemotherapy to gastric carcinoma patients. World J Gastroenterol 2012; 18(29): 3910-3916 [PMID: 22876045 DOI: 10.3748/wjg.v18.i29.3910] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
368 Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist. 2011;16:844-858. [PMID: 21632459 DOI: 10.1634/theoncologist.2010-0387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
369 Liu C, Lu P, Lu Y, Xu H, Wang S, Chen J. Clinical implications of metastatic lymph node ratio in gastric cancer. BMC Cancer. 2007;7:200. [PMID: 17958880 DOI: 10.1186/1471-2407-7-200] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
370 Wiedmann MW, Mössner J. New and emerging combination therapies for esophageal cancer. Cancer Manag Res 2013;5:133-46. [PMID: 23869177 DOI: 10.2147/CMAR.S32199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
371 von Wichert G, Seufferlein T. [Adjuvant chemotherapy of solid tumors of the gastrointestinal tract: where is the progress?]. Internist (Berl) 2007;48:1335-42. [PMID: 17965842 DOI: 10.1007/s00108-007-1974-y] [Reference Citation Analysis]
372 Chen S, Feng X, Li Y, Yuan X, Zhou Z, Chen Y. Efficacy and safety of XELOX and FOLFOX6 adjuvant chemotherapy following radical total gastrectomy. Oncol Lett 2012;3:781-6. [PMID: 22740993 DOI: 10.3892/ol.2012.577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
373 Spolverato G, Kim Y, Ejaz A, Valero V 3rd, Squires MH, Poultsides G, Fields RC, Bloomston M, Weber SM, Acher AW, Votanopoulos K, Schmidt C, Cho CS, Maithel SK, Pawlik TM. A multi-institutional analysis of open versus minimally-invasive surgery for gastric adenocarcinoma: results of the US gastric cancer collaborative. J Gastrointest Surg 2014;18:1563-74. [PMID: 24912915 DOI: 10.1007/s11605-014-2562-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
374 Hsieh CH, Hou ML, Wang LY, Tai HC, Tsai TH, Chen YJ. Local pelvic irradiation modulates Pharmacokinetics of 5-Fluorouracil in the plasma but not in the Lymphatic System. BMC Cancer 2015;15:316. [PMID: 25928348 DOI: 10.1186/s12885-015-1344-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
375 Yusufu A, Tuerdi R, Redati D, Rehemutula A, Zhao ZL, Wang HJ. Expression and clinical correlation of Survivin and PTEN in gastric cancer patients. Oncol Lett 2020;20:297. [PMID: 33101491 DOI: 10.3892/ol.2020.12160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
376 Pruthi DS, Ahmad M, Gupta M, Bansal S, Nautiyal V, Saini S. Assessment of quality of life in resectable gastric cancer patients undergoing chemoradiotherapy as adjuvant treatment. South Asian J Cancer 2018;7:16-20. [PMID: 29600226 DOI: 10.4103/sajc.sajc_196_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
377 Giampieri R, Del Prete M, Cantini L, Baleani MG, Bittoni A, Maccaroni E, Berardi R. Optimal management of resected gastric cancer. Cancer Manag Res 2018;10:1605-18. [PMID: 29950898 DOI: 10.2147/CMAR.S151552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
378 Charalampakis N, Nogueras González GM, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Rogers JE, Harada K, Matamoros A Jr, Sagebiel T, Das P, Minsky BD, Lee JH, Weston B, Bhutani MS, Estrella JS, Badgwell BD, Ajani JA. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology 2016;90:239-47. [PMID: 27046280 DOI: 10.1159/000443506] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
379 Xie H, Li X, Yang W, Yu L, Jiang X, Chen Y, Shen Z, Li C, Gu M, Shi L. N6-(2-hydroxyethyl)-Adenosine Induces Apoptosis via ER Stress and Autophagy of Gastric Carcinoma Cells In Vitro and In Vivo. Int J Mol Sci 2020;21:E5815. [PMID: 32823628 DOI: 10.3390/ijms21165815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
380 Gao SJ, Park HS, Corso CD, Rutter CE, Khan SA, Johung KL. Post-operative radiotherapy is associated with improved survival in esophageal cancer with positive surgical margins. J Gastrointest Oncol 2017;8:953-61. [PMID: 29299354 DOI: 10.21037/jgo.2017.08.12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
381 Wakatsuki T, Yamamoto N, Sano T, Chin K, Kawachi H, Takahari D, Ogura M, Ichimura T, Nakayama I, Osumi H, Matsushima T, Suenaga M, Shinozaki E, Hiki N, Ishikawa Y, Yamaguchi K. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. J Gastroenterol. 2018;53:1186-1195. [PMID: 29633013 DOI: 10.1007/s00535-018-1464-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
382 Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, Hegde P, Zha J, Pandita A, Peterson A, Salgia R. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov. 2011;1:573-579. [PMID: 22389872 DOI: 10.1158/2159-8290.cd-11-0175] [Cited by in Crossref: 86] [Cited by in F6Publishing: 53] [Article Influence: 9.6] [Reference Citation Analysis]
383 Hazard L, O’Connor J, Scaife C. Role of radiation therapy in gastric adenocarcinoma. World J Gastroenterol 2006; 12(10): 1511-1520 [PMID: 16570342 DOI: 10.3748/wjg.v12.i10.1511] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
384 Liakakos T, Roukos DH. Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc 2008;22:1402-4. [PMID: 18365277 DOI: 10.1007/s00464-008-9890-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
385 Chen Y, Wu X, Liu C, Zhou Y. Betulinic acid triggers apoptosis and inhibits migration and invasion of gastric cancer cells by impairing EMT progress. Cell Biochem Funct 2020;38:702-9. [PMID: 32283563 DOI: 10.1002/cbf.3537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
386 Chen X, Chen Y, Hu Y, Lin T, Luo J, Li T, Li T, Huang H, Zhu Y, Li T, Chen H, Liu H, Li G, Yu J. The Methods of Lymph Node Examination Make a Difference to Node Staging and Detection of N3b Node Status for Gastric Cancer. Front Oncol 2020;10:123. [PMID: 32117770 DOI: 10.3389/fonc.2020.00123] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
387 McLoughlin JM. Adenocarcinoma of the stomach: a review. Proc (Bayl Univ Med Cent) 2004;17:391-9. [PMID: 16200126 DOI: 10.1080/08998280.2004.11928001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
388 Woo JW, Ryu KW, Park JY, Eom BW, Kim MJ, Yoon HM, Park SR, Kook MC, Choi IJ, Kim YW, Park YI. Prognostic impact of microscopic tumor involved resection margin in advanced gastric cancer patients after gastric resection. World J Surg 2014;38:439-46. [PMID: 24132828 DOI: 10.1007/s00268-013-2301-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
389 Schuhmacher C, Reim D, Novotny A. Neoadjuvant treatment for gastric cancer. J Gastric Cancer. 2013;13:73-78. [PMID: 23844320 DOI: 10.5230/jgc.2013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
390 Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210-5218. [PMID: 21060024 DOI: 10.1200/jco2009.26.6114] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
391 Schimanski CC, Schlaegel F, Jordan M, Moehler M, Sgourakis G, Drescher DG, Galle PR, Lang H, Gockel I. VEGF-D correlates with metastatic disease in gastric cancer patients undergoing surgery. World J Surg 2011;35:1010-6. [PMID: 21387130 DOI: 10.1007/s00268-011-1041-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
392 Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol. 2017;35:3671-3677. [PMID: 28976791 DOI: 10.1200/jco.2017.74.2130] [Cited by in Crossref: 62] [Cited by in F6Publishing: 22] [Article Influence: 15.5] [Reference Citation Analysis]
393 Li L, Li Y, Huang Y, Ouyang Y, Zhu Y, Wang Y, Guo X, Yuan Y, Gong K. Long non-coding RNA MIF-AS1 promotes gastric cancer cell proliferation and reduces apoptosis to upregulate NDUFA4. Cancer Sci 2018;109:3714-25. [PMID: 30238562 DOI: 10.1111/cas.13801] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 7.7] [Reference Citation Analysis]
394 Ning K, Shao Y, He Y, Wang F, Cui X, Liu F, Li D, Li F. Histone demethylase Jumonji domain-containing 1A inhibits proliferation and progression of gastric cancer by upregulating runt-related transcription factor 3. Cancer Sci 2020;111:3679-92. [PMID: 32762126 DOI: 10.1111/cas.14594] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
395 谢振山, 张谢夫, 刘光辉, 刘涛, 董新华, 杨振. 应用多西他赛联合S-1新辅助化疗方案治疗可切除的进展期胃癌的疗效. 世界华人消化杂志 2014; 22(34): 5334-5338 [DOI: 10.11569/wcjd.v22.i34.5334] [Reference Citation Analysis]
396 Mao QQ, Xu XY, Shang A, Gan RY, Wu DT, Atanasov AG, Li HB. Phytochemicals for the Prevention and Treatment of Gastric Cancer: Effects and Mechanisms. Int J Mol Sci 2020;21:E570. [PMID: 31963129 DOI: 10.3390/ijms21020570] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
397 Choi JH, Lim HY, Joo HJ, Kim HS, Yi JW, Kim HC, Cho YK, Kim MW, Lee KB. Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer. 2002;86:1578-1585. [PMID: 12085207 DOI: 10.1038/sj.bjc.6600305] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
398 Li Y, Zhu Z, Ma F, Xue L, Tian Y. Gastric Signet Ring Cell Carcinoma: Current Management and Future Challenges. Cancer Manag Res 2020;12:7973-81. [PMID: 32943931 DOI: 10.2147/CMAR.S268032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
399 Cho J, Chang YH, Heo YJ, Kim S, Kim NK, Park JO, Kang WK, Lee J, Kim KM. Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. ESMO Open. 2018;3:e000326. [PMID: 29636988 DOI: 10.1136/esmoopen-2018-000326] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
400 Huang CY, Chen YM, Zhao JJ, Chen YB, Jiang SS, Yan SM, Zhao BW, Pan K, Wang DD, Lv L, Li YF, Wang W, Zhou ZW, Xia JC. Decreased expression of transcription elongation factor A-like 7 is associated with gastric adenocarcinoma prognosis. PLoS One 2013;8:e54671. [PMID: 23372750 DOI: 10.1371/journal.pone.0054671] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
401 Sun J, Song Y, Wang Z, Gao P, Chen X, Xu Y, Liang J, Xu H. Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer. 2012;12:526. [PMID: 23153379 DOI: 10.1186/1471-2407-12-526] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
402 Ziogas D, Baltogiannis G, Fatouros M. Continuing debate on D2 lymphadenectomy for gastric cancer. World J Surg 2008;32:2127-8. [PMID: 18563483 DOI: 10.1007/s00268-008-9645-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
403 孙姗姗, 赵爱光, 杨金坤, 赵刚, 蔡泳, 李朝燕. 健脾为基础的复方辨证治疗对胃癌根治术后无病生存期的影响. 世界华人消化杂志 2011; 19(6): 581-587 [DOI: 10.11569/wcjd.v19.i6.581] [Reference Citation Analysis]
404 Cidon EU, Ellis SG, Inam Y, Adeleke S, Zarif S, Geldart T. Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. Cancers (Basel). 2013;5:64-91. [PMID: 24216699 DOI: 10.3390/cancers5010064] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
405 Newton AD, Datta J, Loaiza-Bonilla A, Karakousis GC, Roses RE. Neoadjuvant therapy for gastric cancer: current evidence and future directions. J Gastrointest Oncol. 2015;6:534-543. [PMID: 26487948 DOI: 10.3978/j.issn.2078-6891.2015.047] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
406 Fields RC, Strong VE, Gönen M, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer. 2011;104:1840-1847. [PMID: 21610705 DOI: 10.1038/bjc.2011.175] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 6.3] [Reference Citation Analysis]
407 Voron T, Messager M, Duhamel A, Lefevre J, Mabrut JY, Goere D, Meunier B, Brigand C, Hamy A, Glehen O, Mariette C, Paye F. Is signet-ring cell carcinoma a specific entity among gastric cancers? Gastric Cancer. 2016;19:1027-1040. [PMID: 26606931 DOI: 10.1007/s10120-015-0564-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
408 Jiang JT, Shen YP, Wu CP, Zhu YB, Wei WX, Chen LJ, Zheng X, Sun J, Lu BF, Zhang XG. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol 2010; 16(48): 6155-6162 [PMID: 21182234 DOI: 10.3748/wjg.v16.i48.6155] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
409 Douridas GN, Fountoulakis A, Souglakos J, Gourtsoyianni S, Vini L, Levidou G, Liakakos T, Agalianos C, Dervenis C, Kalogeridi MA, Karavokyros I, Koumarianou A, Kountourakis P, Oikonomopoulos G, Economopoulou P, Sgouros J, Sgouros SN, Stamou K, Triantopoulou C, Zacharoulis D, Gouvas N, Xynos E. Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer. Updates Surg 2020;72:1-19. [PMID: 32112342 DOI: 10.1007/s13304-020-00723-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
410 Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Son T, Jung MR, Heo MH, Kim HK, Park C, Yoo CH, Choi JH, Zang DY, Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Cho SH, Ryu SW, Kook MC, Ryoo BY, Kim HK, Yoo MW, Lee NS, Lee SH, Kim G, Lee Y, Lee JH, Noh SH. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol 2021;39:2903-13. [PMID: 34133211 DOI: 10.1200/JCO.20.02914] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
411 Xu J, Zhu J, Wei Q. Adjuvant Radiochemotherapy vs Chemotherapy Alone for Gastric Cancer: Implications for Target Definition. J Cancer. 2019;10:458-466. [PMID: 30719140 DOI: 10.7150/jca.27335] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
412 Barreto SG, Windsor JA. Redefining early gastric cancer. Surg Endosc. 2015;Epub ahead of print. [PMID: 25829068 DOI: 10.1007/s00464-015-4184-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
413 Li X, Huang Q, Lei Y, Zheng X, Dai S, Leng W, Liu M. Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. Ann Transl Med 2021;9:513. [PMID: 33850910 DOI: 10.21037/atm-21-434] [Reference Citation Analysis]
414 Tan E, Lam S, Han SP, Storey D, Sandroussi C. Perioperative outcomes and survival in elderly patients aged ≥ 75 years undergoing gastrectomy for gastric cancer: an 18-year retrospective analysis in a single Western centre. Langenbecks Arch Surg 2021;406:1057-69. [PMID: 33770264 DOI: 10.1007/s00423-021-02116-w] [Reference Citation Analysis]
415 Zhou ML, Wang L, Wang JZ, Yang W, Hu R, Li GC, Sheng WQ, Zhang Z. Validation of the Memorial Sloan Kettering Cancer Center nomogram to predict disease-specific survival in a Chinese gastric cancer population receiving postoperative chemoradiotherapy after an R0 resection. Oncotarget 2016;7:64757-65. [PMID: 27588465 DOI: 10.18632/oncotarget.11665] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
416 Selcukbiricik F, Buyukunal E, Tural D, Ozguroglu M, Demirelli F, Serdengecti S. Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience. World J Gastroenterol 2013; 19(14): 2154-2161 [PMID: 23599641 DOI: 10.3748/wjg.v19.i14.2154] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
417 Rees J, Hurt CN, Gollins S, Mukherjee S, Maughan T, Falk SJ, Staffurth J, Ray R, Bashir N, Geh JI, Cunningham D, Roy R, Bridgewater J, Griffiths G, Nixon LS, Blazeby JM, Crosby T. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. Br J Cancer 2015;113:603-10. [PMID: 26203761 DOI: 10.1038/bjc.2015.258] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
418 Han JM, Sohng JK, Lee WH, Oh TJ, Jung HJ. Identification of Cyclophilin A as a Potential Anticancer Target of Novel Nargenicin A1 Analog in AGS Gastric Cancer Cells. Int J Mol Sci 2021;22:2473. [PMID: 33804393 DOI: 10.3390/ijms22052473] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
419 Park SC, Chun HJ. Chemotherapy for advanced gastric cancer: review and update of current practices. Gut Liver. 2013;7:385-393. [PMID: 23898376 DOI: 10.5009/gnl.2013.7.4.385] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
420 Delaunoit T. Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag Res 2011;3:257-66. [PMID: 21792334 DOI: 10.2147/CMR.S12713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 0.1] [Reference Citation Analysis]
421 Zhang K, Lu C, Huang X, Cui J, Li J, Gao Y, Liang W, Liu Y, Sun Y, Liu H, Wei B, Chen L. Long noncoding RNA AOC4P regulates tumor cell proliferation and invasion by epithelial-mesenchymal transition in gastric cancer. Therap Adv Gastroenterol 2019;12:1756284819827697. [PMID: 30815034 DOI: 10.1177/1756284819827697] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
422 Taki T, Hoya Y, Watanabe A, Nakayoshi T, Okamoto T, Sekine H, Mitsumori N, Yanaga K. Usefulness of chemoradiotherapy for inoperable gastric cancer. Ann R Coll Surg Engl 2017;99:332-6. [PMID: 27659357 DOI: 10.1308/rcsann.2016.0305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
423 Yan S, He F, Luo R, Wu H, Huang M, Huang C, Li Y, Zhou Z. Decreased expression of BRCA1-associated protein 1 predicts unfavorable survival in gastric adenocarcinoma. Tumour Biol 2016;37:6125-33. [PMID: 26611647 DOI: 10.1007/s13277-015-3983-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
424 Yu WW, Fu XL, Cai XW, Sun MH, Guo YM. Identification of differentially expressed proteins in the locoregional recurrent esophageal squamous cell carcinoma by quantitative proteomics. J Gastrointest Oncol 2021;12:991-1006. [PMID: 34295551 DOI: 10.21037/jgo-21-278] [Reference Citation Analysis]
425 Ruspi L, Galli F, Frattini F, Peverelli C, Di Rocco G, Martignoni F, Rovera F, Boni L, Dionigi G, Rausei S. A “perfect” lymph node staging system requires a “perfect” surgery. Transl Gastroenterol Hepatol. 2016;1:10. [PMID: 28138577 DOI: 10.21037/tgh.2016.01.05] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
426 Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643-655. [PMID: 24061039 DOI: 10.1038/nrclinonc] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
427 Chang JS, Koom WS, Lee Y, Yoon HI, Lee HS. Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: Is radiotherapy necessary after D2-dissection? World J Gastroenterol 2014; 20(36): 12900-12907 [PMID: 25278687 DOI: 10.3748/wjg.v20.i36.12900] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
428 Fields RC, Strong VE, Gönen M, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer. 2011;104:1840-1847. [PMID: 21610705 DOI: 10.1038/bjc.2011.175bjc2011175] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
429 Won E, Shah MA, Schöder H, Strong VE, Coit DG, Brennan MF, Kelsen DP, Janjigian YY, Tang LH, Capanu M, Rizk NP, Allen PJ, Bains MS, Ilson DH. Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. J Gastrointest Oncol 2016;7:506-14. [PMID: 27563439 DOI: 10.21037/jgo.2016.06.01] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
430 Stewart C, Chao J, Chen YJ, Lin J, Sullivan MJ, Melstrom L, Hyung WJ, Fong Y, Paz IB, Woo Y. Multimodality management of locally advanced gastric cancer-the timing and extent of surgery. Transl Gastroenterol Hepatol 2019;4:42. [PMID: 31231709 DOI: 10.21037/tgh.2019.05.02] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
431 Hegemann NS, Koepple R, Walter F, Boeckle D, Fendler WP, Angele MK, Boeck S, Belka C, Roeder F. Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival. Strahlenther Onkol 2018;194:435-43. [PMID: 29349603 DOI: 10.1007/s00066-018-1261-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
432 Li W, Wong CC, Zhang X, Kang W, Nakatsu G, Zhao Q, Chen H, Go MYY, Chiu PWY, Wang X, Ji J, Li X, Cai Z, Ng EKW, Yu J. CAB39L elicited an anti-Warburg effect via a LKB1-AMPK-PGC1α axis to inhibit gastric tumorigenesis. Oncogene 2018;37:6383-98. [PMID: 30054562 DOI: 10.1038/s41388-018-0402-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
433 Biondi A, Lirosi MC, D’Ugo D, Fico V, Ricci R, Santullo F, Rizzuto A, Cananzi FC, Persiani R. Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives. World J Gastrointest Oncol 2015; 7(12): 389-400 [PMID: 26690252 DOI: 10.4251/wjgo.v7.i12.389] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
434 Jabbour SK, Thomas CR Jr. Radiation therapy in the postoperative management of esophageal cancer. J Gastrointest Oncol 2010;1:102-11. [PMID: 22811814 DOI: 10.3978/j.issn.2078-6891.2010.013] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
435 Miao RL, Wu AW. Towards personalized perioperative treatment for advanced gastric cancer. World J Gastroenterol 2014; 20(33): 11586-11594 [PMID: 25206266 DOI: 10.3748/wjg.v20.i33.11586] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
436 Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643-655. [PMID: 24061039 DOI: 10.1038/nrclinonc.2013.170] [Cited by in Crossref: 249] [Cited by in F6Publishing: 244] [Article Influence: 31.1] [Reference Citation Analysis]
437 Ngoc Thi Dang D, Ngoc Thi Nguyen L, Thi Dang N, Quang Dang H, Ta TV. Quality of Life in Vietnamese Gastric Cancer Patients. Biomed Res Int 2019;2019:7167065. [PMID: 31236411 DOI: 10.1155/2019/7167065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
438 Wang Q, Peng L, Han Y, Li T, Dai W, Wang Y, Wu L, Wei Y, Xie T, Fang Q, Li Q, Lang J, Cao B. Preoperative Serum Sodium Level as a Prognostic and Predictive Biomarker for Adjuvant Therapy in Esophageal Cancer. Front Oncol 2020;10:555714. [PMID: 33552948 DOI: 10.3389/fonc.2020.555714] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
439 Foo M, Leong T. Adjuvant therapy for gastric cancer: Current and future directions. World J Gastroenterol 2014; 20(38): 13718-13727 [PMID: 25320509 DOI: 10.3748/wjg.v20.i38.13718] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
440 Müller B, García C, Sola JA, Fernandez W, Werner P, Cerda M, Slater J, Benavides C, Arancibia J, Ascui R, Reyes F, Stevens MA, Miranda JP, Buchholtz M, Corvalan AH. Perioperative chemotherapy in locally advanced gastric cancer in Chile: from evidence to daily practice. Ecancermedicalscience 2021;15:1244. [PMID: 34267800 DOI: 10.3332/ecancer.2021.1244] [Reference Citation Analysis]
441 Kilic L, Ordu C, Yildiz I, Sen F, Keskin S, Ciftci R, Pilanci KN. Current adjuvant treatment modalities for gastric cancer: From history to the future. World J Gastrointest Oncol 2016; 8(5): 439-449 [PMID: 27190583 DOI: 10.4251/wjgo.v8.i5.439] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
442 Ishido K, Higuchi K, Tanabe S, Azuma M, Sasaki T, Katada C, Komori S, Hayakawa K, Hosoda K, Yamashita K, Katada N, Koizumi W. Chemoradiotherapy for patients with recurrent lymph-node metastasis or local recurrence of gastric cancer after curative gastrectomy. Jpn J Radiol 2016;34:35-42. [PMID: 26576774 DOI: 10.1007/s11604-015-0502-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
443 Goldfarb M, Brower S, Schwaitzberg SD. Minimally invasive surgery and cancer: controversies part 1. Surg Endosc. 2010;24:304-334. [PMID: 19572178 DOI: 10.1007/s00464-009-0583-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
444 Huang ZN, Chen QY, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Lin JL, Zheng HL, Huang CM. Are the indications for postoperative radiotherapy in the NCCN guidelines for patients with gastric adenocarcinoma too broad? A study based on the SEER database. BMC Cancer 2018;18:1064. [PMID: 30390644 DOI: 10.1186/s12885-018-4957-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
445 Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8:CD004064. [PMID: 28850174 DOI: 10.1002/14651858.cd004064.pub4] [Cited by in Crossref: 77] [Cited by in F6Publishing: 166] [Article Influence: 19.3] [Reference Citation Analysis]
446 Wang L, Guo J, Wang Q, Zhou J, Xu C, Teng R, Chen Y, Wei Q, Liu ZP. LZTFL1 suppresses gastric cancer cell migration and invasion through regulating nuclear translocation of β-catenin. J Cancer Res Clin Oncol 2014;140:1997-2008. [PMID: 25005785 DOI: 10.1007/s00432-014-1753-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
447 Nishibeppu K, Komatsu S, Ichikawa D, Imamura T, Kosuga T, Okamoto K, Konishi H, Shiozaki A, Fujiwara H, Otsuji E. Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer. BMC Cancer 2018;18:108. [PMID: 29382310 DOI: 10.1186/s12885-018-4052-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
448 Barsky AR, Reddy VK, Plastaras JP, Ben-Josef E, Metz JM, Wojcieszynski AP. Proton beam re-irradiation for gastrointestinal malignancies: a systematic review. J Gastrointest Oncol 2020;11:187-202. [PMID: 32175122 DOI: 10.21037/jgo.2019.09.03] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
449 Keshari RP, Wang W, Zhang Y, Wang DD, Li YF, Yuan SQ, Qiu HB, Huang CY, Chen YM, Xia JC, Zhou ZW. Decreased expression of the GATA3 gene is associated with poor prognosis in primary gastric adenocarcinoma. PLoS One 2014;9:e87195. [PMID: 24504018 DOI: 10.1371/journal.pone.0087195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
450 Matuschek C, Haussmann J, Bölke E, Tamaskovics B, Djiepmo Njanang FJ, Orth K, Peiper M, Gerber PA, Anooshar B, Kammers K, Budach W. Adjuvant radiochemotherapy vs. chemotherapy alone in gastric cancer: a meta-analysis. Strahlenther Onkol 2019;195:695-706. [PMID: 30796495 DOI: 10.1007/s00066-019-01431-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
451 Ozen A, Kocak Z, Sipahi T, Oz-Puyan F, Cakina S, Saynak M, Ibis C, Karagol H. The prognostic significance of p21 and Her-2 gene expression and mutation/polymorphism in patients with gastric adenocarcinoma. Med Oncol 2013;30:357. [PMID: 23275116 DOI: 10.1007/s12032-012-0357-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
452 Cheng X, Zheng Z, Bu Z, Wu X, Zhang L, Xing X, Wang X, Hu Y, Du H, Li L. LAPTM4B-35, a cancer-related gene, is associated with poor prognosis in TNM stages I-III gastric cancer patients. PLoS One. 2015;10:e0121559. [PMID: 25849595 DOI: 10.1371/journal.pone.0121559] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
453 Dikken JL, Verheij M, Cats A, Jansen EP, Hartgrink HH, van de Velde CJ. Extended lymph node dissection for gastric cancer from a European perspective. Gastric Cancer. 2011;14:396-398. [PMID: 21837457 DOI: 10.1007/s10120-011-0081-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
454 Sereno M, De Castro J, Cejas P, García-Cabezas MA, Belda C, Casado E, Feliu J, Gómez C, López M, Barón MG. Expression profile as predictor of relapse after adjuvant treatment in gastric cancer. J Gastrointest Cancer. 2012;43:181-189. [PMID: 21360269 DOI: 10.1007/s12029-011-9267-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
455 Hundahl SA, Peeters KC, Kranenbarg EK, Hartgrink H, van de Velde CJ. Improved regional control and survival with "low Maruyama Index" surgery in gastric cancer: autopsy findings from the Dutch D1-D2 Trial. Gastric Cancer 2007;10:84-6. [PMID: 17577616 DOI: 10.1007/s10120-007-0426-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
456 Yaprak G, Tataroglu D, Dogan B, Pekyurek M. Prognostic factors for survival in patients with gastric cancer: Single-centre experience. North Clin Istanb 2020;7:146-52. [PMID: 32259036 DOI: 10.14744/nci.2019.73549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
457 Tsujinaka T, Fujitani K, Hirao M, Kurokawa Y. Current status of chemoradiotherapy for gastric cancer in Japan. Int J Clin Oncol. 2008;13:117-120. [PMID: 18463954 DOI: 10.1007/s10147-007-0743-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
458 Fornaro L, Spallanzani A, de Vita F, D'Ugo D, Falcone A, Lorenzon L, Tirino G, Cascinu S; GAIN (GAstric Cancer Italian Network). Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). Cancers (Basel) 2021;13:1304. [PMID: 33804024 DOI: 10.3390/cancers13061304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
459 Ojetti V, Persiani R, Cananzi FC, Sensi C, Piscaglia AC, Saulnier N, Biondi A, Gasbarrini A, D'Ugo D. cDNA-microarray analysis as a new tool to predict lymph node metastasis in gastric cancer. World J Surg. 2014;38:2058-2064. [PMID: 24696059 DOI: 10.1007/s00268-014-2529-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
460 Scartozzi M, Loretelli C, Galizia E, Mandolesi A, Pistelli M, Bittoni A, Giampieri R, Faloppi L, Bianconi M, Del Prete M, Bianchi F, Belvederesi L, Bearzi I, Cascinu S. Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. PLoS One 2012;7:e38192. [PMID: 22808003 DOI: 10.1371/journal.pone.0038192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
461 Yeh YS, Huang MY, Ma CJ, Huang CW, Tsai HL, Chen YC, Li CC, Yu FJ, Shih HY, Wang JY. Observational Study Comparing Efficacy and Safety between Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy for Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer. J Oncol 2020;2020:6931317. [PMID: 32963531 DOI: 10.1155/2020/6931317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
462 Wang X, Zhao DB, Yang L, Chi Y, Tang Y, Li N, Wang SL, Song YW, Liu YP, Liu WY, Ren H, Zhang T, Wang JY, Chen XS, Fang H, Wang WH, Li YX, Jin J. S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study. Br J Cancer 2018;118:338-43. [PMID: 29235569 DOI: 10.1038/bjc.2017.424] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
463 Kim SG, Hwang SH. The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer. World J Surg Oncol 2016;14:102. [PMID: 27039375 DOI: 10.1186/s12957-016-0845-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
464 Martin-Richard M, Custodio A, García-Girón C, Grávalos C, Gomez C, Jimenez-Fonseca P, Manzano JL, Pericay C, Rivera F, Carrato A. Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol 2015;17:996-1004. [PMID: 26691658 DOI: 10.1007/s12094-015-1456-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
465 Bystricky B, Okines AF, Cunningham D. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs 2011;71:541-55. [PMID: 21443280 DOI: 10.2165/11585460-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
466 Wei S, Zhong L, Wang X, Zhang W. Low expression of GATA3 promotes cell proliferation and metastasis in gastric cancer. Cancer Manag Res 2017;9:769-80. [PMID: 29263701 DOI: 10.2147/CMAR.S147973] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
467 Li SX, Seo SH, Choi YY, Nakagawa M, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH. Correlation analyses between pre- and post-operative adverse events in gastric cancer patients receiving preoperative treatment and gastrectomy. BMC Cancer 2016;16:29. [PMID: 26786480 DOI: 10.1186/s12885-016-2066-y] [Reference Citation Analysis]
468 Stark AP, Blum MM, Chiang YJ, Das P, Minsky BD, Estrella JS, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer. J Gastric Cancer 2020;20:313-27. [PMID: 33024587 DOI: 10.5230/jgc.2020.20.e29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
469 Montovano M, Zhang M, Oh P, Thor M, Crane C, Yorke E, Wu AJ, Jackson A. Incidence and Dosimetric Predictors of Radiation-Induced Gastric Bleeding After Chemoradiation for Esophageal and Gastroesophageal Junction Cancer. Adv Radiat Oncol 2021;6:100648. [PMID: 34195487 DOI: 10.1016/j.adro.2021.100648] [Reference Citation Analysis]
470 Zhu R, Liu F, Grisotti G, Perez-Irizarry J, Salem RR, Cha CH, Johung KL, Boffa DJ, Zhang Y, Khan SA. Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma. J Gastrointest Oncol 2018;9:517-26. [PMID: 29998017 DOI: 10.21037/jgo.2018.03.05] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
471 Zhang N, Fei Q, Gu J, Yin L, He X. Progress of preoperative and postoperative radiotherapy in gastric cancer. World J Surg Oncol 2018;16:187. [PMID: 30213266 DOI: 10.1186/s12957-018-1490-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
472 Unger JM, Nghiem VT, Hershman DL, Vaidya R, LeBlanc M, Blanke CD. Association of National Cancer Institute-Sponsored Clinical Trial Network Group Studies With Guideline Care and New Drug Indications. JAMA Netw Open 2019;2:e1910593. [PMID: 31483471 DOI: 10.1001/jamanetworkopen.2019.10593] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
473 Xu Y, Chen Q, Yu X, Zhou X, Zheng X, Mao W. Factors influencing the risk of recurrence in patients with esophageal carcinoma treated with surgery: A single institution analysis consisting of 1002 cases. Oncol Lett. 2013;5:185-190. [PMID: 23255917 DOI: 10.3892/ol.2012.1007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
474 Boda-Heggemann J, Weiss C, Schneider V, Hofheinz RD, Haneder S, Michaely H, Wertz H, Ronellenfitsch U, Hochhaus A, Wenz F, Lohr F. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. Strahlenther Onkol 2013;189:417-23. [PMID: 23558673 DOI: 10.1007/s00066-013-0309-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
475 Lee J, Son S, Lee CM, Ahn SH, Park DJ, Kim H. Factors predicting peritoneal recurrence in advanced gastric cancer: implication for adjuvant intraperitoneal chemotherapy. Gastric Cancer 2014;17:529-36. [DOI: 10.1007/s10120-013-0306-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
476 Huang T, Wang L, Liu D, Li P, Xiong H, Zhuang L, Sun L, Yuan X, Qiu H. FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1. Int J Oncol 2017;50:1501-12. [PMID: 28339036 DOI: 10.3892/ijo.2017.3927] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 11.5] [Reference Citation Analysis]
477 Lai S, Su T, He X, Lin Z, Chen S. Prognostic value of resected lymph nodes numbers for Siewert II gastroesophageal junction cancer. Oncotarget 2018;9:2797-809. [PMID: 29416812 DOI: 10.18632/oncotarget.23540] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
478 Wu AW, Ji JF. Neoadjuvant chemotherapy for locally advanced gastric cancer: With or without radiation. World J Gastrointest Surg 2012; 4(2): 27-31 [PMID: 22408715 DOI: 10.4240/wjgs.v4.i2.27] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
479 Weledji EP. The principles of the surgical management of gastric cancer. Int J Surg Oncol (N Y) 2017;2:e11. [PMID: 29177225 DOI: 10.1097/IJ9.0000000000000011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
480 Cunningham SC, Kamangar F, Kim MP, Hammoud S, Haque R, Maitra A, Montgomery E, Heitmiller RE, Choti MA, Lillemoe KD, Cameron JL, Yeo CJ, Schulick RD. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg. 2005;9:718-725. [PMID: 15862270 DOI: 10.1016/j.gassur.2004.12.002] [Cited by in Crossref: 93] [Cited by in F6Publishing: 92] [Article Influence: 5.8] [Reference Citation Analysis]
481 Gunturu KS, Woo Y, Beaubier N, Remotti HE, Saif MW. Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Ther Adv Med Oncol. 2013;5:143-151. [PMID: 23450234 DOI: 10.1177/1758834012469429] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
482 Matsuo T, Nishizuka SS, Ishida K, Endo F, Katagiri H, Kume K, Ikeda M, Koeda K, Wakabayashi G. Evaluation of chemosensitivity prediction using quantitative dose-response curve classification for highly advanced/relapsed gastric cancer. World J Surg Oncol 2013;11:11. [PMID: 23339659 DOI: 10.1186/1477-7819-11-11] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
483 Lorenzon L, Giudicissi R, Scatizzi M, Balducci G, Cantafio S, Biondi A, Persiani R, Mercantini P, D'Ugo D. D1-plus vs D2 nodal dissection in gastric cancer: a propensity score matched comparison and review of published literature. BMC Surg 2020;20:126. [PMID: 32522177 DOI: 10.1186/s12893-020-00714-x] [Reference Citation Analysis]
484 Hsieh CH, Liu CY, Hsieh YJ, Tai HC, Wang LY, Tsai TH, Chen YJ. Matrix metalloproteinase-8 mediates the unfavorable systemic impact of local irradiation on pharmacokinetics of anti-cancer drug 5-Fluorouracil. PLoS One 2011;6:e21000. [PMID: 21695264 DOI: 10.1371/journal.pone.0021000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
485 Wang DD, Chen YB, Pan K, Wang W, Chen SP, Chen JG, Zhao JJ, Lv L, Pan QZ, Li YQ. Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One. 2012;7:e40364. [PMID: 22808142 DOI: 10.1371/journal.pone.0040364] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 7.3] [Reference Citation Analysis]
486 Yao JC, Ajani JA. Adjuvant and preoperative chemotherapy for gastric cancer. Curr Oncol Rep. 2002;4:222-228. [PMID: 11937012 DOI: 10.1007/s11912-002-0019-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
487 Zhou Y, Zhang J, Cao S, Li Y. The evaluation of metastatic lymph node ratio staging system in gastric cancer. Gastric Cancer. 2013;16:309-317. [PMID: 22945599 DOI: 10.1007/s10120-012-0190-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
488 Elimova E, Mizrak Kaya D, Harada K, Ajani JA. Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clin Proc 2016;91:1307-18. [PMID: 27594190 DOI: 10.1016/j.mayocp.2016.07.018] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
489 Xu J, Shen L, Shui Y, Yu W, Guo Q, Yu R, Wu Y, Wei Q. Patterns of recurrence after curative D2 resection for gastric cancer: Implications for postoperative radiotherapy. Cancer Med 2020;9:4724-35. [PMID: 32420703 DOI: 10.1002/cam4.3085] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
490 Lee JH, Chang KK, Yoon C, Tang LH, Strong VE, Yoon SS. Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma. Ann Surg. 2018;267:105-113. [PMID: 27759618 DOI: 10.1097/sla.0000000000002040] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 11.5] [Reference Citation Analysis]
491 Choong NW, Mauer AM, Haraf DC, Ferguson MK, Sandler AB, Kesler KA, Fishkin PA, Ansari RH, Wade J 3rd, Krauss SA, Sciortino DF, Posner MC, Kocherginsky M, Hoffman PC, Szeto L, Vokes EE. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction. Med Oncol 2011;28 Suppl 1:S152-61. [PMID: 20730572 DOI: 10.1007/s12032-010-9658-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
492 Serarslan A, Ozbek Okumus N, Gursel B, Meydan D, Dastan Y, Aksu T. Dosimetric Comparison of Three Different Radiotherapy Techniques in Antrum-Located Stomach Cancer. Asian Pac J Cancer Prev 2017;18:741-6. [PMID: 28441708 DOI: 10.22034/APJCP.2017.18.3.741] [Reference Citation Analysis]
493 Yang K, Hu JK. Gastric cancer treatment: similarity and difference between China and Korea. Transl Gastroenterol Hepatol 2017;2:36. [PMID: 28529990 DOI: 10.21037/tgh.2017.04.02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
494 Semrau R, Vallböhmer D, Hölscher AH, Müller RP. [Neoadjuvant therapy of adenocarcinomas of the upper gastrointestinal tract. Status of radiotherapy]. Chirurg 2009;80:1035-41. [PMID: 19820906 DOI: 10.1007/s00104-009-1737-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
495 Koukourakis GV. Evidence based radiation therapy for locally advanced resectable and unresectable gastric cancer. World J Gastrointest Oncol 2011; 3(9): 131-136 [PMID: 22007277 DOI: 10.4251/wjgo.v3.i9.131] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
496 Mansouri H, Zemni I, Achouri L, Mahjoub N, Ayedi MA, Ben Safta I, Ben Dhiab T, Chargui R, Rahal K. Chemoradiotherapy or chemotherapy as adjuvant treatment for resected gastric cancer: should we use selection criteria? Rep Pract Oncol Radiother 2021;26:266-80. [PMID: 34211778 DOI: 10.5603/RPOR.a2021.0040] [Reference Citation Analysis]
497 Schernberg A, Rivin Del Campo E, Rousseau B, Matzinger O, Loi M, Maingon P, Huguet F. Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives. Clin Transl Radiat Oncol 2018;10:13-22. [PMID: 29928701 DOI: 10.1016/j.ctro.2018.02.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
498 Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer 2019;19:1-48. [PMID: 30944757 DOI: 10.5230/jgc.2019.19.e8] [Cited by in Crossref: 103] [Cited by in F6Publishing: 106] [Article Influence: 51.5] [Reference Citation Analysis]
499 Fuentes E, Ahmad R, Hong TS, Clark JW, Kwak EL, Rattner DW, Mullen JT. Adjuvant Therapy Completion Rates in Patients with Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach. J Gastrointest Surg 2016;20:172-9; discussion 179. [PMID: 26394879 DOI: 10.1007/s11605-015-2954-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
500 Niazi MT, Mok G, Heravi M, Lee L, Vuong T, Aloyz R, Panasci L, Muanza T. Effects of dna-dependent protein kinase inhibition by NU7026 on dna repair and cell survival in irradiated gastric cancer cell line N87. Curr Oncol 2014;21:91-6. [PMID: 24764698 DOI: 10.3747/co.21.1509] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
501 Yoshikawa T, Rino Y, Yukawa N, Oshima T, Tsuburaya A, Masuda M. Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy. Surg Today. 2014;44:11-21. [PMID: 23508452 DOI: 10.1007/s00595-013-0529-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
502 李宏伟, 杨金坤, 赵爱光. 胃癌辅助治疗的研究进展. 世界华人消化杂志 2014; 22(32): 4921-4927 [DOI: 10.11569/wcjd.v22.i32.4921] [Reference Citation Analysis]
503 Zhou J, Wu X, Li G, Gao X, Zhai M, Chen W, Hu H, Tang Z. Prediction of radiosensitive patients with gastric cancer by developing gene signature. Int J Oncol 2017;51:1067-76. [PMID: 28902346 DOI: 10.3892/ijo.2017.4107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
504 Fan M, Li G, Shen L, Zhang H, Liang L, Zhang Z. Identification of patients with lymph node metastasis from gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection--do N3 patients benefit from additional radiation? Br J Radiol 2016;89:20150758. [PMID: 26728420 DOI: 10.1259/bjr.20150758] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
505 Qian C, Yang LJ, Cui H. Recent Advances in Nanotechnology for Dendritic Cell-Based Immunotherapy. Front Pharmacol 2020;11:960. [PMID: 32694998 DOI: 10.3389/fphar.2020.00960] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
506 Badiyan SN, Hallemeier CL, Lin SH, Hall MD, Chuong MD. Proton beam therapy for gastrointestinal cancers: past, present, and future. J Gastrointest Oncol 2018;9:962-71. [PMID: 30505599 DOI: 10.21037/jgo.2017.11.07] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
507 Geng W, Tian D, Wang Q, Shan S, Zhou J, Xu W, Shan H. DNA‑PKcs inhibitor increases the sensitivity of gastric cancer cells to radiotherapy. Oncol Rep 2019;42:561-70. [PMID: 31173270 DOI: 10.3892/or.2019.7187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
508 Yang Y, Yin X, Sheng L, Xu S, Dong L, Liu L. Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis. Sci Rep 2015;5:12850. [PMID: 26242393 DOI: 10.1038/srep12850] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
509 Huang SM, Chen YC, Chen WY, Yang LY, Tsan DL, Tsang NM, Yap WK, Tsai CS, Leung WM, Hong JH, Chang JT, Yeh TS, Wu TH, Chen YC, Lin YH, Huang BS. Optimal Timing for Postsurgical Adjuvant Therapy in Patients with Gastric Cancer: A Propensity Score Matching Study. J Cancer 2019;10:332-40. [PMID: 30719127 DOI: 10.7150/jca.27753] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
510 Girardi DM, de Lima MA, Pereira GCB, Negrão MV, López RVM, Capareli FC, Sabbaga J, Hoff PMG. Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis. BMC Cancer 2018;18:378. [PMID: 29614980 DOI: 10.1186/s12885-018-4305-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
511 Cheng J, Squires MH 3rd, Mikell JL, Fisher SB, Staley CA 3rd, Kooby DA, El-Rayes BF, Curran WJ Jr, Hall WA, Colbert LE, Shelton JW, Maithel SK, Landry J, Yu DS. Radiotherapy patterns of care in gastric adenocarcinoma: a single institution experience. J Gastrointest Oncol 2015;6:247-53. [PMID: 26029450 DOI: 10.3978/j.issn.2078-6891.2015.026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
512 Kondoh C, Shitara K, Nomura M, Takahari D, Ura T, Tachibana H, Tomita N, Kodaira T, Muro K. Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study. BMC Palliat Care 2015;14:37. [PMID: 26238344 DOI: 10.1186/s12904-015-0034-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
513 Mrena J, Mattila A, Böhm J, Jantunen I, Kellokumpu I. Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer. World J Gastroenterol 2015; 21(47): 13294-13301 [PMID: 26715812 DOI: 10.3748/wjg.v21.i47.13294] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
514 Iwasa S, Yamada Y, Fukagawa T, Eguchi Nakajima T, Kato K, Hamaguchi T, Morita S, Saka M, Katai H, Shimada Y. Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification. Gastric Cancer 2011;14:28-34. [PMID: 21327440 DOI: 10.1007/s10120-011-0003-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
515 León-Espinoza C, López-Mozos F, Marti-Obiol R, Garces-Albir M, Ortega-Serrano J. “Magic” of our gastric cancer results on perioperative chemotherapy. World J Gastrointest Pathophysiol 2016; 7(3): 283-287 [PMID: 27574566 DOI: 10.4291/wjgp.v7.i3.283] [Reference Citation Analysis]
516 Mulder KE, Ahmed S, Davies JD, Doll CM, Dowden S, Gill S, Gordon V, Hebbard P, Lim H, McFadden A, McGhie JP, Park J, Wong R. Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11-12 September 2015. Curr Oncol. 2016;23:425-434. [PMID: 28050139 DOI: 10.3747/co.23.3384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
517 Cho M, Eze O, Xu R. Molecular genetics of gastric adenocarcinoma in clinical practice. World J Med Genet 2014; 4(3): 58-68 [DOI: 10.5496/wjmg.v4.i3.58] [Reference Citation Analysis]
518 Tang S, Liu F, Li Y, Zhao L, Wang X, Khan SA, Chen Y, Zhang Y. Treatment Selection and Survival Outcomes in Locally Advanced Proximal Gastric Cancer: A National Cancer Data Base Analysis. Front Oncol 2020;10:537051. [PMID: 33102212 DOI: 10.3389/fonc.2020.537051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
519 Yarema R, de Manzoni G, Fetsych T, Ohorchak M, Pliatsko M, Bencivenga M. On the road to standardization of D2 lymph node dissection in a European population of patients with gastric cancer. World J Gastrointest Oncol 2016; 8(6): 489-497 [PMID: 27326318 DOI: 10.4251/wjgo.v8.i6.489] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
520 Parekh PR, Solano-Gonzalez E, Martins MB, Ma X, Tighe K, Casildo A, Zodda A, Johnstone C, Poirier Y, Mahmood J, Bhalla K, Li S, Lapidus RG, Carrier F. DUOX2, a New Biomarker for Disseminated Gastric Cancer's Response to Low Dose Radiation in Mice. Cancers (Basel) 2021;13:4186. [PMID: 34439340 DOI: 10.3390/cancers13164186] [Reference Citation Analysis]
521 Van Cutsem E, Haller D, Ohtsu A. The role of chemotherapy in the current treatment of gastric cancer. Gastric Cancer. 2002;5 Suppl 1:17-22. [PMID: 12772882 DOI: 10.1007/s10120-002-0219-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
522 Sun A, Yu G, Dou X, Yan X, Yang W, Lin Q. Nedd4-1 is an exceptional prognostic biomarker for gastric cardia adenocarcinoma and functionally associated with metastasis. Mol Cancer. 2014;13:248. [PMID: 25395181 DOI: 10.1186/1476-4598-13-248] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
523 Liang YX, Deng JY, Guo HH, Ding XW, Wang XN, Wang BG, Zhang L, Liang H. Characteristics and prognosis of gastric cancer in patients aged ≥ 70 years. World J Gastroenterol 2013; 19(39): 6568-6578 [PMID: 24151383 DOI: 10.3748/wjg.v19.i39.6568] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 39] [Article Influence: 5.0] [Reference Citation Analysis]
524 Altorki N, Harrison S. What is the role of neoadjuvant chemotherapy, radiation, and adjuvant treatment in resectable esophageal cancer? Ann Cardiothorac Surg. 2017;6:167-174. [PMID: 28447006 DOI: 10.21037/acs.2017.03.16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
525 Kwon SJ. Evaluation of the 7th UICC TNM Staging System of Gastric Cancer. J Gastric Cancer 2011;11:78-85. [PMID: 22076207 DOI: 10.5230/jgc.2011.11.2.78] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis]
526 Wang Y, Guan S, Bi Y, Lin S, Ma J, Xing Q, Liu C, Zhang R, Qu Z, Jiang P, Chen X, Cheng Y. Survival Impact of Delaying Postoperative Radiotherapy in Patients with Esophageal Cancer. Transl Oncol 2018;11:1358-63. [PMID: 30196238 DOI: 10.1016/j.tranon.2018.08.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
527 Liu YY, Liu YW, Chen YY, Wang SH, Chuah SK, Huang GK, Chen YH. The efficacy and toxicity of adjuvant S-1 schedule with 2-week administration followed by 1-week rest in gastric cancer patients. J Gastrointest Oncol 2021;12:297-306. [PMID: 34012627 DOI: 10.21037/jgo-20-477] [Reference Citation Analysis]
528 Pan S, Yin S, Zhu Z, Liu F, Xu H. Decision-making of adjuvant therapy in pT1N1M0 gastric cancer: Should radiotherapy be added to chemotherapy? A propensity score-matched analysis. J Cancer 2021;12:1179-89. [PMID: 33442416 DOI: 10.7150/jca.52123] [Reference Citation Analysis]
529 Liu D, Lu M, Li J, Yang Z, Feng Q, Zhou M, Zhang Z, Shen L. The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Oncol. 2016;14:305. [PMID: 27931221 DOI: 10.1186/s12957-016-1042-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
530 Matuschek C, Bölke E, Peiper M, Knoefel WT, Budach W, Erhardt A, Scherer A, Gerber PA, Buhren BA, Gattermann N, Baldus SE, Rusnak E, Shukla V, Orth K. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. Eur J Med Res 2011;16:265-74. [PMID: 21810561 DOI: 10.1186/2047-783x-16-6-265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
531 Whiting J, Sano T, Saka M, Fukagawa T, Katai H, Sasako M. Follow-up of gastric cancer: a review. Gastric Cancer. 2006;9:74-81. [PMID: 16767361 DOI: 10.1007/s10120-006-0360-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
532 Ito Y, Abe Y, Egawa T, Kitago M, Itano O, Kitagawa Y. Predictive Factors of Early Recurrence in Patients with Distal Cholangiocarcinoma after Pancreaticoduodenectomy. Gastroenterol Res Pract 2018;2018:6431254. [PMID: 29849596 DOI: 10.1155/2018/6431254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
533 Cho J, Lee J, Bang H, Kim ST, Park SH, An JY, Choi MG, Lee JH, Sohn TS, Bae JM. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget. 2017;8:13320-13328. [PMID: 28076847 DOI: 10.18632/oncotarget.14519] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 10.3] [Reference Citation Analysis]
534 Ye S, Wang L, Zuo Z, Bei Y, Liu K. The role of surgery and radiation in advanced gastric cancer: A population-based study of Surveillance, Epidemiology, and End Results database. PLoS One 2019;14:e0213596. [PMID: 30861056 DOI: 10.1371/journal.pone.0213596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
535 Kubota T, Weisenthal L. Chemotherapy sensitivity and resistance testing: to be “standard” or to be individualized, that is the question. Gastric Cancer. 2006;9:82-87. [PMID: 16767362 DOI: 10.1007/s10120-006-0366-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
536 Field K, Michael M, Leong T. Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 2008;68:299-317. [PMID: 18257608 DOI: 10.2165/00003495-200868030-00004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
537 Kaydıhan N, Çepni K, Ergen ŞA, Şenocak MŞ, Öksüz DÇ. Comparison of changes in renal function with dosimetric parameters in gastric cancer patients treated with adjuvant chemoradiotherapy. Jpn J Radiol 2017;35:733-9. [PMID: 29064001 DOI: 10.1007/s11604-017-0692-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
538 Goodman KA, Khalid N, Kachnic LA, Minsky BD, Crozier C, Owen JB, Devlin PM, Thomas CR Jr. Quality Research in Radiation Oncology analysis of clinical performance measures in the management of gastric cancer. Int J Radiat Oncol Biol Phys 2013;85:355-62. [PMID: 23040221 DOI: 10.1016/j.ijrobp.2012.08.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
539 Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol 2011;5:89-99. [PMID: 21603244 DOI: 10.4137/CMO.S6983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
540 He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Ren C, Jin Y, Chen DL, Xu RH. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. World J Gastroenterol 2014; 20(1): 264-273 [PMID: 24415881 DOI: 10.3748/wjg.v20.i1.264] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
541 Scartozzi M, Galizia E, Graziano F, Catalano V, Berardi R, Baldelli AM, Testa E, Mari D, Silva RR, Cascinu S. Over-DI dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. Br J Cancer 2005;92:1051-4. [PMID: 15770210 DOI: 10.1038/sj.bjc.6602468] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
542 Blum MA, Ajani JA. Therapy: localized gastric cancer--a CLASSIC shift in the paradigm? Nat Rev Gastroenterol Hepatol 2012;9:194-5. [PMID: 22392288 DOI: 10.1038/nrgastro.2012.35] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
543 Harada K, Baba H, Ajani JA. Recent trend in gastric cancer treatment in the USA. J Cancer Metastasis Treat 2018;4:18. [PMID: 34113719 DOI: 10.20517/2394-4722.2017.74] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
544 Li J, Huang Q, Zeng F, Li W, He Z, Chen W, Zhu W, Zhang B. The prognostic value of global DNA hypomethylation in cancer: a meta-analysis. PLoS One. 2014;9:e106290. [PMID: 25184628 DOI: 10.1371/journal.pone.0106290] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
545 Saif MW, Shi N, Zelt S. Capecitabine treatment patterns in patients with gastroesophageal cancer in the United States. World J Gastroenterol 2009; 15(35): 4415-4422 [PMID: 19764093 DOI: 10.3748/wjg.15.4415] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
546 Tyczyńska M, Kędzierawski P, Karakuła K, Januszewski J, Kozak K, Sitarz M, Forma A. Treatment Strategies of Gastric Cancer-Molecular Targets for Anti-angiogenic Therapy: a State-of-the-art Review. J Gastrointest Cancer 2021;52:476-88. [PMID: 33761051 DOI: 10.1007/s12029-021-00629-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
547 Lawrence W. Gastric Adenocarcinoma. Curr Treat Options Gastroenterol 2004;7:149-57. [PMID: 15010029 DOI: 10.1007/s11938-004-0036-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
548 Cronin-Fenton DP, Mooney MM, Clegg LX, Harlan LC. Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma. World J Gastroenterol 2008; 14(20): 3165-3173 [PMID: 18506920 DOI: 10.3748/wjg.14.3165] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
549 Wan Z, Huang Z, Chen L. Survival predictors associated with signet ring cell carcinoma of the esophagus (SRCCE): A population-based retrospective cohort study. PLoS One 2017;12:e0181845. [PMID: 28746362 DOI: 10.1371/journal.pone.0181845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
550 Tianhang L, Guoen F, Jianwei B, Liye M. The effect of perineural invasion on overall survival in patients with gastric carcinoma. J Gastrointest Surg. 2008;12:1263-1267. [PMID: 18463928 DOI: 10.1007/s11605-008-0529-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
551 Driessen A, Landuyt W, Pastorekova S, Moons J, Goethals L, Haustermans K, Nafteux P, Penninckx F, Geboes K, Lerut T, Ectors N. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg 2006;243:334-40. [PMID: 16495697 DOI: 10.1097/01.sla.0000201452.09591.f3] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 5.1] [Reference Citation Analysis]
552 陈刚, 焦作义. 弥漫型胃癌治疗的挑战和思考. 世界华人消化杂志 2016; 24(17): 2608-2616 [DOI: 10.11569/wcjd.v24.i17.2608] [Reference Citation Analysis]
553 Zhang Y, Zhang Q, Zhang M, Yuan M, Wang Z, Zhang J, Zhou X, Zhang Y, Lin F, Na H, Ren S, Zuo Y. DC - SIGNR by influencing the lncRNA HNRNPKP2 upregulates the expression of CXCR4 in gastric cancer liver metastasis. Mol Cancer 2017;16:78. [PMID: 28403883 DOI: 10.1186/s12943-017-0639-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
554 Liang B, Zheng W, Fang L, Wu L, Zhou F, Yin X, Yu X, Zou Z. Overexpressed targeting protein for Xklp2 (TPX2) serves as a promising prognostic marker and therapeutic target for gastric cancer. Cancer Biol Ther. 2016;17:824-832. [PMID: 27314162 DOI: 10.1080/15384047.2016.1195046] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
555 Toneto MG, Viola L. CURRENT STATUS OF THE MULTIDISCIPLINARY TREATMENT OF GASTRIC ADENOCARCINOMA. Arq Bras Cir Dig 2018;31:e1373. [PMID: 29972401 DOI: 10.1590/0102-672020180001e1373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
556 Shulman K, Haim N, Wollner M, Bernstein Z, Abdah-Bortnyak R, Bar-Sela G. Postoperative chemotherapy in gastric cancer, consisting of etoposide, doxorubicin and cisplatin, followed by radiotherapy with concomitant cisplatin: A feasibility study. Oncol Lett 2012;3:1154-8. [PMID: 22783410 DOI: 10.3892/ol.2012.617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
557 Wang ZX, Yang XL, He MM, Wang F, Zhang DS, Li YH, Zhou ZW, Zhan YQ, Xu RH. The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis. Medicine (Baltimore) 2016;95:e3214. [PMID: 27100411 DOI: 10.1097/MD.0000000000003214] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
558 Allum W, Garofalo A, Degiuli M, Schuhmacher C. The first European Union Network of Excellence for Gastric Cancer conference, Rome, Italy, April 2008. Gastric Cancer 2009;12:56-65. [PMID: 19390934 DOI: 10.1007/s10120-009-0499-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
559 Tamura S, Takeno A, Miki H. Lymph node dissection in curative gastrectomy for advanced gastric cancer. Int J Surg Oncol. 2011;2011:748745. [PMID: 22312521 DOI: 10.1155/2011/748745] [Cited by in Crossref: 9] [Cited by in F6Publishing: 21] [Article Influence: 0.9] [Reference Citation Analysis]
560 Rivera F, Grávalos C, García-Carbonero R. SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma. Clin Transl Oncol. 2012;14:528-535. [PMID: 22721798 DOI: 10.1007/s12094-012-0836-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
561 Wang SB, Qi WX, Chen JY, Xu C, Cao WG, Cai R, Cao L, Cai G. Identification of Patients With Locally Advanced Gastric Cancer Who May Benefit From Adjuvant Chemoradiotherapy After D2 dissection: A Propensity Score Matching Analysis. Front Oncol 2021;11:648978. [PMID: 33869049 DOI: 10.3389/fonc.2021.648978] [Reference Citation Analysis]
562 Gu L, Zhang Y, Hong J, Xu B, Yang L, Yan K, Zhang J, Chen P, Zheng J, Lin J. Prognostic Value of Pretreatment Overweight/Obesity and Adipose Tissue Distribution in Resectable Gastric Cancer: A Retrospective Cohort Study. Front Oncol 2021;11:680190. [PMID: 34249721 DOI: 10.3389/fonc.2021.680190] [Reference Citation Analysis]
563 Nilsson M. Postgastrectomy follow-up in the West: evidence base, guidelines, and daily practice. Gastric Cancer 2017;20:135-40. [PMID: 27718134 DOI: 10.1007/s10120-016-0654-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
564 González-Domingo M, Ulloa C, Olivares J, Estrada S, González P, Cardozo N. Adjuvant radiochemotherapy in locally advanced gastric cancer: from evidence to daily clinical practice in a single institution. Ecancermedicalscience 2020;14:1137. [PMID: 33281929 DOI: 10.3332/ecancer.2020.1137] [Reference Citation Analysis]
565 Scartozzi M, Pistelli M, Bittoni A, Giampieri R, Galizia E, Berardi R, Faloppi L, Del Prete M, Cascinu S. Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy. Curr Oncol Rep 2010;12:175-85. [PMID: 20425077 DOI: 10.1007/s11912-010-0101-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
566 Yang Q, Wei Y, Chen YX, Zhou SW, Jiang ZM, Xie DR. Indirect comparison showed survival benefit from adjuvant chemoradiotherapy in completely resected gastric cancer with d2 lymphadenectomy. Gastroenterol Res Pract 2013;2013:634929. [PMID: 24194750 DOI: 10.1155/2013/634929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
567 Wang DS, Ren C, Qiu MZ, Luo HY, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumour Biol. 2012;33:749-756. [PMID: 22198641 DOI: 10.1007/s13277-011-0285-z] [Cited by in Crossref: 70] [Cited by in F6Publishing: 75] [Article Influence: 7.0] [Reference Citation Analysis]
568 Aoyama T, Fujikawa H, Cho H, Ogata T, Shirai J, Hayashi T, Rino Y, Masuda M, Oba MS, Morita S. A methylene blue-assisted technique for harvesting lymph nodes after radical surgery for gastric cancer: a prospective, randomized, controlled study. Am J Surg Pathol. 2015;39:266-273. [PMID: 25356528 DOI: 10.1097/pas.0000000000000336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
569 Peeters KC, Hundahl SA, Kranenbarg EK, Hartgrink H, van de Velde CJ. Low Maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial. World J Surg. 2005;29:1576-1584. [PMID: 16317484 DOI: 10.1007/s00268-005-7907-9] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 3.7] [Reference Citation Analysis]
570 Rajagopal I, Niveditha SR, Sahadev R, Nagappa PK, Rajendra SG. HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas. J Clin Diagn Res. 2015;9:EC06-EC10. [PMID: 25954623 DOI: 10.7860/jcdr/2015/12581.5630] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
571 Ratosa I, Oblak I, Anderluh F, Velenik V, But-Hadzic J, Ermenc AS, Jeromen A. Preoperative treatment with radiochemotherapy for locally advanced gastroesophageal junction cancer and unresectable locally advanced gastric cancer. Radiol Oncol. 2015;49:163-172. [PMID: 26029028 DOI: 10.2478/raon-2014-0027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
572 Kucuktulu E, Yurekli AF, Topbas M, Kece C, Guner A, Kucuktulu U. Comparisons between the Dosimetric and Clinical Outcomes of Tomotherapy and 3D Conformal Radiotherapy in Gastric Cancer Treatment. Asian Pac J Cancer Prev 2019;20:595-9. [PMID: 30806065 DOI: 10.31557/APJCP.2019.20.2.595] [Reference Citation Analysis]
573 Chang JS, Choi Y, Shin J, Kim KH, Keum KC, Kim HS, Koom WS, Park EC. Patterns of Care for Radiotherapy in the Neoadjuvant and Adjuvant Treatment of Gastric Cancer: A Twelve-Year Nationwide Cohort Study in Korea. Cancer Res Treat 2018;50:118-28. [PMID: 28279066 DOI: 10.4143/crt.2016.575] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
574 Ciesielski M, Szajewski M, Walczak J, Pęksa R, Lenckowski R, Supeł M, Zieliński J, Kruszewski WJ. Impact of chromosome 17 centromere copy number increase on patient survival and human epidermal growth factor receptor 2 expression in gastric adenocarcinoma. Oncol Lett 2021;21:142. [PMID: 33552261 DOI: 10.3892/ol.2020.12403] [Reference Citation Analysis]
575 Oba K. Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis. Int J Clin Oncol. 2009;14:85-89. [PMID: 19390937 DOI: 10.1007/s10147-009-0877-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
576 Rhome RM, Ru M, Moshier E, Mazumdar M, Buckstein MH. Stage-matched survival differences by ethnicity among gastric cancer patients of Asian ancestry treated in the United States. J Surg Oncol 2019;119:737-48. [PMID: 30694524 DOI: 10.1002/jso.25389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
577 Levine EA, Shen P, Shiver SA, Waters G, Brant A, Geisenger KR. Intraoperative imprint cytology for evaluation of sentinel lymph nodes from visceral malignancies. J Gastrointest Surg 2003;7:687-91. [PMID: 12850683 DOI: 10.1016/s1091-255x(03)00069-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
578 Miccio JA, Oladeru OT, Yang J, Xue Y, Choi M, Zhang Y, Yoon H, Ryu S, Stessin AM. Neoadjuvant vs. adjuvant treatment of Siewert type II gastroesophageal junction cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. J Gastrointest Oncol 2016;7:403-10. [PMID: 27284473 DOI: 10.21037/jgo.2015.10.06] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
579 Katona BW, Rustgi AK. Gastric Cancer Genomics: Advances and Future Directions. Cell Mol Gastroenterol Hepatol. 2017;3:211-217. [PMID: 28275688 DOI: 10.1016/j.jcmgh.2017.01.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
580 Lawrence YR, Vikram B, Dignam JJ, Chakravarti A, Machtay M, Freidlin B, Takebe N, Curran WJ Jr, Bentzen SM, Okunieff P, Coleman CN, Dicker AP. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst 2013;105:11-24. [PMID: 23231975 DOI: 10.1093/jnci/djs472] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
581 Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D, Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086-92. [PMID: 18309943 DOI: 10.1200/JCO.2007.12.9593] [Cited by in Crossref: 860] [Cited by in F6Publishing: 374] [Article Influence: 66.2] [Reference Citation Analysis]
582 Hack SP, Bruey JM, Koeppen H. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget 2014;5:2866-80. [PMID: 24930887 DOI: 10.18632/oncotarget.2003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
583 Wu HC, Lin WL, Lin CL, Lin CY, Chen SW, Chen YX, Chen CH, Lee SW, Chen SH, Tsao CJ, Huang WT, Guo HR. Age as a modifier of the effects of chemoradiotherapy with infusional 5-fluorouracil after D2 dissection in gastric cancer. Aging (Albany NY) 2021;13:17337-48. [PMID: 34226296 DOI: 10.18632/aging.203223] [Reference Citation Analysis]
584 Jagric T, Ilijevec B, Velenik V, Ocvirk J, Potrc S. Impact of perioperative treatment on survival of resectable gastric cancer patients after D2 lymphadenectomy: a single European centre propensity score matching analysis. Radiol Oncol 2019;53:245-55. [PMID: 31103997 DOI: 10.2478/raon-2019-0019] [Reference Citation Analysis]
585 Chang SC, Liu KH, Hung CY, Tsai CY, Hsu JT, Yeh TS, Chen JS, Kuo YC, Hung YS, Chou WC. Adjuvant Chemotherapy Improves Survival in Stage III Gastric Cancer after D2 Surgery. J Cancer 2018;9:81-91. [PMID: 29290772 DOI: 10.7150/jca.21989] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
586 Subasinghe D, Sivaganesh S, Samarsekera A, Kumarasinghe MP, Samarasekera DN, Lokuhetty MDS. Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival. Dig Dis Sci 2017;62:2498-510. [PMID: 28612195 DOI: 10.1007/s10620-017-4647-2] [Reference Citation Analysis]
587 Kim C, Mulder K, Spratlin J. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist. 2014;19:1046-1055. [PMID: 25142842 DOI: 10.1634/theoncologist.2014-0006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
588 Costa WL, Coimbra FJ, Fogaroli RC, Ribeiro HS, Diniz AL, Begnami MD, Mello CA, Fanelli MF, Silva MJ, Fregnani JH. Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center. Radiat Oncol. 2012;7:169. [PMID: 23068190 DOI: 10.1186/1748-717x-7-169] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
589 Gao X, Pan Y, Han W, Hu C, Wang C, Chen L, Guo Y, Shi Y, Pan Y, Xie H, Yao L, Yang J, Zheng J, Li X, Liu X, Hong L, Li J, Li M, Ji G, Li Z, Xia J, Zhao Q, Fan D, Wu K, Nie Y. Association of systemic inflammation and body mass index with survival in patients with resectable gastric or gastroesophageal junction adenocarcinomas. Cancer Biol Med 2021;18:283-97. [PMID: 33628601 DOI: 10.20892/j.issn.2095-3941.2020.0246] [Reference Citation Analysis]
590 Iams WT, Villaflor VM. Neoadjuvant Treatment for Locally Invasive Esophageal Cancer. World J Surg 2017;41:1719-25. [PMID: 28271259 DOI: 10.1007/s00268-017-3959-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
591 Kano K, Yamada T, Yamamoto K, Komori K, Watanabe H, Hara K, Shimoda Y, Maezawa Y, Fujikawa H, Aoyama T, Tamagawa H, Yamamoto N, Cho H, Shiozawa M, Yukawa N, Yoshikawa T, Morinaga S, Rino Y, Masuda M, Ogata T, Oshima T. Association Between Lymph Node Ratio and Survival in Patients with Pathological Stage II/III Gastric Cancer. Ann Surg Oncol 2020;27:4235-47. [PMID: 32424582 DOI: 10.1245/s10434-020-08616-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
592 Mihmanli M, Ilhan E, Idiz UO, Alemdar A, Demir U. Recent developments and innovations in gastric cancer. World J Gastroenterol 2016; 22(17): 4307-4320 [PMID: 27158199 DOI: 10.3748/wjg.v22.i17.4307] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
593 Sun H, Gu J, Li Z, Liu Q, Lin J, Tian Y, Cao J, Qin H, Tang Z. Low Expression of GLIS2 Gene Might Associate with Radiosensitivity of Gastric Cancer. J Oncol 2019;2019:2934925. [PMID: 31281358 DOI: 10.1155/2019/2934925] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
594 McCall MD, Graham PJ, Bathe OF. Quality of life: A critical outcome for all surgical treatments of gastric cancer. World J Gastroenterol 2016; 22(3): 1101-1113 [PMID: 26811650 DOI: 10.3748/wjg.v22.i3.1101] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
595 Metzger R, Warnecke-Eberz U, Alakus H, Kütting F, Brabender J, Vallböhmer D, Grimminger PP, Mönig SP, Drebber U, Hölscher AH. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. J Gastrointest Surg. 2012;16:26-34; discussion 34. [PMID: 21956434 DOI: 10.1007/s11605-011-1700-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
596 Valdivieso M, Corn BW, Dancey JE, Wickerham DL, Horvath LE, Perez EA, Urton A, Cronin WM, Field E, Lackey E, Blanke CD. The Globalization of Cooperative Groups. Semin Oncol 2015;42:693-712. [PMID: 26433551 DOI: 10.1053/j.seminoncol.2015.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
597 Ema A, Waraya M, Yamashita K, Kokubo K, Kobayashi H, Hoshi K, Shinkai Y, Kawamata H, Nakamura K, Nishimiya H, Katada N, Watanabe M. Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer. Cancer Med 2015;4:90-100. [PMID: 25154973 DOI: 10.1002/cam4.311] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
598 Dudeja V, Habermann EB, Abraham A, Zhong W, Parsons HM, Tseng JF, Al-Refaie WB. Is there a role for surgery with adequate nodal evaluation alone in gastric adenocarcinoma? J Gastrointest Surg. 2012;16:238-246; discussion 246-247. [PMID: 22089951 DOI: 10.1007/s11605-011-1756-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
599 Liu Y, Ling Y, Qi Q, Zhu M, Wan M, Zhang Y, Zhang C. Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins. Oncol Lett 2015;9:999-1005. [PMID: 25624920 DOI: 10.3892/ol.2014.2793] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
600 Song XH, Liu K, Yang SJ, Zhang WH, Chen XL, Zhao LY, Chen XZ, Yang K, Zhou ZG, Hu JK. Prognostic Value of Changes in Preoperative and Postoperative Serum CA19-9 Levels in Gastric Cancer. Front Oncol 2020;10:1432. [PMID: 33014781 DOI: 10.3389/fonc.2020.01432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
601 Unger JM, LeBlanc M, Blanke CD. The Effect of Positive SWOG Treatment Trials on Survival of Patients With Cancer in the US Population. JAMA Oncol 2017;3:1345-51. [PMID: 28586789 DOI: 10.1001/jamaoncol.2017.0762] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
602 Yaprak G, Gemici C, Temizkan S, Ozdemir S, Dogan BC, Seseogullari OO. Osteoporosis development and vertebral fractures after abdominal irradiation in patients with gastric cancer. BMC Cancer 2018;18:972. [PMID: 30309324 DOI: 10.1186/s12885-018-4899-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
603 Carcas LP. Gastric cancer review. J Carcinog. 2014;13:14. [PMID: 25589897 DOI: 10.4103/1477-3163.146506] [Cited by in Crossref: 126] [Cited by in F6Publishing: 126] [Article Influence: 18.0] [Reference Citation Analysis]
604 Aoyama T, Nishikawa K, Takiguchi N, Tanabe K, Imano M, Fukushima R, Sakamoto J, Oba MS, Morita S, Kono T, Tsuburaya A. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol 2014;73:1047-54. [PMID: 24652604 DOI: 10.1007/s00280-014-2440-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
605 Zhang Q, Jin XS, Yang ZY, Wei M, Zhu XC, Wang P, Liu BY, Gu QL. Upregulated expression of LOX is a novel independent prognostic marker of worse outcome in gastric cancer patients after curative surgery. Oncol Lett 2013;5:896-902. [PMID: 23425977 DOI: 10.3892/ol.2012.1092] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
606 Zhang H, Wang W, Diao D, Cheng Y, Song Y, Zhu K, Dang C. Ratio of metastatic to examined lymph nodes, a helpful staging system and independent prognostic factor of esophagogastric junction cancer. PLoS One. 2013;8:e73238. [PMID: 23977381 DOI: 10.1371/journal.pone.0073238] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
607 Liu Y, Zhao G, Xu Y, Zhang T, Chen Z, Yan G, Tu W, Hu Y, Chen Y, He X, Li X, Chen H, Yao S, Hu Z, Chen X, Chen T. Phase II Study of Adjuvant Chemoradiotherapy Using Docetaxel/Cisplatin/5-Fluorouracil Before and After Intensity-modulated Radiotherapy With Concurrent Docetaxel in Patients With Completely (R0) Resected Gastric Carcinoma. Am J Clin Oncol 2018;41:619-25. [PMID: 28263232 DOI: 10.1097/COC.0000000000000373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
608 Zhi Y, Lin Z, Ma J, Mou W, Chen X. Distinguish the Role of Radiotherapy From Chemoradiotherapy for Gastric Cancer With Behavior of Metastasis-Indolent in Lymph Node. Technol Cancer Res Treat 2020;19:1533033820959400. [PMID: 33148125 DOI: 10.1177/1533033820959400] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
609 Huntington CR, Walsh K, Han Y, Salo J, Hill J. National Trends in Utilization of Endoscopic Ultrasound for Gastric Cancer: a SEER-Medicare Study. J Gastrointest Surg. 2016;20:154-163; discussion 163-164. [PMID: 26553265 DOI: 10.1007/s11605-015-2988-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
610 Craft JM, Hallahan D. Towards novel radiosensitizing agents: the role of cytosolic PLA2α in combined modality cancer therapy. Future Med Chem 2011;3:835-43. [PMID: 21644828 DOI: 10.4155/fmc.11.38] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
611 Kodera Y, Fujiwara M, Koike M, Nakao A. Chemotherapy as a component of multimodal therapy for gastric carcinoma. World J Gastroenterol 2006; 12(13): 2000-2005 [PMID: 16610047 DOI: 10.3748/wjg.v12.i13.2000] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
612 Schuhmacher C, Novotny A, Meyer HJ. [Treatment of gastric cancer beyond current guideline: state of the art]. Chirurg 2013;84:310-5. [PMID: 23479274 DOI: 10.1007/s00104-012-2454-z] [Reference Citation Analysis]
613 Inoue K, Nakane Y, Michiura T, Yamaki S, Yui R, Sakuramoto K, Iwai A, Tokuhara K, Araki Y, Kim S. Feasibility and accuracy of second-look laparoscopy after gastrectomy for gastric cancer. Surg Endosc. 2009;23:2307-2313. [PMID: 19184202 DOI: 10.1007/s00464-008-0324-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
614 Topal B, Leys E, Ectors N, Aerts R, Penninckx F. Determinants of complications and adequacy of surgical resection in laparoscopic versus open total gastrectomy for adenocarcinoma. Surg Endosc 2008;22:980-4. [PMID: 17690934 DOI: 10.1007/s00464-007-9549-5] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 5.2] [Reference Citation Analysis]
615 Liakakos T, Xeropotamos N, Ziogas D, Roukos D. EGFR as a Prognostic Marker for Gastric Cancer. World J Surg. 2008;32:1225-1226; author reply 1227-1229. [PMID: 18224475 DOI: 10.1007/s00268- 007-9434-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
616 Seyfried F, von Rahden BH, Miras AD, Gasser M, Maeder U, Kunzmann V, Germer CT, Pelz J, Kerscher AG. Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin--a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer 2015;15:73. [PMID: 25879885 DOI: 10.1186/s12885-015-1081-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
617 Liu N, Molena D, Stem M, Blackford AL, Sewell DB, Lidor AO. Underutilization of Treatment for Regional Gastric Cancer Among the Elderly in the USA. J Gastrointest Surg 2018;22:955-63. [PMID: 29404983 DOI: 10.1007/s11605-018-3691-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
618 Liu HC, Hung SK, Huang CJ, Chen CC, Chen MJ, Chang CC, Tai CJ, Tzen CY, Lu LH, Chen YJ. Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy. World J Gastroenterol 2005; 11(34): 5367-5372 [PMID: 16149148 DOI: 10.3748/wjg.v11.i34.5367] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
619 Gotfrit J, Goodwin R, Asmis T, Hyde AJ, Alcindor T, Aubin F, Berry S, Bossé D, Brown C, Burkes R, Burnell M, Colwell B, Corbett J, Craswell J, Daaboul N, Doherty M, Fleming DAB, Galvis L, Goel R, Harb M, Jeyakumar A, Jonker D, Kennedy E, Lock M, Mahmud A, McCrea PH, Nair V, Nassabein R, Nessim C, Ramjeesingh R, Raza M, Saliba W, Samimi S, Singh S, Snow S, Tehfé M, Thirlwell M, Valdes M, Welch S, Vickers M. Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019. Curr Oncol 2021;28:1988-2006. [PMID: 34073199 DOI: 10.3390/curroncol28030185] [Reference Citation Analysis]
620 Sehdev A, Catenacci DV. Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. J Hematol Oncol 2013;6:66. [PMID: 24010946 DOI: 10.1186/1756-8722-6-66] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
621 Ahn HS, Sohn TS, Kim MJ, Cho BK, Kim SM, Kim ST, Yi EC, Lee C. SEPROGADIC - serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy. Sci Rep 2018;8:16892. [PMID: 30442939 DOI: 10.1038/s41598-018-34858-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
622 Yin S, Wang P, Xu X, Tan Y, Huang J, Xu H. The optimal strategy of multimodality therapies for resectable gastric cancer: evidence from a network meta-analysis. J Cancer. 2019;10:3094-3101. [PMID: 31289579 DOI: 10.7150/jca.30456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
623 Wang X, Shen Y, Zhu H, Zhao Y, Li Z, Qiu M, Li Q, Gou H, Yang Y, Cao D, Liu J, Yi C, Liao Z, Luo D, Bi F, Xu F. A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection. Gastric Cancer 2016;19:245-54. [PMID: 25609451 DOI: 10.1007/s10120-015-0461-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
624 Li G, Zhang Z, Ma X, Zhu J, Cai G. Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction. PLoS One 2013;8:e54233. [PMID: 23372688 DOI: 10.1371/journal.pone.0054233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
625 Yavas G, Elsurer R, Yavas C, Ata O. Basal renal function reserve and mean kidney dose predict future radiation-induced kidney injury in stomach cancer patients. Support Care Cancer 2014;22:445-51. [PMID: 24197055 DOI: 10.1007/s00520-013-1996-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
626 Zurlo IV, Basso M, Strippoli A, Calegari MA, Orlandi A, Cassano A, Di Salvatore M, Garufi G, Bria E, Tortora G, Barone C, Pozzo C. Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren's Classification in Pan-Cancer Analysis Era? Cancers (Basel) 2020;12:E1749. [PMID: 32630186 DOI: 10.3390/cancers12071749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
627 Thura M, Al-Aidaroos AQO, Yong WP, Kono K, Gupta A, Lin YB, Mimura K, Thiery JP, Goh BC, Tan P, Soo R, Hong CW, Wang L, Lin SJ, Chen E, Rha SY, Chung HC, Li J, Nandi S, Yuen HF, Zhang SD, Guan YK, So J, Zeng Q. PRL3-zumab, a first-in-class humanized antibody for cancer therapy. JCI Insight 2016;1:e87607. [PMID: 27699276 DOI: 10.1172/jci.insight.87607] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
628 Chen ZM, Huang L, Li MM, Meng L, Ying SC, Xu AM. Inhibitory effects of isocryptotanshinone on gastric cancer. Sci Rep. 2018;8:9307. [PMID: 29915371 DOI: 10.1038/s41598-018-27638-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
629 Hall JJ, Loggie BW, Shen P, Beamer S, Douglas Case L, McQuellon R, Geisinger KR, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2004;8:454-63. [PMID: 15120371 DOI: 10.1016/j.gassur.2003.12.014] [Cited by in Crossref: 96] [Cited by in F6Publishing: 93] [Article Influence: 5.6] [Reference Citation Analysis]
630 Tetzlaff ED, Cheng JD, Ajani JA. Review of docetaxel in the treatment of gastric cancer. Ther Clin Risk Manag 2008;4:999-1007. [PMID: 19209281 DOI: 10.2147/tcrm.s3226] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
631 Sharfo AWM, Stieler F, Kupfer O, Heijmen BJM, Dirkx MLP, Breedveld S, Wenz F, Lohr F, Boda-Heggemann J, Buergy D. Automated VMAT planning for postoperative adjuvant treatment of advanced gastric cancer. Radiat Oncol 2018;13:74. [PMID: 29685166 DOI: 10.1186/s13014-018-1032-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
632 Hultman B, Mahteme H, Sundbom M, Ljungman M, Larsson R, Nygren P. Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy. J Exp Clin Cancer Res. 2014;33:110. [PMID: 25528067 DOI: 10.1186/s13046-014-0110-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
633 Murthy K, Shukeili K, Kumar S, Davis C, Chandran R, Namrata S. Evaluation of dose coverage to target volume and normal tissue sparing in the adjuvant radiotherapy of gastric cancers: 3D-CRT compared with dynamic IMRT. Biomed Imaging Interv J 2010;6:e29. [PMID: 21611046 DOI: 10.2349/biij.6.3.e29] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
634 Yamanaka N, Nagai E, Ohuchida K, Ueda J, Toma H, Shimizu S, Oda Y, Tanaka M. Feasibility of laparoscopic gastrectomy for advanced gastric cancer with positive peritoneal cytology. Surg Today 2013;43:859-64. [PMID: 22983736 DOI: 10.1007/s00595-012-0338-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
635 Liu FF, Okunieff P, Bernhard EJ, Stone HB, Yoo S, Coleman CN, Vikram B, Brown M, Buatti J, Guha C; workshop participants. Lessons learned from radiation oncology clinical trials. Clin Cancer Res 2013;19:6089-100. [PMID: 24043463 DOI: 10.1158/1078-0432.CCR-13-1116] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
636 Mabula JB, McHembe MD, Koy M, Chalya PL, Massaga F, Rambau PF, Masalu N, Jaka H. Gastric cancer at a university teaching hospital in northwestern Tanzania: a retrospective review of 232 cases. World J Surg Oncol. 2012;10:257. [PMID: 23181624 DOI: 10.1186/1477-7819-10-257] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
637 Hawrylewicz L, Leszczyński W, Namysł-Kaletka A, Bronclik I, Wydmański J. Protection of organs at risk during neoadjuvant chemoradiotherapy for gastric cancer based on a comparison between conformal and intensity-modulated radiation therapy. Oncol Lett 2016;12:692-8. [PMID: 27347202 DOI: 10.3892/ol.2016.4633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
638 Lai YC, Yeh TS, Wu RC, Tsai CK, Yang LY, Lin G, Kuo MD. Acute Tumor Transition Angle on Computed Tomography Predicts Chromosomal Instability Status of Primary Gastric Cancer: Radiogenomics Analysis from TCGA and Independent Validation. Cancers (Basel) 2019;11:E641. [PMID: 31075839 DOI: 10.3390/cancers11050641] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
639 Smyth EC, Cunningham D. Targeted Therapy for Gastric Cancer. Curr Treat Options in Oncol 2012;13:377-89. [DOI: 10.1007/s11864-012-0192-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 5.6] [Reference Citation Analysis]
640 Li GC, Zhang Z, Ma XJ, Gu WL, Wang YN, Li J. Are biomarkers correlated with recurrence patterns in patients with resectable gastric adenocarcinoma. Mol Biol Rep. 2012;39:399-405. [PMID: 21559839 DOI: 10.1007/s11033-011-0751-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
641 Liu KT, Wan JF, Yu GH, Bei YP, Chen X, Lu MZ. The recommended treatment strategy for locally advanced gastric cancer in elderly patients aged 75 years and older: a Surveillance, Epidemiology, and End Results database analysis. J Cancer Res Clin Oncol 2017;143:313-20. [PMID: 27757528 DOI: 10.1007/s00432-016-2289-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
642 Thomson IG, Gotley DC, Barbour AP, Martin I, Jayasuria N, Thomas J, Smithers BM. Treatment results of curative gastric resection from a specialist Australian unit: low volume with satisfactory outcomes. Gastric Cancer. 2014;17:152-160. [PMID: 23474836 DOI: 10.1007/s10120-013-0240-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
643 Moehler M, Lyros O, Gockel I, Galle PR, Lang H. Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol 2008; 14(24): 3773-3780 [PMID: 18609699 DOI: 10.3748/wjg.14.3773] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
644 Yamada T, Yoshikawa T, Taguri M, Hayashi T, Aoyama T, Sue-Ling HM, Bonam K, Hayden JD, Grabsch HI. The survival difference between gastric cancer patients from the UK and Japan remains after weighted propensity score analysis considering all background factors. Gastric Cancer 2016;19:479-89. [PMID: 25761964 DOI: 10.1007/s10120-015-0480-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
645 Moorcraft SY, Smyth EC, Cunningham D. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? Gastric Cancer 2015;18:1-10. [PMID: 24638977 DOI: 10.1007/s10120-014-0356-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
646 Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E, Ciardiello F, De Vita F. Treatment of gastric cancer. World J Gastroenterol 2014; 20(7): 1635-1649 [PMID: 24587643 DOI: 10.3748/wjg.v20.i7.1635] [Cited by in CrossRef: 323] [Cited by in F6Publishing: 320] [Article Influence: 46.1] [Reference Citation Analysis]
647 Im S, Yoo C, Jung JH, Choi HJ, Yoo J, Kang CS. Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer: correlation with clinicopathological parameters and prognosis. Int J Med Sci. 2013;10:133-140. [PMID: 23329884 DOI: 10.7150/ijms.5500] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
648 Heo YJ, Lee T, Byeon SJ, Kim EJ, Shin HC, Kim B, Kang SY, Ha SY, Kim KM. Digital image analysis in pathologist-selected regions of interest predicts survival more accurately than whole-slide analysis: a direct comparison study in 153 gastric carcinomas. J Pathol Clin Res 2021;7:42-51. [PMID: 32885920 DOI: 10.1002/cjp2.179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
649 Aoyama T, Yoshikawa T. Adjuvant therapy for locally advanced gastric cancer. Surg Today. 2017;47:1295-1302. [PMID: 28251375 DOI: 10.1007/s00595-017-1493-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
650 Carlomagno C, Matano E, Bianco R, Cimminiello C, Prudente A, Pagliarulo C, Crispo A, Cannella L, DE Stefano A, D'Armiento FP, DE Placido S. Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors. Exp Ther Med 2010;1:611-7. [PMID: 22993584 DOI: 10.3892/etm_00000096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
651 Wang SB, Qi WX, Chen JY, Xu C, Kirova YM, Cao WG, Cai R, Cao L, Yan M, Cai G. Competing risk nomogram predicting initial loco-regional recurrence in gastric cancer patients after D2 gastrectomy. Radiat Oncol 2019;14:128. [PMID: 31315683 DOI: 10.1186/s13014-019-1332-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
652 Li J, Mo M, Chen Z, Chen Z, Sheng Q, Mu H, Zhang F, Zhang Y, Zhi XY, Li H, He B, Zhou HM. Adenoviral delivery of the EMX2 gene suppresses growth in human gastric cancer. PLoS One 2012;7:e45970. [PMID: 23029345 DOI: 10.1371/journal.pone.0045970] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
653 Oshima T, Yoshikawa T, Miyagi Y, Morita S, Yamamoto M, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Yokose T, Hiroshima Y, Aoyama T, Hayashi T, Ogata T, Cho H, Rino Y, Masuda M, Tsuburaya A, Sakamoto J. Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial. Oncotarget 2020;11:2906-18. [PMID: 32774771 DOI: 10.18632/oncotarget.27658] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
654 Snyder RA, Castaldo ET, Bailey CE, Phillips SE, Chakravarthy AB, Merchant NB. Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy and Extended Lymphadenectomy. Int J Surg Oncol. 2012;2012:307670. [PMID: 22778937 DOI: 10.1155/2012/307670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
655 Liakakos T, Roukos D. Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 2008;22:1553-5. [PMID: 18401654 DOI: 10.1007/s00464-008-9869-0] [Cited by in Crossref: 61] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
656 Reutovich MY, Krasko OV, Sukonko OG. Hyperthermic intraperitoneal chemotherapy in prevention of gastric cancer metachronous peritoneal metastases: a systematic review. J Gastrointest Oncol 2021;12:S5-S17. [PMID: 33968422 DOI: 10.21037/jgo-20-129] [Reference Citation Analysis]
657 Chuang J, Gong J, Klempner SJ, Woo Y, Chao J. Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. J Gastrointest Oncol 2018;9:560-72. [PMID: 29998022 DOI: 10.21037/jgo.2018.03.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
658 Strauss J, Hershman DL, Buono D, McBride R, Clark-Garvey S, Woodhouse SA, Abrams JA, Neugut AI. Use of adjuvant 5-fluorouracil and radiation therapy after gastric cancer resection among the elderly and impact on survival. Int J Radiat Oncol Biol Phys 2010;76:1404-12. [PMID: 19540074 DOI: 10.1016/j.ijrobp.2009.03.050] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
659 Bekelman JE, Zelefsky MJ, Jang TL, Basch EM, Schrag D. Variation in adherence to external beam radiotherapy quality measures among elderly men with localized prostate cancer. Int J Radiat Oncol Biol Phys 2007;69:1456-66. [PMID: 17689880 DOI: 10.1016/j.ijrobp.2007.05.020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
660 Chan MM, Sjoquist KM, Zalcberg JR. Clinical utility of ramucirumab in advanced gastric cancer. Biologics 2015;9:93-105. [PMID: 26451083 DOI: 10.2147/BTT.S62777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
661 Adams SR, Yang HC, Savariar EN, Aguilera J, Crisp JL, Jones KA, Whitney MA, Lippman SM, Cohen EE, Tsien RY, Advani SJ. Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. Nat Commun 2016;7:13019. [PMID: 27698471 DOI: 10.1038/ncomms13019] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
662 Korn WM. Prevention and management of early esophageal cancer. Curr Treat Options Oncol. 2004;5:405-416. [PMID: 15341678 DOI: 10.1007/s11864-004-0030-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
663 Novotny AR, Schuhmacher C, Busch R, Kattan MW, Brennan MF, Siewert JR. Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg 2006;243:74-81. [PMID: 16371739 DOI: 10.1097/01.sla.0000194088.81126.85] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 4.9] [Reference Citation Analysis]
664 Lacueva J, Gallego J, Díaz-González JA. Updating controversies on the multidisciplinary management of gastric cancer. Clin Transl Oncol. 2010;12:677-685. [PMID: 20947482 DOI: 10.1007/s12094-010-0577-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
665 Mita K, Ito H, Fukumoto M, Murabayashi R, Koizumi K, Hayashi T, Kikuchi H, Kagaya T. Alternating treatment with S-1 plus low-dose cisplatin and S-1 alone for advanced gastric cancer. J Gastrointest Surg 2011;15:791-6. [PMID: 21512899 DOI: 10.1007/s11605-011-1476-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
666 Hwang JE, Ki MS, Kim K, Jung SH, Shim HJ, Bae WK, Hwang EC, Hur YH, Jeong O, Ryu SY, Park YK, Cho SH, Lee JS, Chung IJ. The optimal chemotherapeutic regimen in D2-resected locally advanced gastric cancer: a propensity score-matched analysis. Oncotarget 2017;8:66559-68. [PMID: 29029536 DOI: 10.18632/oncotarget.16301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
667 Morita S, Fukagawa T, Fujiwara H, Katai H. Questionnaire survey regarding the current status of super-extended lymph node dissection in Japan. World J Gastrointest Oncol 2016; 8(9): 707-714 [PMID: 27672429 DOI: 10.4251/wjgo.v8.i9.707] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
668 Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG, Chun N, Kurian AW, Ford JM. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg. 2007;245:873-879. [PMID: 17522512 DOI: 10.1097/01.sla.0000254370.29893.e4] [Cited by in Crossref: 123] [Cited by in F6Publishing: 108] [Article Influence: 8.8] [Reference Citation Analysis]
669 Conrad T, MacLellan S, Kassam Z, Mackay H, Khalili I, Sykes J, Purdie T, Okrainec A, Ringash J. Retrospective assessment of patterns of recurrence relative to radiotherapy volumes for adjuvant conformal chemoradiotherapy in gastric cancer. Gastric Cancer 2016;19:887-93. [PMID: 26362272 DOI: 10.1007/s10120-015-0534-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
670 Coccolini F, Montori G, Ceresoli M, Cima S, Valli MC, Nita GE, Heyer A, Catena F, Ansaloni L. Advanced gastric cancer: What we know and what we still have to learn. World J Gastroenterol 2016; 22(3): 1139-1159 [PMID: 26811653 DOI: 10.3748/wjg.v22.i3.1139] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
671 Ringash J, Smalley SR, Gunderson LL. Locoregional control remains a critical issue in gastric cancer. Gastric Cancer 2008;11:64-5. [PMID: 18373180 DOI: 10.1007/s10120-008-0454-y] [Reference Citation Analysis]
672 Sastre J, García-Saenz JA, Díaz-Rubio E. Chemotherapy for gastric cancer. World J Gastroenterol 2006; 12(2): 204-213 [PMID: 16482619 DOI: 10.3748/wjg.v12.i2.204] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 58] [Article Influence: 3.9] [Reference Citation Analysis]
673 Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210-5218. [PMID: 21060024 DOI: 10.1200/jco.2009.26.6114] [Cited by in Crossref: 387] [Cited by in F6Publishing: 206] [Article Influence: 35.2] [Reference Citation Analysis]
674 肖鹏, 栗敏, 梅家转, 白桦. SOX方案与XELOX方案同步放疗治疗术后复发胃癌的疗效. 世界华人消化杂志 2014; 22(12): 1720-1724 [DOI: 10.11569/wcjd.v22.i12.1720] [Reference Citation Analysis]
675 Peng J, Wei Y, Zhou F, Dai J, Zhong Y, Xie C, Qin Y, Gong J, Xiong B, Zhou Y. D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy. Cancer Med. 2016;5:2773-2780. [PMID: 27666138 DOI: 10.1002/cam4.873] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [